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ABSTRACT  
   
An estimated 267 million women worldwide are HSV-2 seropositive, including 
roughly 20% of reproductive-aged American women. HSV-2 is a neurotropic virus that 
establishes a persistent, life-long infection that increases risk for STI acquisition in 
individuals. The vaginal epithelium represents a critical first line of defense against 
infection, and during acute infection, underlying immune mechanisms in the epithelium 
may be critical to protect against disease pathogenesis. The recently identified pro-
inflammatory cytokine IL-36g has been shown to be expressed at mucosal epithelia, 
including the female reproductive tract (FRT) and may be an important factor in host 
defense. Although IL-36g has been shown to be induced in the FRT after exposure to 
microbial products, the contributions of IL-36g to host defense mechanisms in response 
to this clinically relevant STI pathogen are not well understood. This dissertation 
describes the regulation of IL-36g in the FRT and explores its contribution to the host 
response against genital HSV-2 infection. 
To test the hypothesis that IL-36g is a key regulator of mucosal inflammation and 
immunity in the FRT, hormonal regulation of IL-36g in the FRT was investigated using 
estrogen- and progesterone-conditioned mice. From this preliminary study, it was shown 
that progesterone dampens IL36G expression relative to estrogen and may potentially 
increase susceptibility to infection. Next, the impact of IL-36g treatment on HSV-2 
infection and replication in human 3-D vaginal epithelial cells was explored. In parallel, 
the impact of intravaginal IL-36g delivery on HSV-2 disease pathogenesis was evaluated 
using a lethal murine challenge model. IL-36g pre-treatment significantly limited HSV-2 
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replication in vitro and in vivo and was associated with transient neutrophil infiltration 
that corresponded with decreased disease severity and increased survival in mice. Last, 
the requirement for IL-36g in host defense was investigated utilizing IL-36g-/- mice in a 
lethal HSV-2 murine challenge model. Following infection, IL-36g-/- mice exhibited 
significantly impaired neutrophil recruitment, decreased overall survival time, and 
significantly increased viral neuroinvasion relative to wild type mice. Collectively, these 
data indicate that IL-36g is a crucial regulator of HSV-2-induced neutrophil infiltration 
and appears to function in a previously uncharacterized manner to limit viral 
neuroinvasion in genital HSV-2 disease pathogenesis. 
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CHAPTER 1: INTRODUCTION 
 
The IL-36 Cytokines: New Kids on the Block 
Characteristics and Mechanisms of Action  
At the turn of the 21st century researchers identified a series of novel, 
uncharacterized genes located on chromosome 2, near the Interleukin-1 (IL-1) locus 
(Barton et al. 2000, Busfield et al. 2000, Mulero et al. 1999). These genes exhibited 
homology to several IL-1 family members, and were originally hypothesized to function 
as important inflammatory mediators (Barton et al. 2000, Busfield et al. 2000, Mulero et 
al. 1999).  Two years after their initial discovery, these cytokines were named IL-1F6, IL-
1F8, IL-1F9 and IL-1F5 and designated as members of the IL-1 superfamily (Sims et al. 
2001). Over time these new IL-1 family members were shown to exhibit distinct biologic 
functions and were subsequently renamed and given unique interleukin designations as 
IL-36alpha (-a), beta (-b), gamma (-g), and receptor antagonist (-Ra) (Dinarello et al. 
2010). The IL-36 cytokines share approximately 20-50% homology to the pro-
inflammatory cytokine IL-1b, and also share homology to IL-1Ra (Gresnigt and van de 
Veerdonk 2013). Additionally, the structure of both IL-36g and IL-36Ra contain a 12-
fold b-trefoil core structure, a common structural feature in many classical IL-1 cytokines 
(Dunn et al. 2003, Gunther and Sundberg 2014). Similar to other IL-1 cytokines, the IL-
36 agonists lack a signal peptide and require cleavage at the N-terminus to be fully 
activated (Towne et al. 2011). A recent report has elucidated mechanisms of IL-36 family 
activation and showed that IL-36a is cleaved and activated by neutrophil elastase and 
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cathepsin G, IL-36b by cathepsin G, and IL-36g is cleaved and activated by neutrophil 
elastase and proteinase-3 (Henry et al. 2016).  
 
 
 
Figure 1. IL-36R signaling activates MAPK and NFkB pathways. 
Binding of the cleaved IL-36 agonists (a, b, or g) recruits IL-1RAcP to the 
IL-36R complex on the plasma membrane surface. IL-36R signaling 
through Toll/Interleukin-1 receptor (TIR) domains is MyD88 dependent. 
 
Activated IL-36 family members signal through their own unique receptor, IL-
36R. Binding of the IL-36 agonists (-a, -b, or -g) to IL-36R initiates the recruitment of 
the IL-1 receptor accessory protein (IL-1RAcP) as an essential co-receptor for signaling 
(Fig. 1) (Towne et al. 2004). Both IL-36R and IL-1RAcP contain an intracellular Toll/IL-
1 (TIR) domain that will then trigger downstream signaling cascades, including NFkB 
and MAPK pathways, through the adaptor protein MyD88 (Towne et al. 2004). 
Activation of NFkB and other transcription factors robustly induce the production of 
  3 
immune mediators that promote inflammation, direct immune cell recruitment and 
polarization, and regulate cellular proliferation and gene expression among other 
processes (Gabay and Towne 2015). In addition to paracrine signaling effects, the IL-36 
cytokines can signal in an autocrine manner, thus amplifying IL-36R signaling and 
downstream immune effects. IL-36Ra functions as an antagonist in the family and will 
bind to IL-36R to prevent agonist binding to the receptor and the subsequent downstream 
signaling cascade (Towne et al. 2004, Towne et al. 2011).  
 
Tissue Expression Profiles of the IL-36 Cytokines 
Although classical IL-1 family members are generally ubiquitously expressed 
throughout the human body, the IL-36 cytokines are expressed in a more tissue-restricted 
manner. The IL-36 family members are expressed in both immune and non-immune cells, 
with predominant expression in the skin and at mucosal epithelia (Gresnigt and van de 
Veerdonk 2013). Researchers have also shown that some IL-36 family members are 
additionally expressed in adipose tissue (Do et al. 2006, van Asseldonk et al. 2010), joints 
(Frey et al. 2013, Magne et al. 2006), the kidneys (Ichii et al. 2010), and the central 
nervous system (Berglof et al. 2003, Li et al. 2018). As outlined in Table 1, the IL-36 
family members are expressed in a wide range of cell types, and in some instances, in a 
non-overlapping manner, indicating that the IL-36 family members may have distinct 
cell- and tissue-specific functions. 
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Table 1. 
Cell Expression Profiles of IL-36 Cytokines 
IL-36 Family Member Cells Expressed In References 
IL-36a 
Keratinocytes 
Epithelial Cells 
Endothelial Cells 
Chondrocytes 
Monocytes 
T/B Lymphocytes 
(Blumberg et al. 2007, Boutet et 
al. 2016, Chustz et al. 2011, 
Conde et al. 2015, Debets et al. 
2001, Smith et al. 2000) 
IL-36b 
Keratinocytes 
Epithelial Cells 
Endothelial Cells 
Monocytes/Macrophages 
Dendritic Cells 
T/B Lymphocytes 
(Boutet et al. 2016, Chustz et al. 
2011, Johnston et al. 2011, Li et 
al. 2010, Magne et al. 2006, 
Smith et al. 2000) 
IL-36g 
Keratinocytes 
Epithelial Cells 
Monocytes/Macrophages 
Dendritic Cells 
Spinal Neurons 
(Ahsan et al. 2016, Bachmann et 
al. 2012, Boutet et al. 2016, 
Debets et al. 2001, Li et al. 
2018, Takahashi et al. 2015, 
Winkle, Throop, and Herbst-
Kralovetz 2016) 
IL-36Ra 
Keratinocytes 
Epithelial Cells 
Monocytes 
Dendritic Cells 
(Blumberg et al. 2007, Boutet et 
al. 2016, Chustz et al. 2011) 
IL-36R 
Keratinocytes 
Epithelial Cells 
Monocytes/Macrophages 
Dendritic Cells 
T Cells 
Glia 
(Ahsan et al. 2016, Berglof et al. 
2003, Foster et al. 2014, 
Johnston et al. 2011, Vigne et al. 
2011, Winkle, Throop, and 
Herbst-Kralovetz 2016) 
 
 
As described above, the IL-36 cytokines are predominately expressed in the skin 
and by epithelial cells at mucosal surfaces, including the gastrointestinal tract, respiratory 
tract, and female reproductive tract (FRT). In the FRT, all IL-36 family members have 
been detected in uterine tissue in mice, with IL-36g as one of the most robustly expressed 
family members (Murrieta-Coxca et al. 2016). Further, Winkle et al. demonstrated that 
IL-36g and IL-36R are expressed in human vaginal and cervical tissue and 3-D human 
vaginal and endocervical epithelial cell models (Winkle, Throop, and Herbst-Kralovetz 
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2016). Data from studies in the FRT and other tissues indicate that IL-36 family member 
expression may be differentially regulated in various tissues and in response to disease 
(Table 2), and future studies may elucidate mechanisms controlling expression patterns 
and responses to different stimuli. 
 
Table 2. 
Tissue- and Disease-Specific Expression of the IL-36 Cytokines 
Tissue IL-36 Family Members  Disease/Infection References 
Adipose IL-36a Obesity (Do et al. 2006, van Asseldonk et al. 2010) 
Blood IL-36a IL-36g SLE (Ichii et al. 2010) 
Central Nervous  
System 
IL-36g 
IL-36Ra 
Brain tissue inflammation 
Chronic inflammation 
(Berglof et al. 2003, Li 
et al. 2018) 
Colon IL-36a IL-36g 
IBD 
Ulcerative colitis 
Crohn’s disease 
Colorectal carcinoma 
(Nishida et al. 2016, 
Russell et al. 2016, 
Weinstein et al. 2017, 
Weinstein et al. 2019) 
Female Reproductive 
Tract 
IL-36a 
IL-36b 
IL-36g 
IL-36Ra 
L. monocytogenes 
Group B Streptococcus 
(Murrieta-Coxca et al. 
2016, Patras et al. 2015, 
Patras et al. 2013) 
Joints IL-36a IL-36b 
Rheumatoid arthritis 
Psoriatic arthritis 
(Frey et al. 2013, Kim et 
al. 2008, Magne et al. 
2006, Wu and Gu 2007) 
Kidney IL-36a 
Nephrotic syndrome 
Tubulointerstitial lesions 
Glomerulonephritis 
Streptozocin-induced diabetes 
(Ichii et al. 2010) 
Lungs 
IL-36a 
IL-36g 
IL-36Ra 
COPD 
Asthma 
K. pneumoniae 
S. pneumoniae 
L. pneumophilia 
Influenza virus 
(Aoyagi et al. 2016, 
Chen et al. 2012, Kovach 
et al. 2017, Nanjo et al. 
2019, Ramadas et al. 
2006) 
Skin 
IL-36a 
IL-36b 
IL-36g 
IL-36Ra 
Psoriasis 
DITRA 
HSV-1 
S. aureus 
(Blumberg et al. 2007, 
Carrier et al. 2011, Mahil 
et al. 2017, Milora et al. 
2017, Ohko et al. 2018) 
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IL-36 and Chronic Inflammatory Diseases 
 Given the pro-inflammatory nature of the IL-36 family members and expression 
in keratinocytes, the IL-36 cytokines were initially investigated in the context of chronic 
inflammatory diseases, including psoriasis. Blumberg et al. first demonstrated that 
transgenic mice overexpressing IL-36a in basal keratinocytes exhibit increased skin 
inflammation and a psoriasis-like phenotype (Blumberg et al. 2007). Subsequent 
investigations utilizing clinical samples and animal models further demonstrated that IL-
36 signaling in psoriasis drives a Th1 and Th17 response and robust leukocyte infiltration 
in psoriatic lesions (Carrier et al. 2011, Mahil et al. 2017). Further, increased levels of the 
IL-36 cytokines, including IL-36g, have been measured in psoriatic lesions, and the IL-36 
agonists were shown to upregulate psoriasis-related genes in keratinocytes to drive 
psoriasis development (Ohko et al. 2018). Deficiencies in IL-36Ra have also been 
observed in individuals, and is associated with increased inflammatory markers, high 
fever and generalized pustular rash referred to as deficiency of the IL-36 receptor 
antagonist (DITRA), highlighting the importance of this antagonist in regulation of IL-
36R signaling and the inflammatory response (Cowen and Goldbach-Mansky 2012, 
Marrakchi et al. 2011). In the lungs, the IL-36 cytokines have been linked to chronic 
obstructive pulmonary disease (Chen et al. 2012) and asthma (Ramadas et al. 2006), and 
in the gut, inflammatory bowel disease (Nishida et al. 2016) and ulcerative colitis 
(Russell et al. 2016), further demonstrating the crucial role the IL-36 cytokines play in 
the regulation of inflammation at epithelia. 
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IL-36g and Cancer 
 Recent reports have additionally shown that there is increased IL-36g expression 
in colorectal carcinoma primary tumors and in cervicovaginal lavages from women with 
cervical cancer (Weinstein et al. 2019, Laniewski et al. 2018). Because IL-36g and IL-
36R signaling promotes Th1 differentiation, IL-36g has been hypothesized to exhibit anti-
tumor activity. Indeed, researchers recently demonstrated that co-delivery of the 
chemotherapeutic doxorubicin with an IL-36g expression plasmid promoted an anti-
metastatic effect and drove a Th1 anti-tumor response that was linked to improved 
overall anti-tumor activity (Chen et al. 2019). Other reports have also indicated that IL-
36g signaling can transform the tumor microenvironment and limit tumor growth by 
regulating both dendritic cell and T cell polarization and function (Tsurutani et al. 2016, 
Wang et al. 2015, Weinstein et al. 2017). Though preliminary, these exciting findings 
indicate a potential function for IL-36g in the tumor microenvironment to limit metastasis 
and regulate the anti-tumor response that may be incorporated into novel cancer 
therapeutics in the future. 
 
Function of IL-36g in Host-Pathogen Interactions 
Over the past few years, researchers have additionally begun investigating the 
function of IL-36g in the context of host-pathogen interactions at mucosal epithelia (Fig. 
2). Notably, in the lungs, IL-36g signaling has been shown to stimulate type-1 and Th17 
cytokine production and promote macrophage polarization to aid in Streptococcus 
pneumoniae and Klebsiella pneumoniae clearance and protect against disease 
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pathogenesis (Kovach et al. 2017). Additionally, in Mycobacterium tuberculosis infection 
of macrophages, IL-36g stimulated the production of crucial antimicrobial peptides and 
pro-inflammatory cytokines that limited M. tuberculosis replication (Ahsan et al. 2016). 
Nanjo et al. also demonstrated that IL-36a and IL-36g may have overlapping roles in host 
defense against L. pneumoniae lung infection, as IL-36R-/- mice, but not IL-36a-/- or IL-
36g-/- mice exhibited increased mortality, delayed bacterial clearance, and decreased 
cytokine and chemokine production (Nanjo et al. 2019). The pro-inflammatory response 
induced by IL-36 signaling can also have negative effects that exacerbate disease 
pathogenesis. IL-36 signaling has been shown to drive neutrophil infiltration to the 
bronchial epithelium that contributes to disease pathogenesis during influenza virus 
infection (Aoyagi et al. 2016). IL-36g-mediated production of prostaglandin E2 in 
response to P. aeruginosa infection also led to decreased bacterial clearance, and 
increased lung damage and mortality after infection (Aoyagi et al. 2017). The IL-36 
cytokines have recently been shown to exhibit important functions in host-pathogen 
interactions at the skin. Using an epicutaneous skin exposure model, Liu et al. 
demonstrated that IL-36R/MyD88 signaling in response to S. aureus exposure induced 
robust skin inflammation (Liu et al. 2017). Further, it was shown that IL-36a signaling in 
T- cells drove the T-cell mediated production of IL-17 and subsequent inflammatory 
cascade (Liu et al. 2017). Milora et al. additionally demonstrated that in a flank skin 
HSV-1 infection model, IL-36b-/- mice exhibited increased mortality after HSV-1 
infection (Milora et al. 2017). IL-36b-/- mice did not exhibit an altered B- or T-cell 
response, and future studies are needed to investigate the impact of IL-36b and the other 
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IL-36 agonists on immune signaling and innate immune cell recruitment in the skin 
(Milora et al. 2017). 
 
Figure 2. IL-36g signaling in host defense. IL-36g is induced in response 
to bacterial and viral infection at mucosal epithelia. Signaling through IL-
36R activates MAPK and NFkB transcription factors to upregulate 
production of cytokines, chemokines and antimicrobial peptides. IL-36g 
signaling additionally promotes neutrophil infiltration to the mucosal 
epithelia.  
 
In addition to functioning in response to infection, a recent report demonstrated 
that the IL-36 cytokines can potentially function as vaccine adjuvants to protect 
individuals against infection. Louis et al. showed that delivery of a plasmid expressing 
DNA-encoded viral antigen and IL-36b promoted a more effective CD4+ T cell response, 
whereas an IL-36g-expressing plasmid combined with the viral antigen drove a more 
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robust CD8+ T cell response in the context of HIV, Influenza, and Zika virus 
immunization (Louis et al. 2019). Delivery of the IL-36g adjuvant further improved the 
humoral response, leading to enhanced antibody binding without a decrease in antibody 
avidity. When evaluating the efficacy of the IL-36g adjuvant in vivo, it was shown that 
delivery of a plasmid encoding IL-36g and Zika prME antigen protected mice against 
lethal intraperitoneal challenge and disease in the murine Zika model (Louis et al. 2019). 
Although this report is the first of its kind and required additional investigation, the study 
provides exciting insights into the potential prophylactic function the IL-36 cytokines can 
play in host defense. 
While the functions of the IL-36 cytokines are beginning to be well-characterized 
in host-pathogen interactions in the lungs and skin, in the FRT the IL-36 cytokines 
remain largely unstudied. Murrieta-Coxca et al. have demonstrated that the IL-36 
cytokines are expressed in murine uterine tissue and are induced by Listeria 
monocytogenes infection in the uterus (Murrieta-Coxca et al. 2016). Additionally, Patras 
et al. found that Group B Streptococcus clinical isolates significantly induced IL-36g in 
human vaginal, ectocervical, and endocervical epithelial cells (Patras et al. 2015, Patras et 
al. 2013). Further, utilizing 3-D human vaginal and endocervical epithelial cell models, it 
was shown that a broad array of microbial products, including the viral mimic poly(I:C), 
robustly induced IL-36g expression (Winkle, Throop, and Herbst-Kralovetz 2016). 
Winkle et al. also demonstrated that treatment of 3-D vaginal and endocervical epithelial 
cells with recombinant IL-36g robustly stimulated the production of cytokines, 
chemokines, and antimicrobial peptides (Winkle, Throop, and Herbst-Kralovetz 2016). 
Together, these data suggest that IL-36g may exhibit an important function in host 
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defense mechanisms in response to bacterial and viral pathogens in the FRT and has led 
us to develop the hypothesis that IL-36g is a crucial regulator of mucosal inflammation in 
the FRT. 
 
HSV-2 and Genital Herpes 
Epidemiology and Disease Pathogenesis  
The World Health Organization recently published a new report that there are 
over 1 million new cases of curable sexually transmitted infections every day (Rowley et 
al. 2019). Genital HSV-2 infection remains one of the most common sexually transmitted 
infections, affecting an estimated 276 women - 15% of all women worldwide (Looker et 
al. 2015b). HSV-2 is a neurotropic alphaherpesvirus that establishes a persistent, lifelong 
infection in individuals that will periodically reactivate. In women, primary infection 
occurs in the vaginal epithelium, where it replicates and spreads to sensory nerve endings 
innervating the vaginal epithelium. Once in neurons, the virus will spread, infect, and 
establish latency in dorsal root ganglia (DRG) in the vertebral column. During 
reactivation episodes, HSV-2 will exit latency and spread back through sensory neurons 
to the vaginal epithelium where it will enter a lytic replication cycle that results in 
shedding at the vaginal mucosa (Johnston and Corey 2016).  
Although herpetic lesions are often formed at the vaginal epithelium during 
reactivation episodes, HSV-2 reactivation and subsequent shedding is frequently 
subclinical, potentially contributing to increased HSV-2 transmission (Wald et al. 1995, 
Wald et al. 2000a). Pregnant women can additionally transmit HSV-2 to newborns in 
utero and during delivery causing neonatal herpes, an infection associated with high 
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morbidity and high mortality as the virus spreads throughout the central nervous system 
(Corey and Wald 2009, Hass 1935). Neuroinvasion of HSV-2 in adults has been observed 
clinically in HSV-2 seropositive individuals complaining of acute urinary retention 
(Caplan, Kleeman, and Berg 1977, Goodell et al. 1983). Individuals with recurrent 
genital herpes generally average approximately five reactivation episodes during the first 
two years after acute infection, with less frequent episodes afterwards (Sen and Barton 
2007). These ulcerative lesions in turn have been shown to increase risk for STI 
acquisition, including HIV (Freeman et al. 2006, Patel et al. 2012, Wald and Link 2002). 
 
Mouse Model of Genital Herpes 
Mouse models have been developed to investigate genital HSV-2 infection and 
have proved valuable tools to investigate disease pathogenesis and mechanisms of the 
immune response to acute infection. Inbred C57Bl/6 or BALB/c mice are the most 
commonly used strains by immunologists, and animals are conditioned with depot-
medroxyprogesterone acetate (DMPA) to synchronize cycles and increase susceptibility 
to infection (Kollias et al. 2015, Parr et al. 1994, Parr and Parr 2003). Upon infection, 
animals are monitored daily and disease progression is scored throughout the course of 
infection. As genital disease progresses, animals will lose hair around the introitis and 
will develop erythema and ulcerative lesions (Gardner and Herbst-Kralovetz 2018). 
Following intravaginal inoculation, the virus will actively replicate and spread throughout 
the vaginal epithelium, infecting innervating autonomic ganglia in the pelvis and spread 
to the DRG (Parr and Parr 2003). Once HSV-2 has infected the DRG, the virus can then 
spread to the autonomic ganglia of the enteric nervous system (ENS) (Khoury-Hanold et 
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al. 2016). Infection of the ENS ganglia leads to the destruction of enteric neurons by 
infiltrating neutrophils that results in a loss of peristalsis, compaction of fecal matter, and 
death (Khoury-Hanold et al. 2016). Spread of HSV-2 to the DRG additionally provides 
HSV-2 with access to the spinal cord and central nervous system where the virus may 
infect the brainstem, causing hind limb paralysis (Parr and Parr 2003, Reinert et al. 2012, 
Song et al. 2016). Animals are euthanized when they exhibit end-stage disease 
symptoms, including hind limb paralysis and moribundity, to minimize pain and 
suffering. Monitoring of disease and survival continues for up to 21 days post-infection 
(dPI). Over the course of infection vaginal swabs can be collected to monitor viral loads 
in the vaginal cavity and characterize immune cell infiltration. Upon necropsy, additional 
tissues can be collected including the genital lymph nodes, colon, spinal cord, dorsal root 
ganglia, and brainstem for virus titration and flow cytometry analysis or 
immunohistochemistry. 
 
Immune Response to Genital Herpes 
As HSV-2 overcomes the mechanical and chemical barriers to infection at the 
vaginal epithelium, initial recognition of the virus occurs as virions are sensed by Toll-
like receptors (TLRs) on the cellular surface or in endocytic vesicles. As the virus enters 
the cell and begins to replicate, TLRs and other immune sensing pathways are triggered 
to lead to the production of pro-inflammatory cytokines, chemokines, and antimicrobial 
peptides. This signaling rapidly recruits innate immune cells including macrophages, 
neutrophils, and NK cells that can induce apoptosis and phagocytose infected cells and 
virions, and contribute to the enhanced production of cytokines and chemokines to 
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protect against infection (Milligan 1999, Milligan, Bourne, and Dudley 2001, Morahan, 
Morse, and McGeorge 1980, Thapa, Kuziel, and Carr 2007). Dendritic cells recruited to 
the vaginal epithelium play a vital role in the processing and presentation of viral 
antigens to lymphocytes in the genital lymph nodes to promote a robust adaptive immune 
response (Yoneyama et al. 2005). Activated B cells will begin to produce neutralizing 
antibodies, often targeting surface glycoproteins, that have been shown to reduce viral 
load and decrease transmission in mouse models (Chu et al. 2008, Sherwood et al. 1996). 
HSV-2 specific IFNg-producing T cells will also be recruited to the vaginal 
microenvironment and are crucial mediators of the cytolytic response (Mueller et al. 
2002). Synergy between the type I IFN and IFNg response in T cells is key for the 
expansion of anti-HSV-2 CD8+ T cells and in the cross-presentation of HSV-2 antigen to 
produce a robust adaptive response that can control infection and promote disease 
resolution in the vaginal epithelium (Le Bon et al. 2006, Le Bon et al. 2003, Sainz and 
Halford 2002). CD4+ T cells have also been shown to contribute to viral clearance 
through the production of IFNg (Johnson, Chu, and Milligan 2008). Ultimately, both the 
innate and adaptive responses are critically important to promote disease resolution in the 
vaginal epithelium and rapidly respond during reactivation episodes to limit virus 
shedding and the duration of episodes. 
 
Drug and Vaccine Development to Combat Genital Herpes 
Acyclovir, the current recommended treatment for genital herpes, was first 
identified in 1974 and clinical trials began three years later (King 1988). A nucleoside 
analogue, acyclovir functions as it is recognized by viral thymidine kinase and causes 
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chain termination as it is incorporated in the growing DNA chain during virus replication 
(Elion et al. 1977). Since the discovery of acyclovir, drugs to treat genital herpes have 
gone largely unchanged from acyclovir and the acyclovir-analogues that are currently 
prescribed today (Johnston and Corey 2016). Treatment is administered either 
episodically as an individual exhibits symptoms of reactivation, or as a chronic 
suppressive therapy. Although acyclovir is highly specific for HSV-2 and does reduce 
reactivation episode length and symptoms, treatment with acyclovir does not prevent 
virus shedding and transmission (Gupta et al. 2004, Johnston et al. 2012). Further, 
episodic treatment is largely ineffective for individuals experiencing a subclinical 
reactivation. Daily, suppressive therapeutics are more effective at reducing recurrences, 
however these regimens require lifelong use and may lead to chronic immunosuppression 
and drug resistance (Jiang et al. 2016). Additional therapeutics are under development to 
limit virus reactivation and shedding, however, none of these treatments can eliminate 
disease due to latent infection in the DRG (Johnston and Corey 2016). 
Extensive effort has been spent over the past half-century in the development a 
prophylactic vaccine to protect against genital HSV-2 infection and the establishment of 
latency. Glycoprotein subunit vaccines (glycoprotein B2 and glycoprotein D2) have 
induced the production of neutralizing antibodies in animal models but have been largely 
ineffective in clinical trials (Belshe et al. 2012). In addition to neutralizing antibodies, an 
effective local T cell response can improve vaccine efficacy. To promote a robust local 
memory T cell response, a “prime and pull” vaccination strategy was devised that utilized 
an initial vaccination to stimulate a robust T-cell response and then the local 
administration of chemokines to recruit these “primed” T cells to the vaginal cavity to 
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establish a protective resident population (Shin and Iwasaki 2012). Additional 
prophylactic vaccines are currently undergoing clinical trials, including one strategy 
using a replication deficient virus (Dropulic et al. 2017). Ultimately, an understanding of 
the contribution of underlying immune mediators in the vaginal epithelium to host 
defense mechanisms can aid in the development of novel therapeutics to treat those with 
recurrent genital herpes and provide important insights in the continued development of a 
vaccine to protect individuals against genital HSV-2 infection.  
 
Overview of Dissertation 
 This body of work evaluates the hypothesis that IL-36g is a crucial regulator of 
mucosal inflammation in response to genital HSV-2 infection to protect against disease 
pathogenesis. To test this hypothesis, a physiologically relevant 3-D human vaginal 
epithelial cell model and murine lethal genital HSV-2 challenge model were utilized. 
Hormonal regulation of IL-36g in the FRT and induction of IL-36g in response to a 
clinically relevant STI pathogen were evaluated. Downstream effects of prophylactic IL-
36g treatment on the immune response and the impact on HSV-2 replication and disease 
pathogenesis were assessed. In addition, the requirement for IL-36g was investigated in 
the response to genital HSV-2 infection, providing essential information regarding the 
function of IL-36g in host defense in the FRT epithelia. 
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CHAPTER 2: THREE-DIMENSIONAL ROTATING WALL VESSEL-DERIVED 
CELL CULTURE MODELS FOR STUDYING VIRUS-HOST INTERACTIONS 
 
Publication Note 
This chapter was previously published in an altered format in Viruses. Jameson K. 
Gardner and Melissa M. Herbst-Kralovetz. 2016. Three-dimensional rotating wall vessel-
derived cell culture models for studying virus-host interactions. Viruses. 8(11). pii:E304.  
 
Abstract 
The key to better understanding complex virus-host interactions is the utilization 
of robust three-dimensional (3-D) human cell cultures that effectively recapitulate native 
tissue architecture and model the microenvironment. A lack of physiologically relevant 
animal models for many viruses has limited the elucidation of factors that influence viral 
pathogenesis and of complex host immune mechanisms. Conventional monolayer cell 
cultures may support viral infection, but are unable to form the tissue structures and 
complex microenvironments that mimic host physiology and therefore limits their 
translational utility. The rotating wall vessel (RWV) bioreactor was designed by NASA 
to model microgravity and was later found to more accurately reproduce features of 
human tissue in vivo. Cells grown in RWV bioreactors develop in a low fluid-shear 
environment, which enables cells to form complex 3-D tissue-like aggregates. A wide 
variety of human tissues (from neuronal to vaginal tissue) have been grown in RWV 
bioreactors and shown to support productive viral infection and physiological meaningful 
host responses. The in vivo-like characteristics and cellular features of the human 3-D 
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RWV-derived aggregates make them ideal model systems to effectively recapitulate 
pathophysiology and host responses necessary to conduct rigorous basic science, 
preclinical and translational studies. 
 
Introduction 
In vitro studies of complex virus-host interactions require robust cell culture 
models that effectively recapitulate in vivo properties and characteristics. Researchers 
have utilized conventional two-dimensional monolayer cell cultures for many decades, 
increasing understanding in viral life cycles and the host immune response. Cells grown 
in conventional monolayer cell cultures however, often lack polarization and architectural 
features of in vivo tissues and therefore may improperly represent key virus-host 
interactions (Abbott 2003, Nickerson, Richter, and Ott 2007, Zhang 2004). Additionally, 
many newly emerging viruses and difficult-to-propagate viruses (Zika virus, Severe 
Acute Respiratory Syndrome coronavirus and hepatitis viruses for example) lack 
sufficient animal models and/or in vitro cell culture models to allow for study of these 
viruses. Therefore, there is a clear need for in vitro models that display key cellular 
components and features that accurately model virus-host interactions. Development of 
new therapeutic agents and treatments for viral infections requires a more complex 
understanding of virus-host interactions, as well as, culture systems that model the in vivo 
environment as accurately as possible. Viruses often require distinct cellular architectural 
features and polarized orientation with receptors for attachment and entry, which may not 
be present on cells grown in conventional monolayer cell cultures. For example, a recent 
review article highlighted the important role of tight junctions in viral entry, replication, 
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dissemination and egress in at least nine different DNA and RNA viruses (Torres-Flores 
and Arias 2015). Tight junction proteins are also key components of the epithelial barrier 
function and integrity that protect against viral infection and potentially influence the 
susceptibility of tissue to viral infection. Mucin production at mucosal epithelial sites 
additionally influences virus-host interactions at the epithelial barrier, and ultimately 
impacts viral infection and transmission (Cohen et al. 2013, Zanin et al. 2016, Zanin et al. 
2015). While some of these features may be present in conventional monolayer cell 
cultures, they often lack the polarity and other topographic features that are present in 
vivo. Rotating wall vessel (RWV) bioreactors effectively model many of these features, 
including tight junctions and unidirectional expression of mucin and key receptor 
proteins, allowing investigators to more effectively study virus-host interactions as they 
exist in vivo in a reproducible fashion. 
Early attempts at three-dimensional (3-D) cell culture utilized explant tissue 
cultures (Carrel 1912, Strangeways 1924). Collection of explant tissue, however, is 
limited by donor availability, and such explants have a short life-span in culture (Grivel 
and Margolis 2009). More recent attempts at 3-D modeling have included scaffold-based 
systems, scaffold-free systems, transwells, and microfluidics (Haycock 2011, Seyring et 
al. 2012, van Duinen et al. 2015). NASA initially developed the RWV bioreactor as a 
way to model the microgravity environment encountered in space and to investigate 
growth, regulatory, and structural processes (Goodwin et al. 1993, Schwarz, Goodwin, 
and Wolf 1992). The RWV bioreactor was found to create a modeled microgravity, low 
fluid-shear environment that provides the necessary oxygenation and nutrients for 
development and polarization. In this environment, cells were observed to form cellular 
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structures and features not readily expressed in conventional monolayer cell culture. 
Since its development, the RWV bioreactor has been utilized for the study of cellular and 
microbial gene expression in microgravity, cellular differentiation, host-pathogen 
interactions and tissue engineering (Barrila et al. 2010, Barzegari and Saei 2012, Grimm 
et al. 2014, Navran 2008).  
In the RWV bioreactor, cells are cultured with microcarrier beads or matrices that 
allow the cells to attach and spontaneously develop 3-D ultrastructures representative of 
the parental tissue. As the cells grow and develop, cellular aggregates form via bead-to-
bead bridges, and cellular aggregates can be sampled at various time points to monitor 
the progress of development (Cherry and Papoutsakis 1988, Jessup et al. 1994). The low 
fluid-shear environment prevents the cells from detaching from the microcarriers and 
protects growing tissue aggregates from damage that can occur from excess agitation 
during culturing (Cherry and Papoutsakis 1988). The low fluid-shear environment also 
promotes the co-localization of particles in the fluid, and leads to the formation of the 
bead-to-bead bridges and cellular aggregates (Schwarz, Goodwin, and Wolf 1992). In 
addition, this low fluid-shear environment mimics the flow in vivo during development 
and thereby promotes cellular differentiation as cells signal and grow in 3-D. Developing 
3-D aggregates are kept in a continuous free-fall state of neutral buoyancy that precludes 
aggregate sedimentation while maintain the low fluid-shear environment, and allows the 
cells to grow around the microcarrier and develop complex structures observed in vivo 
(Fig. 3) (Cherry and Papoutsakis 1988, Gao, Ayyaswamy, and Ducheyne 1997, Goodwin 
et al. 2015, Schwarz, Goodwin, and Wolf 1992). In the RWV bioreactor, oxygenation 
occurs by the diffusion of dissolved gasses, creating a zero headspace environment that 
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provides the necessary oxygenation for the developing aggregates while maintaining the 
low fluid-shear environment (Goodwin et al. 2015). Collectively, these growth conditions 
allow for 3-D tissue aggregates to develop and form organotypic ultrastructures that are 
not readily present in conventional monolayer cell culture and necessary for advancing 
development of in vitro models that effectively recapitulate in vivo tissue. For example, 
epithelial cells grown in the bioreactor express adhesion proteins, form desmosomes and 
tight junctions, produce secretory material and mucus, and also form microvilli and 
microridges(Drummond, Nickerson, and Coyne 2016, Goodwin et al. 1993, Hjelm et al. 
2010, McConkey et al. 2016, Radtke et al. 2012, Dill et al. 2012, Zwezdaryk et al. 2012). 
Notably, cells that are seeded into the bioreactor reflect their phenotype. For example, 
vaginal epithelial cells form a multi-layered stratified squamous epithelium, whereas 
endocervical epithelial cells form a single layer as found in vivo, therefore reflecting the 
authentic microanatomical features of the parental tissue (Hjelm et al. 2010, Dill et al. 
2012). Cancerous cell lines, on the other hand (e.g. MCF-7 cells) no longer require the 
extracellular matrix for growth and do not attach and grow on the collagen-coated 
microcarrier beads, thereby reflecting their cancer phenotype. Fully differentiated 
aggregates can remain in the bioreactor for infection, or aggregates can be harvested and 
plated for downstream experiments including infections. 
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Figure 3. Culturing 3-D aggregates in the RWV bioreactor. A) Cells 
are grown to confluence in 2-D conventional monolayer cell cultures, then 
combined with microcarrier beads and appropriate media in the RWV 
bioreactor. Cells attach to the microcarrier beads in the bioreactor, and 
culture media can be replaced at any time according to the metabolic 
needs of the developing aggregates as described in Radtke et al. (Radtke et 
al. 2012) B) The RWV bioreactor is kept in constant rotation at a low 
speed to create a low fluid-shear simulated microgravity environment that 
prevents cell detachment and sedimentation. Attached cells grow and form 
cell-cell junctions creating large aggregates consisting of multiple 
microcarrier beads. Cells also polarize as they develop and express many 
characteristics of the parental tissue. Inserts at right show scanning 
electron micrographs (SEM) depicting representative 3-D aggregates of 
cells representing cervical, lung, neuronal, placental and vaginal tissues. 
The cervical tissue SEM is modified from Radtke et al. (Dill et al. 2012) 
with permission. The lung tissue SEM is taken from NASA/TP-2012-
217363, Paramyxovirus infection mimics in vivo cellular dynamics in 3-D 
human broncho-epitlial tissue-like assemblies, and used with permission 
from NASA (Goodwin et al. 2012). The neuronal tissue SEM is modified 
from Goodwin et al. (Goodwin et al. 2013) with permission. The placental 
tissue SEM is modified from McConkey et al. (McConkey et al. 2016) 
with permission. This work is licensed under CC BY-NC 
(http://creativecommons.org/licenses/by-nc/4.0/). The vaginal tissue SEM 
is modified from Hjelm et al. (Hjelm et al. 2010) with permission.  
 
 
To date, a wide variety of cell lines and tissues have been successfully cultured and 
reproduced in the RWV bioreactor. The purpose of this review is to highlight those RWV 
bioreactor studies that focus on modeling virus-host interactions in various tissue settings 
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(Table 3). Additionally, we discuss methodological advancements and future 
applications of these reproducible and robust RWV bioreactor-derived models for the 
continued study of virus-host interactions and maximizing their translational utility. 
 
Virus infection and replication in 3-D bioreactor models 
Barrier features, including tight junctions, mucus secretion and microvilli, are not 
often present in cells grown in conventional monolayer cell culture and influence virus-
host interactions (Lee and Luk 2010, Torres-Flores and Arias 2015). Tight junctional 
proteins are receptors for several viruses like hepatitis C virus and adenovirus, and their 
expression in 3-D cell culture can enhance viral attachment and entry (Torres-Flores and 
Arias). The presence of tight junction proteins, mucus and other barrier features can also 
increase resistance to viral infections and more accurately represent in vivo virus-host 
interactions. Our studies, along with those from other researchers, have found that cells 
grown in the RWV bioreactor are more resistant to infection, requiring a higher virus 
multiplicity of infection to productively infect 3-D aggregates when compared to 
conventional monolayer cell culture (Molina-Jimenez et al. 2012, Murakami et al. 2006, 
Radtke et al. 2012). Likewise, cells grown in the RWV bioreactor show increased 
resistance to bacterial infection and infected 3-D cell cultures display decreased bacterial 
replication when compared to infections in conventional monolayer cell culture (David, 
Sayer, and Sarkar-Tyson 2014, McGowin et al. 2013, Nickerson et al. 2001, Radtke et al. 
2012). A study of four veterinary viruses in 3-D RWV bioreactor-derived aggregates 
further supported these findings by directly comparing replication of the viruses in 
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conventional monolayer cell cultures vs. 3-D aggregates. Three-dimensional monkey 
kidney epithelial cell (VERO) aggregates and 3-D bovine kidney epithelial cell (MDBK) 
aggregates were infected with two DNA viruses (suid herpesvirus 1 and bovine 
adenovirus) and two RNA viruses (vesicular stomatitis virus and bovine parainfluenza 
virus). Infections with all four viruses in the 3-D aggregates produced a lower viral titer 
over the course of infection compared to conventional monolayer cell cultures 
(Malenovska 2016). However, despite being more resistant to infection, more infectious 
virions were produced in 3-D aggregates while conventional monolayer cell culture 
produced more noninfectious virions (Malenovska 2016). These findings allow the 
speculation that the increased resistance to infection is due to the barrier features that 
polarized 3-D aggregates exhibit when grown in the RWV bioreactor. The increased 
infectivity of the virions produced is also noteworthy and suggests again that the 3-D 
aggregates better mimic the in vivo environment. For these and other reasons, we argue 
herein that the 3-D cellular aggregates grown in the RWV bioreactor provide a more in 
vivo-like simulation of parental tissues and their susceptibility to virus entry, replication 
and subsequent pathogenesis support their utilization for the study of these processes in 
vitro.  
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Table 3. 
Host-virus interactions in RWV bioreactor-derived 3-D aggregates 
Tissue 
Model Cell Lines  Virus  Virus Replication Host Response Reference 
Neuronal NHNP VZV Productive infection No CPE (Goodwin et al. 2013) 
Tonsil Primary cells HIV Productive infection Lymphocyte migration tracked 
(Margolis et al. 
1997) 
Lymphoid 
P3HR-1 EBV Suppression of EBV reactivation ND 
(Long, Pierson, 
and Hughes 1999) 
P3HR-1 
Daudi 
Ramos 
EBV Suppression of EBV reactivation ND 
(Long and Hughes 
2001) 
BJAB 
Raji EBV 
Suppression of EBV 
reactivation 
Microgravity and radiation 
increased DNA damage in EBV 
positive cells  
(Brinley et al. 
2013) 
Lung 
HBTC 
BEAS-2B 
SARS-
CoV 
No SARS-CoV 
replication detected 
Vacuolization, mitochondria loss 
and chromatin alterations 
(Suderman et al. 
2006) 
HBTC 
BEAS-2B RSV Productive infection 
Signs of cellular damage. Mucus 
produced in 3-D aggregates 
(Goodwin et al. 
2008) 
HBTC 
BEAS-2B 
RSV & 
PIV3 Productive infection 
Cytokine profile in 3-D 
aggregates was similar to human 
airways from RSV and PIV3 
infected patients 
(Goodwin et al. 
2012) 
Liver Huh7 HCV Productive infection 
Expression and localization of 
TJ proteins enhance HCV 
infection 
(Sainz, TenCate, 
and Uprichard 
2009) 
PLC/PRF/5 HEV Productive infection No CPE (Berto et al. 2013) 
Small 
Intestine INT-407 HuNoV 
Increase in viral RNA 
copies detected 
Vacuolization, shortening of 
apical microvilli, cell 
detachment from bead 
(Straub et al. 2007) 
No HuNoV replication 
detected 
Clumping and detachment of 
cells from microcarrier beads 
(Herbst-Kralovetz 
et al. 2013) 
No HuNoV replication 
detected No CPE 
(Papafragkou et al. 
2014, Takanashi et 
al. 2014) 
Colon Caco-2 
HuNoV 
Increase in HuNoV 
RNA copies detected 
Shortening of apical microvilli 
and formation of vacuoles (Straub et al. 2011) 
No HuNoV replication 
detected No CPE 
(Papafragkou et al. 
2014, Takanashi et 
al. 2014) 
CVB Productive infection 
Increased expression of 
proliferation and differentiation 
genes  
(Drummond, 
Nickerson, and 
Coyne 2016) 
Placenta 
TBPC HCMV Productive infection ND (Swan et al. 2015) 
JEG-3 VSV No VSV replication detected 
Resistance to infection mimics 
in vivo response to infection 
(McConkey et al. 
2016) 
Vagina V19I HSV-1 HSV-2 Productive infection 
Mucosal epithelial barrier 
features mimic in vivo 
characteristics, aggregates are 
more resistant to HSV infection 
(Dill et al. 2012, 
Gardner, Winkle, 
and Herbst-
Kralovetz) 
CPE, cytopathic effects; ND, not determined 
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Three-dimensional models of human neuronal cells to study persistent viral 
infections 
Varicella zoster virus (VZV) is an alphaherpesvirus that belongs to the 
Herpesviridae family that establishes a latent infection in ganglionic neurons following 
an initial phase of acute infection. The virus will often reactivate in later years, causing 
zoster, a localized dermatomal rash and also neurologic diseases including 
meningoencephalitis and myelopathy. Over 90% of the worldwide population is 
seropositive, and, although a vaccine has been developed and is currently available, there 
remains a risk of virus reactivation (LaRussa et al. 2000, Virgin, Wherry, and Ahmed 
2009). A lack of animal models and limited availability of VZV-free human ganglionic 
neurons has limited study of the virus. Recently, normal human neuronal progenitor 
(NHNP) cells have been utilized to study VZV infection and latency. When NHNP cells 
are cultured in the RWV bioreactor they become partially differentiated, leading to the 
formation of 3-D aggregates that display features observed in human trigeminal ganglia 
(Goodwin et al. 2013). These 3-D aggregates express mature neuronal markers such as 
glial fibrary acidic protein, neuron-specific nuclear protein, b-tubulin III and microtubule 
associated protein A&B after 180 days in culture (Goodwin et al. 2013). Three-
dimensional NHNP aggregates also express additional neuronal markers (nestin and 
tubulin) at levels similar to those seen in human trigeminal ganglia, however, late stage 
neuronal development markers CD105, CD90 and CD49f, are expressed at lower levels 
(Goodwin et al. 2013).  
Three-dimensional NHNP aggregates support persistent VZV infections with 
limited or little lytic replication, and sporadic reactivation at later time points (Goodwin 
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et al. 2013). NHNP cellular aggregates infected with fluorescently labeled VZV in the 
bioreactor showed a significant increase of VZV genome copies over an 18-day period, 
yet aggregates remained viable in culture over a three-month course of infection 
(Goodwin et al. 2013). The VZV genome was able to stably replicate and infectious virus 
progeny was detected in the cell culture supernatant intermittently throughout the course 
of infection (Goodwin et al. 2013). The maintenance of viable 3-D aggregates over a 
three-month course of infection, while not exactly modeling in vivo infections, does allow 
for the study of persistent VZV infections over an extended period of time. Prolonged 
studies of VZV infections enable researchers to identify key interactions that may 
influence virus gene expression, replication and potentially establishment of latency. 
Prior to the development of the 3-D NHNP aggregates, many other cell lines had been 
utilized to study VZV infection, including human neuroblastoma (IMR-32), monkey 
kidney epithelial (VERO), primary human foreskin fibroblasts (HFF), human melanoma 
(MeWo) and peripheral blood mononuclear cells (PBMC). In these cell lines, however, 
VZV infections are lytic and preclude prolonged culturing and the study of VZV latency 
and reactivation cycles (Bourdon-Wouters et al. 1990, Brazeau et al. 2010, Goodwin et 
al. 2013, Hood et al. 2003, König et al. 2003). It should be noted that a non-lytic VZV 
infection was achieved with differentiated human neural stem cells (NSC); however, 
these infections were nonproductive (Pugazhenthi et al. 2011). Despite its limitations, the 
development of 3-D NHNP aggregates grown in the RWV bioreactor represents a step 
forward in the study of VZV virus-host interactions. Further development of 3-D 
aggregates to model virus latency and reactivation can provide new insights into 
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mechanisms of VZV pathogenesis, and could potentially be utilized in the study of other 
neurotropic viruses, such as other herpesviruses.  
 
Three-dimensional models of lymphoid tissue and circulating lymphocytes for long-
term culture to study virus replication, latency and reactivation 
One of the first viruses studied utilizing the RWV bioreactor developed by NASA 
was Epstein-Barr Virus (EBV) (Table 3). EBV is a member of the Herpesviridae family 
and approximately 90% of adults are seropositive for the virus (Cohen 2000). The virus 
infects epithelial cells and B lymphocytes and establishes latency in resting memory B 
cells (Babcock et al. 1998). In humans, B cells circulate through the periphery, often in a 
quasi-gravity state where gene expression and cell metabolism may be different from that 
observed in conventional monolayer cell culture (Long, Pierson, and Hughes 1999). 
Simulated microgravity has been shown to alter the gene expression, proliferation and 
cellular interactions of non-adherent cells compared to when they are cultured in non-
rotating, static environments (Bechler et al. 1992, Cogoli and Cogoli-Greuter 1997). As 
already noted, the RWV bioreactor provides a simulated microgravity environment to 
reproduce conditions in circulation, and is therefore ideally suited for the in vitro study of 
EBV-infected B cells. P3HR-1, Daudi and Ramos B-cell lines have been cultured in the 
RWV bioreactor to study factors influencing EBV latency and reactivation (Brinley et al. 
2013, Long and Hughes 2001, Long, Pierson, and Hughes 1999). Indirect 
immunofluorescence assays showed that EBV-positive P3HR-1 and Daudi cells cultured 
in RWV bioreactors displayed significantly lower expression levels of lytic cycle proteins 
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compared to cells grown in conventional monolayer cell culture, suggesting that EBV 
reactivation is suppressed in microgravity environments (Long, Pierson, and Hughes 
1999). 
Human Immunodeficiency Virus (HIV) is a member of the Retroviridae family, 
that also infects lymphoid tissue and circulating lymphocytes. In addition to the 
formation of 3-D aggregates from cells grown in conventional monolayer cultures, the 
RWV bioreactor can be utilized for culturing tissue blocks in the simulated microgravity 
environment, thereby maintaining their in vivo cellular organization and structure while 
allowing for the delivery of nutrients (Margolis et al. 1997). Margolis et al. inserted 
blocks of human tonsil tissue into the RWV bioreactor, and cultured these blocks with 
additional cells from the same tonsil. These cultures were not only viable for up to three 
weeks, but also contained lymphocytes that migrated throughout the tissue and cell 
culture media. Infection of these cultures with HIV-1 isolates was productive, with 
exponential viral replication during the first week of infection (Margolis et al. 1997). In 
situ hybridization for HIV RNA confirmed a productive infection, with 1-3% of the cells 
in the tissue blocks becoming infected (Margolis et al. 1997). Flow cytometry 
demonstrated a decrease in CD4+ cells over the course of the infection, confirming the 
productive infection of CD4+ T cells (Margolis et al. 1997). Additionally, transfer of 
HIV-positive tissue blocks to RWV bioreactors containing HIV-negative tissue blocks 
led to the infection of the HIV-negative tissue blocks, and virus was detected in the cell 
culture supernatant (Margolis et al. 1997). Culturing tissue blocks in the RWV bioreactor 
thus creates an in vitro model system that could provide new insights into HIV infections 
and virus interactions with lymphoid tissue. 
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Three-dimensional models for respiratory viral infections 
The respiratory epithelium forms a robust barrier to prevent infection. Tight 
junctions, cilia, and mucus secretion are some of the important features of this barrier. 
Conventional cell culture techniques are often used for the study of respiratory viruses, 
but lack many of the important features of the intact human respiratory epithelium like 
mucus, microvilli and cell-cell junction proteins. Cultures of 3-D respiratory epithelial 
cell aggregates have therefore been applied to the study of the host immune response to 
bacterial infections in the lungs, and can be effective models for studying emerging 
respiratory viruses and difficult-to-propagate viruses that previously lacked a robust 
model for study (David, Sayer, and Sarkar-Tyson 2014). 
Two widely prevalent paramyxoviruses, parainfluenza virus type 3 (PIV3) and 
respiratory syncytial virus (RSV) cause severe respiratory disease in young children. 
Both of these viruses have proven to be difficult to propagate in conventional cultures 
and also lack robust animal models that accurately model viral infection, pathogenesis 
and the host immune response (Bem, Domachowske, and Rosenberg 2011). Recently, it 
has been shown that immortalized human broncho-tracheal epithelial (BEAS-2B) cells 
and primary normal human bronchial epithelial (NHBE) cells grown as 3-D aggregates in 
the RWV bioreactor are permissive to RSV and PIV3 infection (Table 1). Transmission 
electron microscopy further demonstrated that the aggregates grow in a multi-layered 
structure that exhibits tight junctions and microvilli, thus displaying key features of the in 
vivo tissue (Goodwin et al. 2008). These respiratory 3-D aggregates have been cultured 
for more than 35 days while maintaining functional cell markers and, when challenged 
with RSV, display cellular damage and active viral infections, including budding virions 
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(Goodwin et al. 2008). Cytokine profiles from the RSV-infected and PIV3-infected 3-D 
lung epithelial aggregates demonstrated an induction of pro-inflammatory cytokines, 
chemokines and other immune factors including IL-1b, IL-8, MIP-1a, RANTES and G-
CSF at levels that were similar to those observed in nasal washes from children with RSV 
and PIV3 infections (Goodwin et al. 2012). In contrast, cytokine profiles from 
conventional monolayers infected with RSV and PIV3 were not similar to the levels 
observed clinically. Taken together, these data support the utilization of 3-D aggregates 
as models of in vivo RSV and PIV3 infections with regard to the function of epithelial 
cells in host response and barrier defense to these viruses (Goodwin et al. 2012).  
Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) is an emerging 
virus first identified in China in 2002 (Zhao et al. 2003). Animal models for SARS-CoV 
have been developed, although there currently are no FDA-approved vaccines or 
antivirals available (Gretebeck and Subbarao 2015). Initial experiments with SARS-CoV 
suggest that 3-D human broncho-tracheal epithelial (BEAS-2B) aggregates provide a 
more physiologically relevant and species-specific model that may be more permissive to 
viral infection by SARS-CoV and potentially other emerging human viruses (Table 1). 
Characterization of the 3-D aggregates has revealed cellular differentiation and increased 
expression of collagen IV, MUC1 and tight junction protein ZO-1 at levels similar to in 
vivo human tissue (Suderman et al. 2006). Infectious virions were not detected in cell 
culture supernatants by standard plaque assay when the 3-D aggregates were infected 
with SARS-CoV; however, immunocytochemistry illustrated cross-reactivity with 
antibodies to viral spike and nuclear proteins at the cytoplasm and plasma membrane in 
SARS-CoV infected aggregates (Suderman et al. 2006). Cytoplasmic vacuoles also 
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increased over the course of the infection, mitochrondria became swollen and decreased 
in number, and endoplasmic reticula were disrupted, all clear signs of viral infection 
(Suderman et al. 2006). At 10 days post infection (dPI), cells began shedding off the 
microcarrier beads, but, again, no budding virions were observed at any time during the 
course of infection (Suderman et al. 2006). Nevertheless, the positive 
immunocytochemistry and the visualization of cytoplasmic vacuoles appear to confirm a 
permissive SARS-CoV infection of the 3-D aggregates, suggesting that these cultures 
could provide useful information about SARS-CoV infection and pathogenesis, and 
contribute to the development novel interventions even in the absence of virion 
formation. These initial studies with 3-D respiratory aggregates are encouraging and 
could be applied to other newly emerging respiratory viruses such as Middle East 
Respiratory Syndrome coronavirus (MERS-CoV).  
 
Three-dimensional models for studying viral gastroenteritis 
Over 200,000 children under the age of five die from human norovirus (HuNoV) 
infections, with norovirus infection representing the second leading cause of diarrheal 
death in this age group (Lopman et al. 2016, Patel et al. 2008, Scallan et al. 2011). An 
effective cell culture model for modeling HuNoV infections and interactions with 
intestinal epithelial cells has been elusive, slowing the development of urgently needed 
interventions for this deadly illness (Riddle and Walker 2016).  
Early studies investigated over 27 cell lines and approximately 33 different 
HuNoV strains for propagation of the virus using in vitro monolayers and were 
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unsuccessful (Duizer et al. 2004). It was hypothesized that 3-D structures or other co-
factors may be required for successful cultivation of HuNoV in vitro. Human small 
intestine (INT-407) epithelial cells were initially grown in the RWV bioreactor with 
collagen coated beads to form 3-D aggregates to study HuNoV (Table 1) (Herbst-
Kralovetz et al. 2013, Straub et al. 2011, Straub et al. 2007, Takanashi et al. 2014). INT-
407 epithelial aggregates have been shown to differentiate, and subsequently stain 
positive for tight junction markers occludin, claudin-1, E-cadherin and ZO-1 by 
immunofluorescence (Straub et al. 2007). The 3-D aggregates possess apical microvilli, 
though these microvilli are shorter than those on in vivo human intestinal epithelial cells 
(Takanashi et al. 2014). Three-dimensional aggregates developed from an alternate cell 
line, Caco-2 colon carcinoma, also express tight junction markers ZO-1 and occludin, and 
apical microvilli on these aggregates were more similar to the human intestinal 
epithelium in vivo (Drummond, Nickerson, and Coyne 2016, Straub et al. 2011, 
Takanashi et al. 2014). The 3-D Caco-2 aggregates also displayed increased expression of 
MUC1, MUC13 and MUC17, which are highly expressed mucins in the intestine that 
could potentially influence virus-host interactions (Drummond, Nickerson, and Coyne 
2016). Both 3-D Caco-2 and INT-407 aggregates also expressed histo-blood group 
antigens (HBGA) H1 and H2, cellular receptors for HuNoVs (Herbst-Kralovetz et al. 
2013, Hutson et al. 2003, Takanashi et al. 2014). INT-407 and Caco-2 aggregates were 
challenged with HuNoV, and harvested for viral RNA titers as measured by RT-PCR. 
Straub et al. reported successful HuNoV infection and detected viral replication in 3-D 
INT-407 and 3-D Caco-2 aggregates, however, these results have not been able to be 
replicated in either 3-D INT-407 or 3-D Caco-2 intestinal epithelial models (Herbst-
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Kralovetz et al. 2013, Papafragkou et al. 2014, Takanashi et al. 2014). Additionally, the 
INT-407 cell line has been reported to be contaminated with HeLa cells, and therefore 
could explain why these studies of HuNoV cannot be replicated and is not a robust or 
reproducible model for the study of HuNoV-host interactions (Lavappa 1978, Nelson-
Rees, Daniels, and Flandermeyer 1981). 
Recent advances in the culture of HuNoV demonstrated the need for additional 
factors including gut bacteria and/or bile for successful HuNoV replication. Bacteria from 
the gut have been shown to express HBGA and facilitate HuNoV infection of human B 
cells (Jones et al. 2014). Additionally, it has been shown that intestinal milieu, including 
bile, are important factors that enhance HuNoV replication in human intestinal enteroids 
(Ettayebi et al. 2016).  
Although 3-D Caco-2 aggregates alone do not support productive HuNoV 
infection, they possess in vivo-like properties that can aid researchers in understanding 
the interactions between intestinal epithelial cells and other gastrointestinal viruses like 
coxsackievirus B (CVB). Currently there is no vaccine for CVB, and CVB infections 
cause mild gastroenteritis, myocarditis and persistent infections have been linked to type 
1 diabetes development (Hober and Sane 2010, Hober and Sauter 2010). Three-
dimensional Caco-2 aggregates have supported productive CVB infection, and produce 
more infectious virions than infections in conventional monolayer cell culture (Table 1) 
(Drummond, Nickerson, and Coyne 2016). Further study of CVB and other enteric 
viruses in 3-D colonic epithelial aggregates promises new insights into the factors 
influencing viral entry and host-virus interactions. 
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Three-dimensional models of liver tissue for studying hepatitis viral infections 
Two hepatotropic viruses, Hepatitis C Virus (HCV) and Hepatitis E Virus (HEV) 
have proven difficult to propagate in vitro and only in recent years have researchers been 
able to study these viruses in conventional cell culture.  
HEV is a member of the Hepeviridae family and causes acute liver disease in 
humans. Transmission of certain HEV genotypes can be zoonotic (from pigs), and affects 
much of the developing world, especially East and South Asia (179). Human cell culture 
models for HEV include PLC/PRF/5 hepatocarcinoma cells grown in conventional 
monolayer cell culture, which have inconsistently supported viral replication (Berto et al. 
2013). PLC/PRF/5 have been grown in the RWV bioreactor, where they form aggregates 
that also support viral replication (Table 1) (Berto et al. 2013, Takahashi et al. 2007, 
Tanaka et al. 2007). The 3-D aggregates become fully differentiated after a 28-day 
culture period, and are viable in culture for over five months (Berto et al. 2013). HEV 
RNA has been detected in supernatants from RWV cultures at the majority of collection 
points over a 175-day period (Berto et al. 2013). In contrast, PLC/PRF/5 cells grown in 
conventional monolayer cell cultures contain no HEV RNA in the supernatants (Berto et 
al. 2013). Scanning electron microscope (SEM) micrographs of RWV bioreactor 
supernatants demonstrate virions, and subsequent experiments showed that these virions 
are infective, confirming a productive infection (Berto et al. 2013). Taken together, these 
data support the use of the RWV bioreactor to study the virus-host interactions that 
influence HEV infectivity and transmission in a culture system that closely resembles in 
vivo liver tissue.  
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HCV is a member of the Flaviviridae family and has chronically infected over 
185 million people worldwide (Mohd Hanafiah et al. 2013). Despite this massive 
prevalence, the lack of model systems for HCV has limited researchers’ ability to study 
virus-host interactions in vitro. Conventional monolayer cell cultures of Huh7 human 
hepatoma epithelial-like cells are permissive to HCV infection, but have decreased 
expression of cellular features including occludin and claudin-1, which are known to 
impact viral uptake (Table 1) (Sainz, TenCate, and Uprichard 2009). Three-dimensional 
Huh7 aggregates, in contrast, provide a more physiologically relevant system that is 
highly permissive to HCV infection. Light micrographs have shown that fully 
differentiated aggregates are multilayered, and RT-PCR of cellular RNA showed 
increased expression of hepatocyte nuclear factors that regulate hepatocyte differentiation 
(Sainz, TenCate, and Uprichard 2009). In addition, aggregates stained positive for tight 
junction proteins (occludin-1 and E-cadherin), cell adhesion proteins and HCV receptor 
(CD81 and SR-B1) by immunofluorescence (Sainz, TenCate, and Uprichard 2009). This 
degree of differentiation and polarization of Huh7 cells allows for studies of interactions 
between HCV and barrier proteins regulating viral entry that was previously impossible 
in conventional monolayer cell culture. Three-dimensional Huh7 liver aggregates have 
been productively infected with HCV, and viral RNA was detected in aggregates 
throughout a two-week period of infection (Sainz, TenCate, and Uprichard 2009). 
Infection of the Huh7 aggregates was further confirmed through immunofluorescence at 
days 1, 7 and 14 post infection (Sainz, TenCate, and Uprichard 2009). Cellular 
differentiation of the 3-D aggregates and the increased expression of tight junction 
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proteins enables the study of these difficult-to-propagate viruses, and could be utilized in 
the study of other hepatotropic viruses. 
 
Three-dimensional models of female reproductive tract tissues for studying sexually 
transmitted infections and emerging viruses 
The female reproductive tract (FRT) is divided into the upper tract, consisting of 
the endocervix, uterus, placenta, fallopian tubes and ovaries, a transitional ectocervix 
zone, and the lower tract, consisting of the vagina and vulva (Quayle 2002). The FRT is 
exposed to a myriad of microbes including sexually transmitted pathogens, many of 
which are able to establish chronic infections that are difficult to clear and can cause 
long-term reproductive and gynecologic sequelae. However, site-specific differences in 
the epithelial structure between the upper and lower genital tract necessitate the need to 
model these different tissues for the study of sexually transmitted infections (STI) and 
other viruses. Our laboratory was the first to develop and characterize 3-D models of 
human cervical and vaginal tissue using the RWV bioreactor (Hjelm et al. 2010, Radtke 
et al. 2012). Human models of the upper FRT, including the endometrium, have also 
recently been developed and characterized in our laboratory (Laniewski et al. 2017). In 
addition, human placental models have been successfully created and used to model 
microbial resistance at this site (LaMarca et al. 2005, McConkey et al. 2016, Swan et al. 
2015, Zwezdaryk et al. 2012).  
Human vaginal epithelial (V19I) cells cultured in the RWV bioreactor develop in 
vivo-like properties that are not present when cells are grown in conventional monolayer 
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cell cultures (Hjelm et al. 2010). Scanning and transmission electron microscopy of 3-D 
vaginal aggregates has demonstrated the presence of tight junctions/desmosomes, 
microridges, microvilli and mucus secretion, all of which influence viral interactions with 
host epithelial cells (Fig. 4) (Hjelm et al. 2010, Radtke et al. 2012). The 3-D aggregates 
can be used to test vaginal microbicides and recapitulated toxicity and host cytokine 
responses similar to human explant tissue thereby demonstrating the translational 
capability of this model (Hjelm et al. 2010). Three-dimensional cervical and vaginal 
aggregates exposed to microbial products including poly(I:C) (a viral mimic and toll-like 
receptor 3 agonist) exhibit induction of acute-phase and pro-inflammatory cytokines and 
mucus secretion, similar to primary human cells and have been used to model the host 
immune response to viral infections (Gardner, Winkle, and Herbst-Kralovetz , Radtke 
and Herbst-Kralovetz 2012, Winkle, Throop, and Herbst-Kralovetz 2016). 
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Figure 4. Example of physiological features of RWV bioreactor-
derived human 3-D vaginal aggregates. A) Phase micrograph of 3-D 
vaginal epithelial cell aggregates consisting of multiple microcarrier beads 
connected by cell-cell junctions at an early stage of development. B) 
Immunofluorescence of 3-D aggregates by laser scanning confocal 
microscopy demonstrating localized mucus secretion modified from 
Hjelm et al. (Hjelm et al. 2010) with permission. Nuclei are stained with 
DAPI (blue), actin filaments are stained with Phalloidin (red) and MUC1 
is stained with FITC (green). C) Transmission electron microscope (TEM) 
image of 3-D vaginal aggregates showing microvilli (MV) modified from 
Hjelm et al. (Hjelm et al. 2010) with permission. D) TEM micrograph 
depicting desmosomes (D) at cell-cell junctions between vaginal epithelial 
cells. E) Scanning electron microscope (SEM) image showing formation 
of microridges (MR) at cell-cell junctions during late-stage development 
of 3-D aggregates. F) Production of secretory material (S) by vaginal 3-D 
aggregates as shown by SEM. 
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Herpes simplex virus type 2 (HSV-2) is the leading cause of genital herpes 
infections and causes persistent, life-long infections that increase risk for STI and human 
immunodeficiency virus (HIV) acquisition (Garland and Steben 2014). Although antiviral 
drugs are available, viral reactivation and shedding can occur in many who are 
asymptomatic and an effective vaccine remains elusive (Wald et al. 2000b). Vaginal and 
cervical epithelial aggregates are susceptible to FRT pathogens, including HSV-2 as 
shown by immunofluorescence and standard VERO plaque assay (Table 3) (Gardner, 
Winkle, and Herbst-Kralovetz , Radtke and Herbst-Kralovetz 2012). As mentioned 
previously, a higher MOI is required to infect 3-D vaginal or cervical aggregates relative 
to conventional monolayers, most likely due to enhanced epithelial barrier features 
(Gardner, Winkle, and Herbst-Kralovetz). HSV-2 infections of 3-D vaginal aggregates 
induce secretion of cytokines, chemokines, mucus and anti-microbial products (AMP), 
and may provide a more accurate host immune response relative to conventional 
monolayers (Gardner, Winkle, and Herbst-Kralovetz , Radtke and Herbst-Kralovetz 
2012). More recently, our laboratory has reported that exposure of 3-D human vaginal 
and cervical aggregates to microbial products, including poly(I:C), induces expression of 
a novel pro-inflammatory cytokine, IL-36g (Winkle, Throop, and Herbst-Kralovetz 
2016). While this cytokine has been identified at other mucosal sites, this was the first 
report of this cytokine in the FRT and was validated with human tissue (Gabay and 
Towne 2015, Gresnigt and van de Veerdonk 2013, Winkle, Throop, and Herbst-
Kralovetz 2016). We hypothesize it may play a key role in mucosal host defense at this 
site. Collectively, these physiologically relevant features support the use of 3-D FRT 
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aggregates from RWV bioreactors to study host immune mechanisms to other viral STI, 
including HIV and human papillomavirus. 
The placenta is an important site for exchange of nutrients and gasses during 
pregnancy, and virus-host interactions at the placenta have significant health implications 
for both mother and developing fetus. Human choriocarcinoma trophoblast cells (using 
the JEG-3 cell line) have been shown to produce 3-D aggregates in the RWV bioreactor 
when the cells are co-cultured with placental microvascular cells (McConkey et al. 2016). 
The JEG-3/microvascular aggregates form over a 21-day period and display increased 
expression of placental differentiation markers including human chorionic gonadotropin 
beta subunit (bhcg), human placental lactogen (hPL) and syncytian (McConkey et al. 
2016). Transcriptome profiles of the 3-D aggregates were significantly different from 
profiles of cells grown in conventional monolayer, and were more similar to profiles from 
primary human trophoblasts (McConkey et al. 2016). The 3-D aggregates also form 
syncytia and brush borders that are additional markers of cellular differentiation and that 
are not observed in conventional monolayer cell culture (McConkey et al. 2016). The 
syncytia and brush borders present in the 3-D aggregates provide resistance to vesicular 
stomatitis virus (VSV) infection, whereas cells in conventional monolayers remain 
susceptible to VSV infection as shown by RT-PCR (McConkey et al. 2016). These 
results support the protective nature of placental trophoblasts (both in vivo and in 3-D 
aggregates) against VSV infection. This 3-D placenta model may also be useful for 
studying the interactions between emerging viruses, including the Zika virus and its 
severe effects in pregnancy (e.g. irreversible microcephaly) observed in newborn babies 
from Zika-infected mothers (Johansson et al. 2016). 
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Future directions for RWV bioreactors 
Considering the site-specific microbiome for advancement of RWV-derived tissue 
models 
Recent research has implicated virus-host-microbiome interactions in the 
processes of viral entry, pathogenesis and the host immune response (Berkhout 2015, 
Bosch et al. 2013, Lynch 2014, Miura et al. 2013, Pfeiffer and Virgin 2016, Robinson 
and Pfeiffer 2014). For example, in the FRT commensal microbiota play a key role in 
maintaining a healthy, homeostatic microenvironment, and disruption of this microbiota 
increases risk for STI acquisition. Our laboratory has successfully modeled commensal 
and bacterial vaginosis-associated bacteria from the vaginal microbiome using 3-D 
RWV-derived vaginal aggregates (Doerflinger, Throop, and Herbst-Kralovetz 2014, 
Herbst-Kralovetz et al. 2016). Virus-microbiome interactions can also be studied using 
other mucosal models (e.g. lung and intestinal models), and site-specific microbiota 
should be included in future tissue modeling of mucosal sites (Doerflinger, Throop, and 
Herbst-Kralovetz 2014). Use of clinical samples or isolates may be required to 
recapitulate the microbial milieu at these sites. Culturing of 3-D aggregates with site-
specific microbiota in the context of viral infection could provide novel insights into 
virus-host and virus-microbiome mechanisms. 
 
Advancing RWV bioreactor tissue models with enhanced cellular complexity 
Human tissues are complex multi-cellular microenvironments, and interactions 
between different cell types in a tissue will influence host immune mechanisms. Co-
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culturing with lymphocytes and other immune cells increases the complexity of the 
tissues that can be modeled in the RWV bioreactor and can more faithfully recapitulate 
the host immune response, however it is challenging to create autologous environments 
with limited availability and lifespan of primary cell lines and optimization of diverse 
culture requirements. Application of stem cells and stromal cells to the RWV bioreactor 
may further enhance tissue complexity of the 3-D aggregates. For example, neural stem 
cells and neural progenitor cells are able to differentiate and develop into neurons and 
glia when grown in the RWV bioreactor (Lin et al. 2004, Luo et al. 2015, Ma et al. 2004). 
Other examples include embryonic stem cells, pluripotent stem cells and mesenchymal 
stem cells, all which have been successfully propagated in RWV bioreactors and could 
advance RWV bioreactor-derived models (Cerwinka et al. 2012, Luo et al. 2015, 
Rungarunlert, Ferreira, and Dinnyes 2016, Teo et al. 2014, Vidyasekar et al. 2016). The 
increasing utilization of RWV bioreactors for cell lines from a wide variety of tissues 
holds the promise of enhancing our ability to study emerging viruses that have drastic 
public health implications. New therapeutic agents and antiviral drugs can also be 
screened for toxicity and efficacy using 3-D human aggregates to give a more faithful 
representation of in vivo microenvironments and provide superior preclinical data prior to 
advancing to clinical trials. Although challenging, advancing RWV bioreactor model 
systems to reproduce these complex in vivo cell-cell interactions could improve the 
translational impact of these robust 3-D models in elucidating key virus-host interactions. 
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Conclusions  
In this review, we have highlighted studies using 3-D RWV-derived models to 
investigate virus-host interactions (Table 3). Three-dimensional RWV bioreactor-derived 
aggregates express cellular architectural and structural features not readily expressed in 
conventional monolayer cell culture, including tight junction proteins, mucus and 
microvilli, that are important for analysis of virus-host interactions. Fully differentiated 
aggregates can be further utilized in highly reproducible downstream gene expression 
analyses, high throughput and “omics” analyses, microscopy, toxicology/drug 
development and gene editing studies. In conclusion, RWV-derived 3-D models can be 
employed to better understand the key interactions that influence viral pathogenesis and 
the host immune response to viral infection in a physiologically meaningful context that 
enhance their translational utility.  
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CHAPTER 3: HORMONAL REGULATION OF IL-36g AND HOST DEFENSE 
MECHANISMS IN THE FEMALE REPRODUCTIVE TRACT 
 
Abstract 
 The gonadal steroids estrogen and progesterone (commonly referred to as sex 
hormones) exhibit essential functions in the female reproductive tract (FRT), and levels 
of these hormones fluctuate through menstrual cycle. Recently, the commonly-used 
contraceptive Depo Provera (DMPA), a synthetic progestin, has been linked to an 
increased risk for sexually transmitted infection acquisition among high-risk women. 
While many factors may contribute to this increased risk for infection, we sought to 
evaluate the impact of estrogen and progesterone on epithelial barrier feature and immune 
mediators, including the IL-36 family members. We found that relative to estrogen 
conditioned mice, DMPA conditioned mice exhibited significantly reduced expression of 
desmocollin and desmoglein, two key components of desmosomes. We further measured 
the expression of several immune mediators, including IL-36b and IL-36g, and found that 
they were reduced in DMPA conditioned mice relative to estrogen conditioned mice. 
Additionally, we measured site specific differences in expression of these key barrier 
features and immune mediators, with elevated expression in the lower FRT relative to the 
upper FRT. Together, these data indicate that the sex hormones estrogen and 
progesterone regulate factors influencing host defense in the FRT, and the hormonal 
regulation of the IL-36 cytokines may ultimately impact susceptibility to infection.  
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Introduction 
Epithelial cells (EC) function as a first line of defense against pathogens at 
mucosal sites, forming a physical barrier to infection and contributing to the secreted 
chemical barrier to protect against pathogens. The formation of tight junctions, adherens 
junctions, and desmosomes that join EC together and form a physical barrier that 
excludes the transmigration of pathogens across the epithelium. In the lower FRT, 
vaginal EC form a stratified squamous epithelium, whereas in the upper FRT, 
endometrial and endocervical EC form a columnar epithelium (Wira, Grant-Tschudy, and 
Crane-Godreau 2005). ECs additionally contribute to the chemical barrier to infection 
through the secretion of cytokines, chemokines, and antimicrobial peptides as pattern 
recognition receptors on the EC plasma member detect pathogen signatures and initiate 
immune signaling in response to these invaders (Kaushic, Grant, et al. 2000, Kaushic, 
Zhou, et al. 2000, Robertson, Mayrhofer, and Seamark 1996, Wira, Grant-Tschudy, and 
Crane-Godreau 2005). These FRT EC barriers are crucial in the maintenance of 
homeostasis and are regulated in part by the gonadal steroids, estrogen and progesterone, 
that fluctuate throughout the different stages of the menstrual cycle (Pessina et al. 2006).  
Parr and Parr were the first to show that mice treated with Depo Provera, the 
widely-used synthetic progestin contraceptive, were susceptible to genital HSV-2 
infection, although the mechanisms by which DMPA increased susceptibility to infection 
were not well understood at the time (Parr et al. 1994). The researchers initially 
hypothesized that the thinned epithelium and increased epithelial permeability in a 
progesterone-dominant environment may increase susceptibility to infection and facilitate 
penetration of the virus through the epithelial barrier. This was recently confirmed in a 
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study that demonstrated that DMPA modifies the physical barrier to infection by 
decreasing epithelial barrier thickness, increasing permeability, and decreasing barrier 
integrity that enhance susceptibility to genital HSV-2 infection and virus spread beyond 
the vaginal epithelium (Quispe Calla et al. 2016). Others have also shown that DMPA 
treatment thins the vaginal epithelium in non-human primate models (Butler et al. 2013, 
Butler et al. 2015), however, DMPA-mediated thinning of the FRT epithelium in humans 
has not consistently been observed and measured (Bahamondes et al. 2000, Bahamondes 
et al. 2014, Miller et al. 2000). In contrast to DMPA-mediated epithelium thinning, 
treatment with estrogen to produce an estrogen-dominant environment has been shown to 
lead to hyperplasia in the vaginal epithelium (Pessina et al. 2006). Estrogen-conditioned 
mice maintain a robust epithelium that protects against genital HSV-2 infection (Parr et 
al. 1994, Quispe Calla et al. 2016). In fact, intravaginal bacterial infections often require 
mice to be conditioned with b-estradiol to thicken the epithelia and provide a more 
amenable environment for bacterial colonization (Jerse 1999, Jerse et al. 2011, Packiam 
et al. 2010). Hormonal regulation of FRT tissue varies throughout the menstrual/estrous 
cycle as levels of estrogen and progesterone fluctuate, and this regulation of the barrier is 
essential for maintenance of tissue architecture and can potentially impact host defense in 
the FRT (Pessina et al. 2006). 
In addition to the regulation of physical barrier to infection in the vaginal 
microenvironment, in several reports DMPA has been shown to both dampen and elevate 
levels of inflammatory mediators in clinical studies that may ultimately influence 
susceptibility to sexually transmitted infections (STIs). These conflicting reports of up- or 
down-regulation of immune mediators in women using DMPA may be attributed to 
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several different factors, including, ethnicity, FRT infections, sexual behavior, and 
vaginal hygiene practices. Despite these inconsistencies, several recent reports have 
shown that levels of pro-inflammatory cytokines and chemokines are significantly 
decreased in cervicovaginal lavages from women using DMPA, and may adversely 
impact the host response to infection (Govender et al. 2014, Huijbregts et al. 2013, 
Ngcapu et al. 2015, Smith-McCune et al. 2017). Further, it has been demonstrated that 
physiologically relevant doses of DMPA inhibits T cell and dendritic cell activation, 
highlighting additional immunosuppressive effects resulting from DMPA use 
(Huijbregts, Michel, and Hel 2014). Interestingly, DMPA use has recently been linked to 
an increased risk for STI acquisition in high-risk women, suggesting that DMPA-
mediated dampening of the immune response may contribute to STI susceptibility (Butler 
et al. 2015, Kleinschmidt et al. 2007, Smith-McCune et al. 2017, Socias et al. 2017). On 
the other hand, elevated estrogen levels have been linked with enhanced T cell homing 
(Mo et al. 2005), dendritic cell maturation (Kovats 2012), and the promotion of the type I 
interferon response (Panchanathan, Liu, and Choubey 2013, Panchanathan et al. 2009, 
Shen et al. 2010), suggesting an improved immune response in an estrogen-dominant 
environment. Together, these studies highlight the role of estrogen and progesterone in 
the FRT in maintaining balance in the immune system and the potential impact that these 
fluctuations can have during health and disease. 
 IL-36g is a pro-inflammatory member of the IL-1 superfamily of cytokines that is 
expressed at mucosal sites, including the FRT. Murrieta-Coxca et al. showed that the IL-
36 cytokines are expressed in the uterus of mice and that cytokine expression fluctuated 
throughout the estrous cycle, with expression at the lowest level during diestrus, and 
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peaking during estrus (Murrieta-Coxca et al. 2016). Winkle et al. and Patras et al. have 
demonstrated that IL-36g is induced in the FRT after exposure to microbial products and 
Group B Streptococcus, suggesting a function in host defense mechanisms in the FRT 
(Patras et al. 2015, Patras et al. 2013, Winkle, Throop, and Herbst-Kralovetz 2016). 
While the hormonal regulation of several immune mediators in the FRT has been 
described, regulation of IL-36g and the other IL-36 family members in the lower FRT by 
estrogen and progesterone has not previously been investigated and could provide 
essential insights into the regulation and function of IL-36g in host defense in the FRT. 
 In this chapter the impact of the gonadal steroids on epithelial barrier features and 
immune mediators, including the IL-36 cytokines, was evaluated. Collectively, we 
demonstrate that in the upper and lower FRT estrogen and progesterone function to 
regulate expression of the IL-36 cytokines, other immune mediators, and key epithelial 
barrier features that further suggest that IL-36g may exhibit a crucial function in host 
defense mechanisms in the FRT. 
 
Materials and Methods 
Ethics Statement 
All animals were housed in accordance with Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) standards, provided unlimited access to food and 
water, and all procedures and handling for this study were approved by the University of 
Arizona (UA) Institutional Animal Care and Use Committee (IACUC) and performed in 
accordance with the Animal Welfare Act. 
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Hormone preparation and treatment in mice 
Water soluble b-estradiol (MilliporeSigma, St. Louis, MO) was resuspended in 
sterile water for injections (Henry Schein, Melville, NY) at a concentration of 5 mg/ml 
and filter sterilized. Medroxyprogesterone (DMPA; Upjohn Company, Kalamazoo, MI) 
was diluted in sterile 0.9% saline to a concentration of 10 mg/ml. Mice were acclimated 
for one week before being randomly grouped. Female six- to eight-week-old C57Bl/6 
mice were conditioned with DMPA (1 mg/mouse) on day -7 and day -1 as previously 
described (n =5). Mice were conditioned with b-estradiol by i.p. injection as previously 
described (n = 5). On day 0, mice were euthanized, and female reproductive tracts were 
collected. Upper and lower reproductive tracts were separated at the branch point for the 
uterine horns and stored in DNA/RNA shield until RNA extraction (Zymo Research, 
Irvine, CA). 
 
RNA extraction and qRT-PCR analysis 
RNA was extracted from murine upper and lower FRT tissue using the Zymo 
Quick-RNA kit following the manufacturer’s instructions (Zymo Research). cDNA was 
synthesized from 1 µg RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA) and then analyzed by qRT-PCR using iTAQ Universal SYBR Green Supermix (Bio-
Rad) with an Applied Biosystems QuantStudio6 Flex Real Time PCR System (Thermo 
Fisher Scientific Life Technologies, Waltham, MA). Gene expression was normalized to 
Gapdh. Primers sequences are listed in Table 4. 
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Statistics 
Statistical analyses were performed by unpaired two-tailed Student t-test with 
Welch’s correction or one-way ANOVA with Bonferroni’s multiple comparison test 
using Prism software version 8 (GraphPad, San Diego, CA). A p value of < 0.05 was 
considered significant. 
 
Table 4. 
Primers used in qPCR 
Gene Forward (5¢-3¢) Reverse (5¢-3¢) 
GAPDH TCATGACCACAGTCCATGCCA CCCTGTTGCTGTAGCCAAATT 
IL36G CCCAGTCACTGTTGCTGTTA CAGTCTTGGCACGGTAGAAA 
Cxcl1 CAATGAGCTGCGCTGTCAGTG CTTGGGGACACCTTTTAGCATC 
Dsc1 GATGGTCAAAGGAGGCCACA ACACCTTTTCACCAAGCCGA 
Dsg1 TCCCGCAAGAGCTACTTTGTT AAACTTTCAAACCTAGGCATCTTC 
Gapdh AAATTCAACGGCACAGTCAAG TGGTGGTGAAGACACCAGTAG 
Il1a CTCTAGAGCACCATGCTACAGAC TGGAATCCAGGGGAAACACTG 
Il1b AGCAACGACAAAATACCTGTG TCTTCTTTGGGTATTGCTTGG 
Il36a ACAAAGGATGGGGAGCAGCCTGT CCAGGGAAGGCTGCAGACTCAAAT 
Il36b ACAAAAAGCCTTTCTGTTCTATCAT CCATGTTGGATTTACTTCTCAGACT 
Il36g ATGGACACCCTACTTTGCTG TGTCCGGGTGTGGTAAAACA 
Il36rn GGGCACTATGCTTCCGAATG CTTTGATTCCTTGGCCCCGA 
Il36r AAACACCTAGCAAAAGCCCAG AGACTGCCCGATTTTCCTATG 
Slpi AAGTCCTGCGGCCTTTTACCT GGCATTGTGGCTTCTCAAGCT 
Tnf CCACCACGCTCTTCTGTCTAC AGGGTCTGGGCCATAGAACT 
 
 
Results 
Sex Hormones Regulate Expression of Epithelial Barrier Features and Immune Mediators 
Because mice are often treated with either DMPA or b-estradiol prior to 
intravaginal viral or bacterial infection, we first sought to determine the impact of these 
sex hormones on basal expression of key epithelial barrier features and immune 
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mediators. Wild type C57Bl/6 mice were 
hormonally conditioned with either DMPA or 
b-estradiol and mice were sacrificed and FRT 
tissue was collected. Interestingly, the FRT in 
b-estradiol conditioned mice appeared to be 
larger and more swollen than the FRT from 
DMPA conditioned mice (Fig. 5). The uterine 
horns were separated from the lower FRT and 
expression of barrier features and immune 
mediators was analyzed by qPCR in both upper 
and lower FRT tissue. We found that basal 
expression of desmocollin (Dsc1) and desmoglein (Dsg1), two cadherins present in 
desmosomes, was elevated in the lower FRT relative to the upper FRT, regardless of 
hormone treatment (Fig. 6A, B). In the lower FRT, expression of these Dsc1 was 
increased 89-fold in b-estradiol conditioned mice relative to DMPA conditioned mice. 
Similarly, Dsg1 expression was upregulated in the lower FRT in b-estradiol conditioned 
mice 430-fold relative to DMPA conditioned mice (Fig. 6B).  Interestingly, in the upper 
FRT, we measured small differences in Dsc1 (-1.61-fold change) and Dsg1 (1.54-fold 
change) expression in b-estradiol conditioned mice relative to DMPA conditioned mice.  
 
 
 
Figure 5. Effect of sex 
hormones on mouse FRT 
tissue. Representative images 
of FRT from DMPA (A) and 
b-estradiol (B) conditioned 
mice. 
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Figure 6. Sex hormones regulate expression of barrier feature in the 
FRT. Six- to eight-week-old mice (n=5/group) were conditioned with 
DMPA or b-estradiol. Expression of barrier features in upper (A) and 
lower (B) FRT was assessed by qPCR. Expression was evaluated relative 
to GAPDH and data represent two independent animal experiments. Data 
depict mean expression ± SD and statistical significance was determined 
by unpaired two-tailed Student t-test. *, p < 0.05; **, p < 0.01. 
 
After evaluating features of the epithelial barrier, we then sought to assess 
expression of immune mediators in the FRT in estrogen-dominant and progesterone-
dominant microenvironments. Similar to our findings in barrier features, we found that 
basal expression of several immune mediators was elevated in the lower FRT relative to 
the upper FRT (Fig. 7). In the lower FRT, the immune mediators Il1a, Tnf, Cxcl1, and 
Slpi all exhibited elevated expression in b-estradiol conditioned mice (13-fold, 9-fold, 8-
fold, and 5-fold, respectively) relative to DMPA conditioned mice. We likewise 
measured increased expression of Il1a (23-fold), Tnf (340-fold), Cxcl1 (42-fold), and Slpi 
(49-fold) in the upper FRT in b-estradiol treated mice relative to DMPA treated mice, 
albeit at lower expression levels than what we measured in the lower FRT. Together, 
these data demonstrate site-specific differences in basal expression of barrier feature and 
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immune mediators between lower and upper murine FRT tissue, and show that estrogen 
may promote epithelial barrier integrity and elevated expression of immune mediators, 
whereas progesterone appears to dampen barrier feature and immune mediator expression 
in the lower FRT. 
 
Figure 7. Sex hormones regulate immune mediator expression in the 
FRT. Six- to eight-week-old mice (n=5/group) were conditioned with 
DMPA or b-estradiol. Expression of immune mediators in upper (A) and 
lower (B) FRT was assessed by qPCR. Expression was evaluated relative 
to GAPDH and data represent two independent animal experiments. Data 
depict mean expression ± SD and statistical significance was determined 
by unpaired two-tailed Student t-test. *, p < 0.05; **, p < 0.01. 
 
Hormonal Regulation of the IL-36 Family in the Murine FRT 
 Because expression of the IL-36 cytokines is more tissue restricted than other 
immune mediators, we next set out to evaluate the extent to which the sex hormones 
estrogen and progesterone regulate expression of the IL-36 cytokines in the murine FRT. 
All IL-36 cytokines were detected by qPCR in the upper and lower FRT, albeit at lower 
expression levels in the upper FRT relative to the lower FRT (Fig. 8). We further found 
that b-estradiol elevated expression of all IL-36 family members in the lower FRT 
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relative to expression in DMPA conditioned mice. Il36b and Il36g expression in lower 
FRT tissue were significantly increased 17-fold (p < 0.001) and 26-fold (p < 0.0001), 
respectively, in b-estradiol conditioned mice relative to DMPA conditioned mice. Il36a, 
Il36rn, and Il1rl2 expression in b-estradiol treated mice was elevated 20-fold, 331-fold, 
and 8-fold relative to DMPA treated mice, respectively, although these increases were not 
statistically significant. Interestingly, we observed that IL-36 cytokine expression is less 
influenced by the sex hormones in the upper FRT relative to the lower FRT. In the upper 
FRT we measured decreased expression of Il36a (-1.8-fold), Il36rn (-4.2-fold), and Il1rl2 
(-3.5-fold), and increased expression of Il36b (2.3-fold) and Il36g (15.6-fold) in b-
estradiol treated mice relative to DMPA treated mice. Surprisingly, IL-36g was the IL-36 
family member that exhibited the largest change in expression between the two hormone 
treatments. Collectively, these data demonstrate that IL-36 cytokine expression is 
hormonally regulated in the FRT, and this regulation may influence susceptibility to 
infection and ultimately impact host defense mechanisms. 
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Figure 8. Hormonal regulation of the IL-36 cytokines. Female six- to 
eight-week-old C57Bl/6 mice were conditioned with either b-estradiol or 
DMPA. Levels of the IL-36 family members were evaluated in the upper 
and lower FRT. Expression was calculated relative to Gapdh and data 
depict mean ± SD. Results are representative of two independent animal 
studies. Statistical significance was evaluated by one-way ANOVA with 
Bonferroni’s multiple comparisons test. *, p < 0.05; ***, p < 0.001; ****, 
p < 0.0001. 
 
Discussion 
Several reports have recently linked hormonal contraceptives to increased STI 
acquisition, directing researchers to investigate the role of hormones in regulating 
immunity in the FRT. In fact, high-risk women (e.g. sex workers) using DMPA as a 
contraceptive have been shown to exhibit an increased risk for HSV-2 infection 
(Grabowski et al. 2015, Socias et al. 2017). DMPA use has also been linked to HIV 
acquisition, and in 2016 the World Health Organization initiated a large randomized trial 
to better characterize relationships between DMPA use, STI acquisition, and host defense 
in the FRT (Hofmeyr et al. 2017, Polis et al. 2016). In this chapter, we demonstrate that 
the IL-36 cytokines and other factors influencing host defense are hormonally regulated 
in response to estrogen and progesterone in the upper and lower FRT and may ultimately 
impact the host response to pathogens and susceptibility to infection.  
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Desmocollin and desmoglein are two essential cadherins that functionally make 
up desmosomes, important cell junction molecules that adhere cells together and 
physically exclude pathogens (Delva, Tucker, and Kowalczyk 2009, Kowalczyk and 
Green 2013). Quispe Calla et al. demonstrated that DMPA treatment in mice significantly 
reduced expression of DSC1 and DSG1 and decreased epithelium thickness that 
corresponded with increased genital mucosal permeability in mice and in human 
ectocervical biopsies (Quispe Calla et al. 2016). Similarly, we show significantly reduced 
expression of DSC1 and DSG1 in DMPA conditioned mice relative to mice conditioned 
with b-estradiol, indicating the potential role that these sex hormones may exhibit in 
regulating key barriers to infection. In fact, DMPA conditioning is required for 
intravaginal viral infection, due in part to the thinning of the vaginal epithelium (Kaushic 
et al. 2003, Kaushic, Zhou, et al. 2000, Parr et al. 1994, Parr and Parr 2003, Quispe Calla 
et al. 2016). Quispe Calla et al. and others have demonstrated that mice treated with b-
estradiol or in the estrous stage are protected against intravaginal HSV-2 infection, and 
exhibit decrease epithelium permeability and increased thickness (Kaushic et al. 2003, 
Kaushic, Zhou, et al. 2000, Quispe Calla et al. 2016). Collectively, our findings support 
the conclusion that the sex hormones estrogen and progesterone function in an important 
manner to regulate epithelial barrier integrity and the physical barrier to infection. 
 In addition to the regulation of the physical barrier to infection, current evidence 
suggests that the sex hormones estrogen and progesterone additionally function to 
regulate the chemical barrier to infection and production immune mediators that are 
crucial components of the host response to pathogens in the FRT mucosa (Wira et al. 
2010, Wira, Rodriguez-Garcia, and Patel 2015). In humans, DMPA and other progestins 
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have inconsistently been shown to suppress levels of immune mediators in the FRT 
(Deese et al. 2015, Francis et al. 2016, Govender et al. 2014, Huijbregts et al. 2013, 
Ngcapu et al. 2015, Smith-McCune et al. 2017), and this may be due to a wide-array of 
factors, including ethnicity (Murphy and Mitchell 2016, Nguyen et al. 2004, Ryckman et 
al. 2008), vaginal health(Campos et al. 2012, Hemalatha et al. 2012, Mitchell et al. 2008), 
and vaginal hygiene practices (Alcaide et al. 2017, Birse et al. 2017) among others. In the 
murine model, we are able to exclude many of these potentially confounding variables to 
better understand the impact of estrogen and progesterone on the immune mechanisms, 
and particularly how the sex hormones influence the basal expression of several immune 
mediators that exhibit crucial functions in mucosal immunity. Our data demonstrate that 
DMPA treatment results in decreased expression of several immune mediators, including 
Il1a, Tnfa, Cxcl1, and Slpi in naïve FRT tissue. We observed higher expression levels of 
these immune mediators in lower FRT tissue relative to upper FRT tissue, demonstrating 
that basal expression of these pro-inflammatory immune mediators is site-specific in the 
FRT. This can in part be attributed to the fact that the lower FRT faces a barrage of 
pathogens that require a robust immune response, whereas the upper FRT generally does 
not encounter FRT pathogens in healthy states (Baker, Chase, and Herbst-Kralovetz 
2018). When mice were treated with estrogen, we observed a significant increase in 
expression of I1a (13.2-fold, p < 0.05), Tnf (8.8-fold, p < 0.01), Cxcl1 (7.7-fold, p < 
0.01), and Slpi (5.1-fold, p < 0.05) in the lower FRT relative to levels when mice were 
treated with DMPA. Altogether, these data indicate that in the murine model, DMPA 
suppresses expression of several key inflammatory mediators relative to b-estradiol 
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treatment, suggesting that DMPA use may contribute to increased susceptibility to genital 
HSV-2 infection through the dampening of the immune response. 
 Given that we measured decreased expression levels of several immune mediators 
in DMPA-conditioned mice relative to b-estradiol treated mice, we sought to evaluate 
hormonal regulation of the IL-36 family, cytokines that are robustly expressed at mucosal 
sites. Recently, a proteomics study of Kenyan women indicated that elevated IL-36g 
levels were associated with DMPA use and various vaginal hygiene practices, including 
vaginal washing and drying (Birse et al. 2017). Interestingly, 70% of participants using 
DMPA were HSV-2 seropositive, and 26% of the women had bacterial vaginosis (Birse 
et al. 2017), and these FRT infections and vaginal hygiene practices may have led to the 
elevated IL-36g levels that were detected in the study. In the murine model we can 
eliminate many of these potentially confounding factors and evaluate hormonal 
regulation of the IL-36 cytokines in naïve mice. We detected significantly decreased 
expression of Il36b (16.6-fold decrease, p < 0.001) and Il36g (26.2-fold decrease, p < 
0.001) in the lower FRT of DMPA treated mice relative to b-estradiol treated mice, 
indicating that expression of the IL-36 cytokines may in-part be hormonally regulated. 
All family members were expressed in murine FRT tissue, and we additionally measured 
decreased expression of Il36a (20.1-fold decrease), Il36rn (331-fold decrease), and Il36r 
(8-fold decrease) in the lower FRT of DMPA treated mice relative to b-estradiol treated 
mice, though these decreases were not statistically significant. Similar to our findings 
with other immune mediators, we measured site-specific differences in expression of the 
IL-36 family members, with increased expression in the lower FRT relative to the upper 
FRT. We have previously shown that IL-36g is induced in response to an array of 
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microbial products (Winkle, Throop, and Herbst-Kralovetz 2016), and suppression of IL-
36g by DMPA treatment may result in a suppression of IL-36g and IL-36R signaling, 
resulting in an insufficient immune response and increased susceptibility to infection. We 
have demonstrated that expression of the IL-36 cytokines is regulated in-part through the 
sex hormones estrogen and progesterone, and this regulation may ultimately impact the 
host response to pathogens in the FRT and susceptibility to STIs.  
 Collectively, in this chapter we demonstrate that the sex hormones estrogen and 
progesterone function to regulate the epithelial barrier to infection, as well as the 
chemical barrier to infection in mice. We show that the synthetic progestin, DMPA, 
reduces expression of the key epithelial barrier features Dsc1 and Dsg1, suggesting a 
weakening of the epithelial barrier. We additionally demonstrate that DMPA treatment 
results in decreased expression of several pro-inflammatory immune mediators, including 
the IL-36 cytokines, and IL-36g specifically. Together, we hypothesize that the dampened 
expression of IL-36g, coupled with the reduced expression of other immune mediators 
and weakened epithelial barrier may contribute to the increased susceptibility to FRT 
infection after DMPA use. 
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CHAPTER 4: IL-36g INDUCES A TRANSIENT HSV-2 RESISTANT 
ENVIRONMENT THAT PROTECTS AGAINST GENITAL DISEASE AND 
PATHOGENESIS 
 
Publication Note 
The research reported in this chapter was previously published in an altered format in 
Cytokine. Jameson K. Gardner and Melissa M. Herbst-Kralovetz. IL-36g induces a 
transient HSV-2 resistant environment that protects against genital disease and 
pathogenesis. Cytokine. 111:63-71. doi: 10.1016/j.cyto.2018.07.034. 
 
Abstract 
Herpes simplex virus 2 (HSV-2) causes a persistent, lifelong infection that 
increases risk for sexually transmitted infection acquisition. Both the lack of a vaccine 
and the need for chronic suppressive therapies to control infection presents the need to 
further understand immune mechanisms in response to acute HSV-2 infection. The IL-36 
cytokines are recently identified members of the IL-1 family and function as 
inflammatory mediators at epithelial sites. Here, we first used a well-characterized three-
dimensional (3-D) human vaginal epithelial cell (VEC) model to understand the role of 
IL-36g in the context of HSV-2 infection. In 3-D VEC, IL-36g is induced by HSV-2 
infection, and pretreatment with exogenous IL-36g significantly reduced HSV-2 
replication. To assess the impact of IL-36g treatment on HSV-2 disease pathogenesis, we 
employed a lethal genital infection model. We showed that IL-36g treatment in mice prior 
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to lethal intravaginal challenge significantly limited vaginal viral replication, delayed 
disease onset, decreased disease severity, and significantly increased survival. We 
demonstrated that IL-36g treatment transiently induced pro-inflammatory cytokines, 
chemokines, and antimicrobial peptides in murine lower female reproductive tract (FRT) 
tissue and vaginal lavages. Induction of the chemokines CCL20 and KC in IL-36g treated 
mice also corresponded with increased polymorphonuclear (PMN) leukocyte infiltration 
observed in vaginal smears. Altogether, these studies demonstrate that IL-36g drives the 
transient production of immune mediators and promotes PMN recruitment in the vaginal 
microenvironment that increases resistance to HSV-2 infection and disease. Our data 
indicate that IL-36g may participate as a key player in host defense mechanisms against 
invading pathogens in the FRT. 
 
Introduction 
Genital herpes simplex virus 2 (HSV-2) infections remain one of the most common 
sexually transmitted infections (STI), affecting over 250 million women worldwide 
(Looker et al. 2015a). HSV-2 causes a persistent, lifelong infection that increases risk for 
STI acquisition, including human immunodeficiency virus (Freeman et al. 2006). Despite 
the availability of therapeutic interventions to limit HSV-2 disease, the virus can be 
transmitted through asymptomatic shedding and even during chronic suppressive therapy 
(Johnston and Corey 2016, Johnston et al. 2012, Wald et al. 2000a).  
The vaginal epithelium is a first-line of defense against acute genital HSV-2 
infection, forming a physical barrier to infection. Initiation of innate immune signaling by 
  63 
vaginal epithelial cells is crucial for the production of pro-inflammatory cytokines, 
chemokines, and antimicrobial peptides (AMP) to control acute HSV-2 infection 
(Johnson, Koelle, and Wald 2011, Shin and Iwasaki 2013). These soluble immune 
mediators produced in the vaginal epithelium are vital components of the barrier to 
infection, and can protect against HSV-2 infection by blocking binding and entry (Hazrati 
et al. 2006, John et al. 2005, Shust et al. 2010, Yarbrough, Winkle, and Herbst-Kralovetz 
2015). Despite our current understanding of host defense mechanisms, there still exists a 
need to understand underlying innate immune mechanisms in the vaginal epithelium that 
can inhibit virus replication during acute HSV-2 infection, and ultimately limit the spread 
and establishment of latency and recurrent HSV-2 disease. We have previously shown 
that interleukin (IL)-36g, a novel pro-inflammatory cytokine, is expressed in the lower 
FRT and is induced in a Toll-like receptor (TLR)-mediated manner in response to 
microbial products, including the viral dsRNA mimic, poly(I:C) (Winkle, Throop, and 
Herbst-Kralovetz 2016). Additionally, we demonstrated that IL-36g signals in an 
autocrine manner, creating a self-sustaining loop that amplifies IL-36g and cytokine, 
chemokine, and AMP production in the FRT (Winkle, Throop, and Herbst-Kralovetz 
2016).  
Several studies have recently shown that the IL-36 cytokines, including IL-36a, -
b, and -g, are key inflammatory mediators in host defense against bacteria, fungi, and 
viruses at various epithelial sites (Ahsan et al. 2016, Aoyagi et al. 2016, Braegelmann et 
al. 2018, Gabay and Towne 2015, Huynh et al. 2016, Kovach et al. 2017, Kovach et al. 
2016, Winkle, Throop, and Herbst-Kralovetz 2016). These family members share 
between 15-85% sequence similarity at the amino acid level, with IL-36a and IL-36g 
  64 
being the most similar among the cytokines (Milora et al. 2017). Despite similarity 
among the three agonists, the differential expression patterns of the IL-36 family 
members suggest that these cytokines may have cell- and/or tissue-specific functions 
(Bassoy, Towne, and Gabay 2018, Gresnigt and van de Veerdonk 2013). IL-36a, - b, and 
-g are all expressed in nonhematopoietic cells, including keratinocytes and mucosal 
epithelial cells, but are induced in response to different inflammatory stimuli (Walsh and 
Fallon 2016). For example, IL-36a and IL-36g have been shown to be robustly induced 
in bronchial epithelial cells in response to microbial products, bacterial infection, and 
viral infection, suggesting that the IL-36 cytokines may play an important role in 
epithelial host defense (Aoyagi et al. 2016, Bochkov et al. 2010, Chustz et al. 2011, 
Kovach et al. 2017, Kovach et al. 2016). Indeed, IL-36g -/- mice exhibited delayed 
clearance of Streptococcus pneumoniae and Klebsiella pneumoniae in lung infections, 
decreased Th1 and Th17 cytokine levels, and increased mortality (Kovach et al. 2017). In 
Mycobacterium tuberculosis infections, IL-36g promotes the production of AMPs that 
limit bacterial growth (Ahsan et al. 2018, Ahsan et al. 2016). In another study, it was 
found that IL-36R signaling and IL-36a promoted the production of immune mediators 
and increased influx of neutrophils and monocytes in response to influenza virus 
infection in the lungs, indicating that the IL-36 cytokines may have distinct functions in 
response to specific inflammatory stimuli(Aoyagi et al. 2016). It has been well 
documented that the viral RNA mimic poly(I:C) induces IL-36g, further demonstrating 
that IL-36g may play a role in host antiviral defense mechanisms (Lian et al. 2012, Rana 
et al. 2015, Winkle, Throop, and Herbst-Kralovetz 2016). However, IL-36b, but not IL-
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36a or IL-36g, has been shown to protect against HSV-1 disease in keratinocytes and a 
flank skin infection model (Milora et al. 2017). This finding indicates that the IL-36 
cytokines may have site-specific functions in host defense. In the upper female 
reproductive tract it has been shown that Listeria monocytogenes infection robustly 
induced the IL-36 cytokines in the uteri of pregnant mice, however, the impact of the IL-
36 cytokines on infection and pregnancy is still unclear (Murrieta-Coxca et al. 2016). 
Recently, our laboratory measured increased levels of IL-36g in cervicovaginal lavages 
(CVLs) from cervical cancer patients (Laniewski et al. 2018). Additionally, clinical 
proteomic studies have also measured an increase in the relative abundance of IL-36g in 
CVLs from HSV-2 seropositive Depo-Provera users (Birse et al. 2017), and an increase 
in IL-36 cytokines in women with bacterial vaginosis (Borgdorff et al. 2016). Together, 
these studies suggest that IL-36g may play an important role in host defense mechanisms 
in the FRT.  
We aimed to better understand IL-36g in the context of HSV-2, a clinically 
relevant viral STI. In this study, we utilized an innovative three-dimensional (3-D) human 
vaginal epithelial cell (VEC) model (Gardner and Herbst-Kralovetz 2016) and a lethal 
genital infection model to identify the extent to which IL-36g impacts HSV-2 disease. We 
also investigated the level to which IL-36g treatment modulated production of immune 
mediators and recruitment of immune cells in the vaginal microenvironment as potential 
mechanisms by which IL-36g limits genital HSV-2 disease. Collectively, our data 
suggests that IL-36g may participate as a key regulator of mucosal inflammation and host 
defense in the FRT. 
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Materials and Methods 
3-D VEC culture  
Three-dimensional human vaginal epithelial (V19I) cells were cultured as 
previously described (Hjelm et al. 2010, Radtke and Herbst-Kralovetz 2012, Winkle, 
Throop, and Herbst-Kralovetz 2016). The V19I cell line was validated by short tandem 
repeat (STR) profiling and shown to be free of contamination from other cell lines. 
Briefly, V19I cells were combined with collagen-coated dextran microcarrier beads in a 
1:1 mixture of supplemented keratinocyte serum free medium (KSFM) and EpiLife 
medium (Life Technologies, Grand Island, NY). Cell and bead mixtures were transferred 
to a slow turning lateral vessel bioreactor (Synthecon, Houston, TX) and incubated over a 
28-day period at 37°C. Fully-differentiated aggregates were quantified and cell viability 
was measured by trypan blue exclusion using a Countess machine (Life Technologies). 
For all in vitro experiments, 3-D aggregates were transferred into 24-well plates (1 ´ 105–
5 ´ 105 cells/ml).  
 
HSV-2 propagation and plaque assay 
HSV-2 186 was generously provided by Dr. Richard Pyles (UTMB, Galveston, 
TX), and used for all studies. Stocks were prepared from infected Vero cell monolayers 
and frozen at -80°C. Vero cell monolayers (ATCC CCL-81) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM; Corning, Manassas, VA) as previously described 
(Pyles et al. 2002). All HSV-2 infections in vitro were performed at a multiplicity of 
infection (MOI) of 0.1 (1 ´ 104–5 ´ 104 PFU/ml depending on 3-D cell density in 
individual experiments). Virus titers were quantified by standard plaque assay using Vero 
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cell monolayers as previously described (Herbst-Kralovetz and Pyles 2006a). The 
University of Arizona (UA) Institutional Biosafety Committee (IBC) approved all safety 
and handling of HSV-2 in the laboratory. 
 
In vitro cytokine and TLR agonist treatment 
Three-dimensional aggregates were treated with poly(I:C) (Invivogen, San Diego, 
CA) at 100 µg/ml, recombinant human IL-36g (Peprotech, Rocky Hill, NJ) at 100 or 500 
ng/ml as previously described (Winkle, Throop, and Herbst-Kralovetz 2016), or 
recombinant IL-36Ra (BioLegend, San Diego, CA) at 100 ng/ml. These concentrations 
are consistent with prior reports in the literature studying IL-36g in the lung, skin, and 
intestines (Chustz et al. 2011, Harusato et al. 2017, Jiang et al. 2017, Scheibe et al. 2017, 
Zhang et al. 2017). Aggregates were treated with acyclovir (ACV; GlaxoSmithKline, 
Research Triangle Park, NC) at 20 µg/ml as a positive control, or left untreated as a 
negative control.  
 
Genital HSV-2 mouse model 
Female six- to eight-week-old C57Bl/6 mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME, USA). All animals were housed in accordance with 
American Association for Laboratory Animal Care (AALAC) standards, provided 
unlimited access to food and water, and all procedures and handling for this study were 
approved by the UA Institutional Animal Care and Use Committee (IACUC) and 
performed in accordance with the Animal Welfare Act to minimize pain and suffering. 
Animals were acclimated for 7 days before being grouped (n=5-10, groupings described 
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in figure legends) prior to treatment and HSV-2 infection. All mice were pretreated with 
medroxyprogesterone acetate (1 mg/mouse; Up John Company, Kalamazoo, MI) at day -
7 and day -1 as previously described (Herbst-Kralovetz and Pyles 2006a). Mice were 
i.vag. treated by instilling recombinant murine IL-36g (100 ng, 250 ng, or 500 ng; 
BioLegend) or PBS (Corning, Manassas, VA) in 10 µl total volume. Mice were i.vag. 
challenged with HSV-2 186 (1 ´ 103 or 1 ´ 104 PFU) in 10 µl total volume in DMEM 
media as previously described (Herbst-Kralovetz and Pyles 2006a). Survival and disease 
incidence in mice were measured over a 21-day period. The vaginal mucosa was visually 
inspected daily for hair loss, erythema, and ulceration by the trained investigators in the 
study. Disease severity was scored daily according to the following scale: no pathology 
(0), mild vulvar erythema (1), moderate vulvar erythema (2), severe vulvar erythema and 
hair loss (3), perineal ulceration (4), extension of perineal ulceration to surrounding tissue 
and/or hind limb paralysis (5). Moribund mice and those scoring a 5 were euthanized to 
minimize pain and suffering. Mice scoring a 4 that were euthanized were scored a 5 the 
following day. Disease onset/incidence was defined by erythema and hair loss (a score of 
3). Vaginal swabs were collected at 2 and 3 days post inoculation (d.p.i.) using sterile 
urethro-genital calcium alginate tipped swabs (Puritan; Guilford, ME) in 1 mL DMEM 
stored at -80°C. Vaginal viral replication was measured in vaginal swabs by standard 
plaque assay as described.  
 
IL-36g treatment in mice  
Mice were pretreated with medroxyprogesterone acetate as described above and 
then treated by i.vag. instillation with recombinant murine IL-36g (250 ng or 500 ng; 
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BioLegend) in 10 µl total volume. Control mock-treated mice were administered 10 µl 
PBS. Vaginal lavages were collected from mice by i.vag. instilling 125 µl of sterile PBS 
and lavaging the vaginal cavity using an oral feeding tube (Fisher Scientific, Waltham, 
MA). Lavage fluid was stored at -80°C until cytometric bead array analysis. Female 
reproductive tract tissue was collected at 4h and 24h after treatment and stored in 
DNA/RNA Shield (Zymo Research, Irvine, CA) at -20°C until RNA extraction and qRT-
PCR analysis. 
 
Vaginal smears 
Mice were conditioned with medroxyprogesterone acetate and treated with 
recombinant murine IL-36g (250 ng; BioLegend) or mock-treated with PBS as described 
above. Four hours and 24h after treatment mice were swabbed with a PBS soaked 
urethro-genital calcium alginate tipped swab (Puritan). Swabs were smeared on 
Fisherbrand Selectfrost microscope slides (Fisher Scientific) and allowed to air dry. 
Slides were stained with modified Wright stain (Volu-Sol, Salt Lake City, UT) and 
imaged on a Zeiss AxioImager M2 (Zeiss, Oberkochen, Germany) at 20´ and 40´ 
magnification to identify cell populations. Cell counting was performed by selecting five 
unique fields on a smear at 20´ magnification. The number of epithelial cells, PMN, and 
total cells in each field were enumerated for each mouse in the treatment groups and the 
average count/mm2 was calculated. The field of view at 20´ magnification has an area of 
1 mm2. 
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RNA extraction and qRT-PCR analysis 
RNA was extracted from 3-D V19I aggregates and mouse FRT tissue using the 
Zymo Quick-RNA kit following the manufacturer’s instructions (Zymo Research). 
Mouse FRT tissue was stored in DNA/RNA shield prior to RNA extraction. cDNA was 
synthesized from 1 µg RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA) and then analyzed by qRT-PCR using iTAQ Universal SYBR Green Supermix (Bio-
Rad). qRT-PCR was performed with an Applied Biosystems QuantStudio6 Flex Real 
Time PCR System (Life Technologies). Gene expression was normalized to GAPDH and 
fold change was calculated relative to controls. Primers used for all qRT-PCR analyses 
are listed in Table 5. 
Initial gene expression screens were performed using cDNA synthesized using a 
RT2 First-Strand kit (Qiagen, Valencia, CA) from 500 ng pooled RNA from murine FRT 
tissue treated with IL-36g (500 ng) or PBS collected 4h and 24h after exposure and 
analyzed using Mouse Antiviral response and Mouse Toll-like receptor signaling RT2 
arrays (Qiagen). qRT-PCR was performed as described above. Fold change was 
calculated by delta delta Ct analysis using RT2 Profiler PCR Array Data Analysis 
software (v3.5) and then log2 transformed (Qiagen). 
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Table 5. 
Primers used in this study 
Gene Forward (5¢-3¢) Reverse (5¢-3¢) 
Human GAPDH TCATGACCACAGTCCATGCCA CCCTGTTGCTGTAGCCAAATT 
Human IL36A CCAGACGCTCATAGCAGTCC AGATGGGGTTCCCTCTGTCTT 
Human IL36B ACCAAGGAGAGAGGCATAACTAAT AGTGAACTCAGTCGCATAATGATC 
Human IL36G CCCAGTCACTGTTGCTGTTA CAGTCTTGGCACGGTAGAAA 
Human IL1RL2 GCTGGAGTGTCCACAGCATA GCGATAAGCCCTCCTATCAA 
Human IL36RN ACTCGGCATTGAAGGTGCTTT GGGACCACGCTGATCTCTT 
Murine Ccl20 CGACTGTTGCCTCTCGTACA CACCCAGTTCTGCTTTGGAT 
Murine Ccl4 AAACCTAACCCCGAGCAACA CCATTGGTGCTGAGAACCCT 
Murine Clec4e CTGTAAGTTCTGCCCGGAAA GGATGCTTCAAAAACTCCCA 
Murine Cxcl1 CAATGAGCTGCGCTGTCAGTG CTTGGGGACACCTTTTAGCATC 
Murine Defb3 GTCAGATTGGCAGTTGTGGA GCTAGGGAGCACTTGTTTGC 
Murine Il1a CTCTAGAGCACCATGCTACAGAC TGGAATCCAGGGGAAACACTG 
Murine Il1b AGCAACGACAAAATACCTGTG TCTTCTTTGGGTATTGCTTGG 
Murine Il36g ATGGACACCCTACTTTGCTG TGTCCGGGTGTGGTAAAACA 
Murine Il6 AGATAACAAGAAAGACAAAGCCAGAGTC GCATTGGAAATTGGGGTAGGAAG 
Murine Gapdh AAATTCAACGGCACAGTCAAG TGGTGGTGAAGACACCAGTAG 
Murine Ltf AAACAAGCATCGGGATTCCAG ACAATGCAGTCTTCCGTGGTG 
Murine Muc13 TGCGTGATGCTACAAAGGAC TGTCCTGGCATTTACTGCTG 
Murine Nlrp3 TGCTCTTCACTGCTATCAAGCCCT ACAAGCCTTTGCTCCAGACCCTAT 
Murine Slpi AAGTCCTGCGGCCTTTTACCT GGCATTGTGGCTTCTCAAGCT 
 
Cytometric bead array analysis of CVLs 
Cytokine levels in murine vaginal lavages were measured by cytometric bead 
array analysis using a Mouse High Sensitivity T Cell Magnetic Bead Panel (containing 
IL-1a, IL-1b, IL-6, TNFa, CCL20, and CXCL1/keratinocyte chemoattractant (KC)) and 
a Mouse Cytokine/Chemokine Magnetic Bead Panel (containing IL-1b, IL-6, TNFa, IP-
10, and KC) following the manufacturer’s protocol (Millipore Sigma, Billerica, MA). 
Assays were performed using a Bio-Plex 200 system with Bio-Plex 5.0 Manager software 
(Bio-Rad). 
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Statistics 
Disease incidence and survival in mouse models were analyzed by log-rank 
analysis as previously described (Herbst-Kralovetz and Pyles 2006a). Disease severity 
and resolution were analyzed by Area Under Curve (AUC) analysis with an unpaired 
two-tailed Student t-test with Welch’s correction. Unpaired two-tailed Student t-test with 
Welch’s correction, one-way ANOVA with Bonferroni’s multiple comparisons test, and 
two-way ANOVA with Bonferroni’s multiple comparisons test were performed for 
comparisons as indicated using Prism software version 7 (GraphPad, San Diego, CA). A 
P value of <0.05 was considered significant. 
 
Results 
IL-36g is induced by poly(I:C) and HSV-2, and treatment with IL-36g limits HSV-2 
infection in human 3-D VEC 
Microbial products, including the viral mimic poly(I:C), have been shown to 
induce expression of IL36G mRNA and protein (Chustz et al. 2011, Lian et al. 2012, 
Rana et al. 2015, Winkle, Throop, and Herbst-Kralovetz 2016). To determine if HSV-2 
infection induces mRNA expression of IL-36 family members, 3-D human VEC were 
challenged with HSV-2 186 (MOI of 0.1) or treated with poly(I:C) (100 µg/ml). 
Aggregates were collected after 4h, and expression of IL-36a, IL-36b, IL-36g, IL-36R 
(IL1RL2), and IL-36Ra (IL36RN) mRNA transcripts was measured by qRT-PCR. HSV-2 
infection significantly (P < 0.01) induced expression of IL36G 6.5-fold relative to 
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untreated controls (Fig. 9A). Expression of other IL-36 family member gene transcripts 
were not significantly altered after HSV-2 infection, suggesting that IL-36g may play an 
important role in antiviral host defense in the FRT. The induction of IL36G after HSV-2 
infection was similar to poly(I:C) treatment, a viral RNA mimic, and known inducer of 
IL-36g (Fig. 9B). 
 
Figure 9. IL-36γ is induced by HSV-2 infection and IL-36g treatment 
limits HSV-2 infection in 3-D VEC. (A) Three-dimensional human VEC 
were infected with HSV-2 186 (MOI 0.1) for 4h. IL-36 family member 
mRNA transcript levels were measured by qRT-PCR, normalized to 
GAPDH and expressed as fold-change relative to untreated controls. (B) 
Three-dimensional human VEC were infected with HSV-2 186 (MOI 0.1) 
or treated with poly(I:C) (100 µg/ml), a known inducer of IL36G, for 4h. 
IL36G mRNA transcript levels were measured by qRT-PCR and 
normalized to GAPDH. (C) HSV-2 replication was measured in 3-D VEC 
treated with recombinant IL-36γ (100 ng/ml or 500 ng/ml), Poly(I:C) (100 
µg/ml), or left untreated 24h prior or 4h prior to infection with HSV-2 186 
(MOI 0.1). Aggregates were treated with acyclovir (20 µg/ml) 2h prior to 
infection as a positive control. Viral titers were measured after 24h as 
PFU/ml by standard plaque assay. Dashed line indicates limit of detection 
for assay. Data represent mean ± SD from biological replicates from three 
independent experiments. Statistical significance was determined by one-
way ANOVA with Bonferroni’s multiple comparisons test (A, B) and 
two-way ANOVA with Bonferroni’s multiple comparisons test (C).  **, P 
< 0.01; ***, P < 0.001; ****, P < 0.0001. 
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As a potential host defense mechanism in response to HSV-2 infection, we sought 
to determine the level to which IL-36g impacted HSV-2 replication in a well-
characterized 3-D human VEC model (Gardner and Herbst-Kralovetz 2016). Three-
dimensional VEC aggregates were treated with IL-36g (100 ng/ml or 500 ng/ml) or 
poly(I:C) (100 µg/ml) 24h prior or 4h prior to HSV-2 challenge. Aggregates were treated 
with acyclovir (ACV; 20 µg/ml) 2h prior to infection as a positive control to limit HSV-2 
replication, or left untreated as a negative control. Twenty-four hours post inoculation, 
viral titers were measured by standard plaque assay. Treatment with IL-36g (100 ng/ml) 
both 24h and 4h prior to infection resulted in a significant (P < 0.05) reduction in viral 
titers compared to untreated controls (Fig. 9C). Exposure to a higher dose of IL-36g (500 
ng/ml) 24h or 4h prior to infection reduced viral titers similar to treatment with IL-36g at 
100 ng/ml. Poly(I:C) treatment also significantly (P < 0.01) reduced viral titers similar to 
IL-36g treatments at both time points. The relatively short half-life of ACV (Hodge and 
Perkins 1989, Schiffer et al. 2013, Weinberg et al. 1992), the administration of a single 
dose of ACV over a 24h period (Weinberg et al. 1992), and the high infectious dose (1 ´ 
104 – 5 ´ 104 PFU) used in this study may explain the incomplete blockade of HSV-2 
replication beyond the measured ~50-fold reduction. IL-36 signaling through IL-36R was 
blocked by treating 3-D human VEC with recombinant IL-36 receptor antagonist (IL-
36Ra), and inhibition of IL-36g signaling was confirmed by qRT-PCR (data not shown). 
Pretreatment with IL-36Ra (100 ng/ml) prior to HSV-2 challenge did not significantly 
increase viral titers relative to controls, suggesting that other mechanisms (e.g. NFkB 
activation, Type I IFN) may compensate to control HSV-2 infection in human VEC 
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(Appendix A). To extend these findings, we sought to understand the role of IL-36g in 
the context of HSV-2 disease pathogenesis in a complex multicellular microenvironment 
using a well-established animal model. 
 
Treatment with IL-36g limits vaginal viral replication, delays disease onset, and decreases 
disease severity to protect against lethal HSV-2 challenge 
To determine the extent to which IL-36g exposure limits HSV-2 disease 
pathogenesis, female C57Bl/6 mice were treated with IL-36g prior to lethal HSV-2 
challenge. In initial studies to examine the impact of IL-36g dose on HSV-2 disease, 
medroxyprogesterone acetate conditioned mice were i.vag. treated with recombinant 
murine IL-36g (100 ng, 250 ng, or 500 ng) or mock treated with PBS (n = 5-10/group) 4h 
prior to lethal HSV-2 challenge with a rigorous challenge dose of 1 ´ 104 PFU (35X 
LD50). We found that mice treated with IL-36g (250 ng) 4h prior to infection had a 
significant (P < 0.0001) delay in disease onset, and survived significantly (P < 0.0001) 
longer relative to PBS controls (Appendix A). Similar to mice treated with the 250 ng 
dose, mice treated with IL-36g (500 ng) exhibited a significant (P < 0.0001) delay in 
symptoms, and increased survival time compared to controls. However, there was no 
difference in the time to symptoms or survival time between mice that were treated with 
IL-36g (100 ng) and controls. Further, when mice were treated with IL-36g (250ng) 24h 
prior to lethal challenge, there was no difference in disease onset or survival time relative 
to controls. These initial studies demonstrated that both the dose of IL-36g and timing of 
delivery are important in limiting HSV-2 disease.  
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We then sought to determine the impact of IL-36g treatment on HSV-2 disease 
pathogenesis using a lower challenge dose (LD100) previously reported (Herbst-Kralovetz 
and Pyles 2006a, Rose, McGowin, and Pyles 2009, Tsunobuchi et al. 2000). 
Medroxyprogesterone acetate conditioned mice were i.vag. treated with IL-36g (250 ng) 
or mock-treated with PBS (n = 10/group) 4h prior to challenge with 1 ´ 103 PFU HSV-2 
186 (LD100). Vaginal viral titers were measured in vaginal swabs collected 2 and 3 days 
post-inoculation (d.p.i.). Vaginal viral titers were significantly (P < 0.0001) reduced in 
mice treated with IL-36g compared to PBS controls on both day 2 and 3 p.i., and several 
IL-36g treated mice had no detectable titers at either 2 or 3 d.p.i. (Fig. 10A). Survival and 
disease incidence was measured over a 21-day period and the disease severity was 
recorded daily on a 1-5 scale to monitor disease progression. IL-36g treated mice had 
significantly (P < 0.01) less severe disease relative to PBS controls, and 3/20 (15%) IL-
36g treated mice exhibited no disease symptoms over the 21-day period (Fig. 10B). Of 
the 17 IL-36g treated mice that developed disease, five mice (29.4%) exhibited less 
severe pathology that did not progress in severity beyond a score of 2/5. Treatment with 
IL-36g significantly (P < 0.0001) delayed the onset of disease, and reduced the number of 
mice presenting both hair loss and erythema at the introitus and surrounding tissue to just 
12/20 (60%), compared to 20/20 (100%) of mice in the PBS group (Fig. 10C). In the IL-
36g treated mice that did develop erythema and hair loss, onset was delayed by two days 
compared to controls. Moreover, IL-36g treatment significantly (P < 0.0001) protected 
from lethal challenge, as 8/20 (40%) of IL-36g treated mice survived, whereas 20/20 
(100%) of PBS treated mice succumbed to disease (Fig. 10D). IL-36g treated mice that 
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died from lethal infection exhibited a three-day delay in death. These data demonstrate 
that IL-36g treatment limits viral replication, decreases disease severity, and increases 
survival, suggesting that IL-36g enhances protection against a lethal HSV-2 challenge in 
the vaginal epithelium. 
 
Figure 10. IL-36g treatment 4h prior to infection significantly protects 
against HSV-2 disease incidence, reduces disease severity, and 
enhances survival. Female six- to eight-week-old C57Bl/6 mice were 
treated with murine recombinant IL-36g (250 ng) 4h prior to infection 
(n=10), or mock-treated with PBS (n = 10). Mice were then intravaginally 
challenged with a lethal dose of HSV-2 186 (103 PFU). (A) Vaginal swabs 
were collected at days 2 and 3 post-inoculation and HSV-2 replication was 
measured in duplicate by standard plaque assay. Each symbol represents 
an individual mouse, and mean ± SD is depicted. Dashed line represents 
minimum detectable level for assay. Several IL-36g-treated mice had 
undetectable titers and are depicted on the graph as half of the minimum 
detectable level. Disease severity (B) was measured daily and scored on a 
0-5 scale. Once a mouse scored 5 and died it was no longer included in 
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scoring. Incidence of disease was measured by the presence of both 
erythema and hair loss (C), and survival (D) was recorded over a 21-day 
period. Data is representative of two independent animal studies. 
Statistical analyses were performed by one-way ANOVA with 
Bonferroni’s multiple comparisons test (A), Area Under Curve (AUC) 
analysis with an unpaired two-tailed Student t-test with Welch’s correction 
(B), and log-rank analysis (C, D). **, P < 0.01; ****, P < 0.0001. 
 
IL-36g drives the transient production of immune mediators in murine lower FRT tissue 
and vaginal lavages 
Previously, we have demonstrated that IL-36g induces expression and secretion of 
pro-inflammatory cytokines and chemokines 24h after treatment in a human 3-D VEC 
model (Winkle, Throop, and Herbst-Kralovetz 2016), and this may be a mechanism 
whereby IL-36g treatment can limit HSV-2 replication and disease. In an initial screen, 
we employed gene expression arrays to assay over 130 unique genes involved in the 
antiviral response and Toll-like receptor signaling to identify key immunoregulatory 
genes that could be modulated by IL-36g exposure in murine FRT tissue. We collected 
FRT tissue from mice treated with IL-36g (500 ng) or mock-treated with PBS 4h and 24h 
after exposure, and pooled RNA from mice in the treatment groups for cDNA synthesis 
and analysis. From this initial screen (Appendix A), we identified several cytokines, 
chemokines and immune signaling molecules that were upregulated in the murine FRT 
4h after treatment with IL-36g to further investigate and validate. Many of these genes 
have been shown to be important in the immune response to HSV-2 (Chan et al. 2011, 
LeBlanc et al. 1999, Milora et al. 2014, Sergerie, Rivest, and Boivin 2007, Thapa and 
Carr 2008). We also identified several antimicrobial peptides (AMP) that have previously 
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been demonstrated to limit HSV-2 infection (Hazrati et al. 2006, John et al. 2005, Shust 
et al. 2010) that were not included in the arrays for subsequent analysis.  
Murine lower FRT tissue was collected 4h and 24h after treatment (n = 5/time 
point) with IL-36g (250 ng) and qRT-PCR was performed. We measured a transient 
induction of the IL-1 family members Il1b and Il36g 4h after treatment with IL-36g, with 
levels increased 7.7-fold and 12.9-fold, respectively (Fig. 11A). Levels of Il1b and Il36g 
decreased by 24h treatment, and were induced 1.8-fold and 2.5-fold, respectively. 
Expression of the cytokine IL-6, in contrast, was significantly (P < 0.01) increased 4.6-fold 
24h after IL-36g treatment. Levels of the chemokines Ccl20 and Cxcl1 (KC) were 
transiently increased 4h after treatment 9-fold and 5.9-fold respectively, and levels 
decreased by 24h after treatment. Additional chemokines were initially screened in the 
gene expression arrays, including Ccl2, Ccl3, Ccl4, Ccl5, Csf2, Csf3, and expression of 
these targets was not significantly altered by IL-36g treatment (Appendix A). In addition 
to cytokines and chemokines, we measured levels of the AMP defensin beta 3 (Defb3), 
Lactotransferrin (Ltf), and secretory leukocyte peptidase inhibitor (Slpi). Slpi was 
transiently induced, with levels at 4h after treatment significantly (P < 0.05) increased 4.8-
fold relative to PBS controls. No significant changes in expression of Defb or Ltf was 
observed. Interestingly, the C-type lectin, Clec4e, was robustly induced 24.8-fold 4h after 
IL-36g exposure, and at 24h after treatment Clec4e expression was increased 6.4-fold 
relative to controls. We observed no significant changes in expression of the mucin Muc13 
and the inflammasome component Nlrp3 at either 4h or 24h after IL-36g exposure. 
Altogether, these data demonstrate that IL-36g induces the transient expression of immune 
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mediators at 4h in the murine FRT that may contribute to resistance to genital HSV-2 
disease. 
 
Figure 11. IL-36g treatment induces the transient production of 
immune mediators in murine lower FRT tissue and vaginal lavages. 
(A) Female reproductive tract tissue was removed from C57Bl/6 mice 4h 
or 24h after i.vag. IL-36g treatment (250 ng) and the lower FRT was 
isolated for RNA extraction (n = 5/time point). Expression of genes was 
measured by qRT-PCR and was normalized relative to Gapdh. Data is 
representative of two independent animal experiments and represent mean 
fold change ± SD relative to PBS treated controls. (B) Female C57Bl/6 
mice were treated with murine recombinant IL-36γ (250 ng) or PBS. 
Vaginal lavages (n = 5 mice per time point) were collected at 4, 24 and 
48h after exposure. Levels of the chemokines; CCL20, IP-10, and KC 
were quantified by cytometric bead array analysis. Minimum detectable 
concentration is indicated by dashed line. Data shown are representative of 
two independent animal experiments and are presented as the mean ± SD. 
Statistical analyses were performed by two-way ANOVA with 
Bonferroni’s multiple comparisons test.  *, P < 0.05; **, P < 0.01; ***, P 
< 0.005.  
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To understand the kinetics of cytokine and chemokine secretion following IL-36g 
treatment, murine vaginal lavages were evaluated by cytometric bead array analysis to 
measure protein levels of soluble immune mediators. Vaginal lavages were collected 
from mice treated i.vag. with recombinant murine IL-36g (250 ng) or PBS in the absence 
of HSV-2 challenge. Levels of cytokines (IL-1a, IL-1b, IL-6, TNFa) and chemokines 
(CCL20, KC, IP-10) shown to be important in limiting HSV-2 infection were evaluated 
in lavages at 4, 24, and 48h after treatment (n = 5/time point) using a high sensitivity 
murine cytokine/chemokine panel. IL-36g significantly (P < 0.05) increased CCL20 
levels 62-fold compared to PBS controls 4h after treatment (Fig. 11B). IP-10 levels were 
increased 4h after IL-36g treatment, but at a lower fold induction (5-fold). Likewise, IL-
36g treatment significantly (P < 0.01) increased KC levels 11-fold compared to PBS 
controls at 4h. By 24h after treatment, levels of chemokines were lower when compared 
to 4h, and returned to baseline levels by 48h. The cytokines IL-1a, IL-1b, IL-6, and 
TNFa were not significantly induced relative to PBS controls at all time points (data not 
shown). Overall, these results demonstrate a significant transient increase in chemokine 
secretion following IL-36g treatment in murine vaginal lavages that correlated with gene 
expression data (Fig. 11A, B) and may have contributed to limiting HSV-2 replication 
and increasing survival. 
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IL-36g promotes the transient recruitment of neutrophils in the local vaginal 
microenvironment 
The high levels of chemokines measured in vaginal lavages and murine FRT tissue 
following IL-36g treatment led us to investigate the extent to which IL-36g treatment 
impacted immune cell infiltration in the lower FRT. Medroxyprogesterone acetate-
conditioned female C57Bl/6 mice were treated i.vag. with recombinant murine IL-36g 
(250 ng) or PBS. Vaginal swabs were collected 4h and 24h following treatment (n = 
5/treatment), and smeared on slides and allowed to air dry. Slides were then stained with 
modified Wright stain and imaged to characterize immune cell infiltration. Treatment 
with IL-36g significantly (P < 0.01) enhanced infiltration of polymorphonuclear 
leukocytes (PMNs) (shown by black arrows) in vaginal smears 7.7-fold relative to PBS 
controls at 4h post-treatment (Fig. 12). This was a homogenous infiltration of cells that 
consistently exhibited PMN morphology. The increase in PMNs corresponded with the 
elevated levels of the chemokines CCL20 and KC after IL-36g treatment that recruit 
PMN, as well as the induction of IP-10, a chemokine produced by PMN. PMN 
infiltration decreased by 24h post-treatment, and was comparable to PBS controls. 
Epithelial cells were present in vaginal swabs from both treatment groups, albeit at lower 
levels relative to PMNs. This could be due to the progesterone treatment all mice 
received, which has been demonstrated to thin the vaginal epithelium, and mice remain in 
diestrus for at least one month (Kaushic et al. 2003, Quispe Calla et al. 2016). Together, 
the enhanced recruitment of PMNs following IL-36g treatment could be a potential 
mechanism whereby IL-36g treatment protects against genital HSV-2 disease. 
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Figure 12. IL-36γ transiently promotes polymorphonuclear leukocyte 
infiltration in the vaginal microenvironment. Female C57Bl/6 mice 
were treated with murine recombinant IL-36γ (250 ng) or PBS and vaginal 
swabs were collected 4h (A, B, C) and 24h (data not shown) after 
treatment (n = 5 mice/treatment). Vaginal smears were prepared on slides 
and allowed to air dry. Slides were stained with modified Wright stain and 
imaged at 20× and 40× magnification. Black arrows indicate 
polymorphonuclear leukocytes (PMN) and white arrows indicate epithelial 
cells. Scale bar is 50 µm. Cells in fields at 20× were enumerated and 
graphed as average number of total cells/mm2 (D), average number of 
epithelial cells/mm2 (E), and average number of PMN/mm2 (F). Statistical 
significance was determined by two-way ANOVA with Bonferroni’s 
multiple comparisons test. ***, P < 0.001; ****, P < 0.0001. 
 
Discussion 
We have previously demonstrated that IL-36g is expressed in FRT tissue, and 
promotes the secretion of cytokines, chemokines and AMP in response to microbial 
products (Winkle, Throop, and Herbst-Kralovetz 2016). In addition, recent proteomic 
studies evaluating human CVLs have found an increased relative abundance of IL-36g in 
women with bacterial vaginosis and HSV-2 seropositive women using the contraceptive 
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Depo-Provera (Birse et al. 2017, Borgdorff et al. 2016). In this report, we investigated the 
role of IL-36g in the vaginal microenvironment and in protecting against a prototypical 
viral STI, HSV-2. Herein we demonstrated that IL-36g treatment can limit HSV-2 
replication, decrease disease severity, and protect against a lethal HSV-2 challenge.  
Early in infections, microbial products trigger TLRs in the vaginal 
epithelium(Herbst-Kralovetz et al. 2008) and stimulate the innate immune response. In 
HSV-2 infections, envelope glycoproteins will be sensed by TLR2, whereas the nucleic 
acid sensing TLR3 and TLR9 will be triggered by viral nucleic acid products during HSV 
replication (Herbst-Kralovetz and Pyles 2006b, Ma and He 2014). Poly(I:C), a viral 
dsRNA mimic, has previously been shown to protect against lethal HSV-2 challenge 
(Herbst-Kralovetz and Pyles 2006a), and induce IL-36g in vitro (Chustz et al. 2011, Lian 
et al. 2012, Rana et al. 2015, Winkle, Throop, and Herbst-Kralovetz 2016), suggesting 
that IL-36g could participate in antiviral host defense. Herein, we demonstrated that 
HSV-2 infection robustly induced IL36G expression, but did not significantly alter 
expression of other IL-36 family members. This finding suggests that IL-36g, 
specifically, may play a key role in antiviral host defense in the vaginal epithelium. 
Induction of IL-36g in response to HSV-2 may be TLR-mediated, as TLR2, TLR3, and 
TLR9 are all stimulated during HSV infection (Ma and He 2014).  
We investigated the role of IL-36g in the FRT and innate immune mechanisms 
that can contribute to the inflammatory response during acute HSV-2 infections that may 
influence virus replication and, ultimately, disease pathogenesis. Data from both our in 
vitro and in vivo models suggest that IL-36g may limit HSV-2 replication and disease 
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through multiple innate immune mechanisms. We have previously demonstrated that 
exposure to IL-36g for 24h promotes the production of the pro-inflammatory cytokines 
IL-1a, IL-1b, IL-6, and TNFa in VEC (Winkle, Throop, and Herbst-Kralovetz 2016). In 
IL-36g treated murine FRT tissue we also observed an increase in expression of Il1a and 
Il1b however, this was a more transient induction with levels the highest after exposure 
for 4h (Fig. 11A). IL-1a and IL-1b are important pro-inflammatory cytokines that have 
been shown to regulate HSV replication and disease and may be contributing to the 
antiviral environment we observed after IL-36g treatment (Carr and Campbell 1999, 
Chucair-Elliott et al. 2014, LeBlanc et al. 1999, Lucinda et al. 2017, Milora et al. 2014, 
Sergerie, Rivest, and Boivin 2007). AMP, including Slpi, Defb3, and Ltf, are also key 
soluble immune mediators that have been shown to inhibit HSV infection (Hazrati et al. 
2006, John et al. 2005, Shust et al. 2010), and are induced by IL-36g in human VEC 
(Winkle, Throop, and Herbst-Kralovetz 2016). Likewise, we measured elevated levels of 
Slpi following IL-36g treatment in murine FRT tissue (Fig. 11). Interestingly, IL-36g 
exposure significantly increased expression of the C-type lectin Clec4e 24-fold (Fig. 
11A). While C-type lectin receptors (CLR) are mostly known for their role in antifungal 
immunity, there is evidence of CLRs protecting against viral infection, including HSV-1  
(Hoving, Wilson, and Brown 2014, Zelenay et al. 2012). Future studies are required to 
determine if Clec4e can contribute in host defense against genital HSV-2 infection. 
Collectively, increased production of these immune mediators may contribute to the 
HSV-resistant environment that is induced by IL-36g treatment to limit viral replication 
and enhance survival. 
  86 
In the complex multicellular vaginal microenvironment, innate immune cells can 
also contribute to enhanced resistance to genital HSV-2 infection, control viral replication 
and clear infections. Signaling by IL-36g and IL-36R has previously been shown to 
increase chemokine levels and promote leukocyte recruitment in both the skin and lungs 
(Ainscough et al. 2017, Aoyagi et al. 2016, Foster et al. 2014, Ramadas et al. 2011). 
Indeed, we observed that IL-36g exposure elicited significantly increased levels of the 
chemokines CCL20 and KC measured in both FRT tissue and vaginal lavages 4h 
following treatment (Fig. 11). KC and CCL20 can both function to recruit 
polymorphonuclear leukocytes (PMN), including neutrophils, that are important for 
protection against HSV infection in animal models (Milligan 1999, Thapa and Carr 2008, 
Thomas et al. 1997, Tumpey et al. 1996). HSV-2 infection does promote the recruitment 
of PMN in the FRT; however, this is not until approximately 24h after infection (Iversen 
et al. 2016, Milligan 1999). We observed an increase in the recruitment of PMN in 
vaginal smears collected from mice 4h after treatment with IL-36g that corresponded with 
increased levels CCL20 and KC measured in vaginal lavages (Fig. 11B, 12). There was a 
homogenous infiltration of cells that consistently exhibited PMN morphology. Other 
immune cell populations besides PMNs were not morphologically identified in vaginal 
smears from either IL-36g treated or control animals. Further, we did not measure a 
significant induction in chemokines that recruit monocytes/macrophages (Ccl2, Ccl3, 
Ccl5), basophils (Ccl2), eosinophils (Ccl5), T-cells (Ccl3, Ccl4, Ccl5, Cxcl9, Cxcl11), 
NK cells (Ccl4,), and other immune cell populations. This suggests that these cells are 
not being recruited to the vaginal microenvironment at 4h or 24h after IL-36g treatment, 
which was further supported by the vaginal smears. However, the presence and 
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contribution of other immune cell subsets cannot be ruled out and require additional 
analyses. PMN have been shown to be important in suppressing viral replication 
(Milligan 1999), and our data suggest that the increase of PMN in the vaginal epithelium 
may contribute to the decreased levels of vaginal viral replication we measured in IL-36g 
treated mice (Fig. 10A, 12). Neutrophils are important producers of proteases, including 
elastase, which has recently been shown to cleave and activate IL-36g (Henry et al. 
2016). Therefore, IL-36g-mediated neutrophil recruitment could increase levels of 
elastase, and enhance cleavage and activity of IL-36g. Another important function of 
PMN is the production of soluble immune mediators, including AMP and other 
chemokines that could contribute to the HSV-resistant environment induced following 
IL-36g treatment. An important chemokine produced by PMN is IP-10, a T-cell 
chemoattractant that contributes to controlling HSV replication in vivo (Molesworth-
Kenyon et al. 2012, Wuest et al. 2006, Wuest and Carr 2008). We measured elevated 
levels of IP-10 (5-fold) in vaginal lavages 4h after IL-36g treatment, that corresponded 
with increased CCL20 and KC levels at the same time point (Fig. 11B). The robust 
induction of CCL20 and KC that we measured could be key in recruiting PMN early to 
combat genital HSV-2 infection in the FRT by decreasing disease severity, promoting 
disease resolution, and enhancing survival following a lethal viral challenge. 
 Previously, we demonstrated that microbial products stimulate IL-36g in human 
models of the FRT and that IL-36g could regulate host defense mechanisms at this site 
(Winkle, Throop, and Herbst-Kralovetz 2016). We extend these findings here in the 
context of a highly relevant STI pathogen, HSV-2. Consistent with a recent clinical 
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report, we found that HSV-2 robustly induces IL-36g (Birse et al. 2017). Furthermore, we 
found that pretreatment with IL-36g significantly decreased vaginal viral replication in 
vitro. This translated to significantly limiting vaginal viral replication, decreasing disease 
severity and incidence, and increasing survival in a lethal HSV-2 mouse model. In 
summary, our data suggests that IL-36g exposure induces a HSV-2 resistant environment 
through the transient induction of cytokines and chemokines that can inhibit viral 
replication and promote PMN recruitment in the vaginal microenvironment to protect 
against genital HSV-2 disease. The animal model dependence on the dose and timing of 
IL-36g delivery facilitates the pursuit of future studies to investigate IL-36-mediated 
protection in the FRT, and the translational impact of these findings. Our data indicate 
that IL-36g functions as a key regulator of innate immune signaling in genital HSV-2 
infection and may play a role in host defense against other STI pathogens in the FRT
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CHAPTER 5: IL-36g IS A KEY REGULATOR OF NEUTROPHIL INFILTRATION IN 
THE VAGINAL MICROENVIRONMENT AND LIMITS NEUROINVASION IN 
GENITAL HSV-2 INFECTION 
 
Publication Note 
The research reported in this chapter is published in an altered format in The Journal of 
Immunology. Jameson K. Gardner, Alison Swaims-Kohlmeier, and Melissa M. Herbst-
Kralovetz. IL-36g is a key regulator of neutrophil infiltration in the vaginal 
microenvironment and limits neuroinvasion in genital HSV-2 infection. J Immunol. 
ji1900280; doi: 10.4049/jimmunol.1900280.  
 
Abstract 
Herpes simplex virus 2 is a neurotropic virus that causes a persistent, life-long infection 
that increases risk for other sexually transmitted infections. The vaginal epithelium is the 
first line of defense against HSV-2 and coordinates the immune response through the 
secretion of immune mediators, including the pro-inflammatory cytokine IL-36g. 
Previously, we showed that IL-36g treatment promoted transient polymorphonuclear cell 
infiltration to the vaginal cavity and protected against lethal HSV-2 challenge. In this 
report, we reveal that IL-36g specifically induces transient neutrophil infiltration, but 
does not impact monocyte and macrophage recruitment. Utilizing IL-36g-/- mice in a 
lethal HSV-2 challenge model, we show that neutrophils counts are significantly reduced 
at 1- and 2-days post infection and that KC-mediated mature neutrophil recruitment is 
impaired in IL-36g-/- mice. Additionally, IL-36g-/- mice develop genital disease more 
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rapidly, have significantly reduced survival time, and exhibit an increased incidence of 
hind limb paralysis that is linked to productive HSV-2 infection in the brainstem. IL-36g-
/- mice also exhibit a significant delay in clearance of the virus from the vaginal 
epithelium and a more rapid spread of HSV-2 to the spinal cord, bladder, and colon. We 
further show that the decreased survival time and increased virus spread observed in IL-
36g-/- mice is not neutrophil-dependent, suggesting that IL-36g may function to limit 
HSV-2 spread in the nervous system. Ultimately, we demonstrate that IL-36g is a key 
regulator of neutrophil recruitment in the vaginal microenvironment and may function to 
limit HSV-2 neuroinvasion. 
 
Introduction 
Herpes simplex virus-2 (HSV-2) is a sexually transmitted virus that affects an 
estimated 11% of the global population, with an increased incidence in women (Looker et 
al. 2015b). The vaginal epithelium is the first line of defense against HSV-2 infection, 
and the innate immune response triggered by vaginal epithelial cells is crucial in 
controlling viral replication and spread during the initial stages of infection (Herbst-
Kralovetz and Pyles 2006b, Herbst-Kralovetz and Pyles 2006a, Leoni et al. 2012, Lund et 
al. 2003, Rasmussen et al. 2007). The IL-36 cytokines were first characterized as 
members of the IL-1 superfamily that are expressed by epithelial cells at mucosal sites 
(Gresnigt and van de Veerdonk 2013, Kumar et al. 2000). Subsequent study of the IL-36 
cytokines, including the agonists IL-36a, -b, and -g, identified these cytokines as key 
drivers of chronic inflammatory diseases, including psoriasis (D'Erme et al. 2015, Foster 
et al. 2014, Johnston et al. 2011, Towne and Sims 2012, Walsh and Fallon 2016). 
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However, the function of the IL-36 cytokines in host-pathogen interactions is not as well 
understood. Recently, the IL-36 cytokines have been shown to promote neutrophil 
recruitment and play a role in both bacterial and viral infections in the lungs (Ahsan et al. 
2016, Aoyagi et al. 2016, Kovach et al. 2017, Kovach et al. 2016, Milora et al. 2017). We 
have demonstrated that IL-36g is expressed in the female reproductive tract (FRT) and is 
induced in response to an array of microbial products, suggesting a role in host defense 
mechanisms (Winkle, Throop, and Herbst-Kralovetz 2016). Indeed, we found that HSV-2 
stimulated IL36G expression, and that treatment with IL-36g induced an antiviral state 
that limited viral replication in a human 3-D cell culture model and protected against 
disease pathogenesis after lethal challenge in mice (Gardner and Herbst-Kralovetz 2018). 
We further revealed that IL-36g transiently induced polymorphonuclear cell recruitment 
in the FRT that corresponded with decreased vaginal viral titers and increased survival 
(Gardner and Herbst-Kralovetz 2018).  
 
Neutrophils are one of the predominant immune cells present in the FRT, and 
function as early responders to pathogens (Amjadi et al. 2014, Lee et al. 2015). Genital 
HSV-2 infection robustly recruits neutrophils to the vaginal cavity by 24h post-infection, 
and these neutrophils aid in virus clearance from the vaginal mucosa (Milligan 1999). We 
have shown that neutrophil infiltration to the vaginal cavity corresponded with decreased 
HSV-2 production and protection against disease pathogenesis after intravaginal (i.vag.) 
challenge (Gardner and Herbst-Kralovetz 2018). In addition to aiding in HSV-2 
clearance, neutrophils can function to provide broad immune protection against 
pathogens at the FRT barrier through production of antimicrobial peptides, cytokines, 
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chemokines, and reactive oxygen species (Amjadi et al. 2014). Interestingly, neutrophil 
elastase has recently been shown to cleave and activate IL-36g from its pro-form (Clancy 
et al. 2018, Henry et al. 2016), suggesting an important link between IL-36g and 
neutrophils in host defense mechanisms at mucosal sites.  
 
When genital HSV-2 infection spreads beyond the vaginal epithelium, the virus 
infiltrates autonomic ganglion of the pelvis and the dorsal root ganglia, where it 
establishes latency (Fleck et al. 1993, McDermott et al. 1987, McDermott et al. 1984, 
Parr et al. 1994). Periodic virus reactivation can cause ulcerative disease in individuals, 
however asymptomatic virus shedding can also occur (Johnston and Corey 2016, Wald et 
al. 1995). While herpetic lesions are the most well-known symptom of genital HSV-2 
disease, HSV-2 is a neurotropic virus that can spread through the nervous system. Spread 
of HSV-2 into the pelvic ganglion can cause damage to the enteric nervous system that 
leads to urinary retention and constipation in some individuals (Caplan, Kleeman, and 
Berg 1977, Goodell et al. 1983, Khoury-Hanold et al. 2016). Parr and Parr also 
demonstrated that the spread of HSV-2 to the dorsal root ganglia provides a pathway for 
the virus to spread to the spinal cord and brain (Parr and Parr 2003). Symptoms of HSV-2 
neuroinvasion following i.vag. infection in mice include urinary retention, toxic 
megacolon, and hind limb paralysis (Khoury-Hanold et al. 2016, Parr and Parr 2003, 
Reinert et al. 2012). 
 
In this study, we aimed to determine the requirement for IL-36g in protection 
against genital HSV-2 disease pathogenesis. We evaluated IL-36g-mediated immune cell 
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recruitment to the vaginal microenvironment after i.vag. HSV-2 infection, and 
additionally investigated HSV-2 spread and neuroinvasion to better understand the 
function of IL-36g in host defense mechanisms locally in the FRT and systemically after 
viral infection. Collectively, we demonstrate that IL-36g plays a key role in recruiting 
mature neutrophils to the vaginal microenvironment after HSV-2 infection and that IL-
36g may function in a manner that protects against neuroinvasion and HSV-2 disease 
pathogenesis. 
 
Materials and Methods 
HSV-2 propagation and plaque assay 
HSV-2 186 was used in all studies and generously provided by Dr. Richard Pyles 
(UTMB, Galveston, TX). Stocks were prepared from infected Vero cell culture 
monolayers and frozen at -80°C. Vero cells were grown in DMEM (Corning, Manassas, 
VA) as described previously (Pyles et al. 2002). Virus titers in HSV-2 stocks and infected 
samples were determined using standard plaque assay as previously described (Herbst-
Kralovetz and Pyles 2006a).  
 
Animals and genital HSV-2 infection model 
C57Bl/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). IL-
36g-/- mice were kindly provided by Dr. Tim Denning (Georgia State University, Atlanta, 
GA). All animals were housed in accordance with the American Association for 
Laboratory Animal Care (AALAC) standards and provided unlimited access to food and 
water. All procedures and handling were approved by the University of Arizona 
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Institutional Animal Care and Use Committee and performed in accordance with the 
Animal Welfare Act to minimize pain and suffering. Mice were treated with depot 
medroxyprogesterone acetate (DMPA; Greenstone, Peapack, NJ) at day -7 and day -1 to 
synchronize cycles and increase mucosal permeability and susceptibility to infection as 
previously described (Herbst-Kralovetz and Pyles 2006a). For IL-36g treatment, mice 
were treated with recombinant murine IL-36g (250 ng, BioLegend, San Diego, CA) or 
PBS in 10 µl total volume by i.vag. instillation. At time of challenge in HSV-2 infection 
experiments, 103 PFU HSV-2 186 in 10 µl DMEM was i.vag. instilled. Mice were 
visually inspected daily for disease progression and survival over a 16-day period. 
Disease severity was scored on a scale from 0-5 as previously described (Gardner and 
Herbst-Kralovetz 2018). Briefly, no pathology (0), mild vulvar erythema (1), moderate 
vulvar erythema (2), hair loss & erythema (3), perineal ulceration (4), extension of 
perineal ulceration to surrounding tissue and/or hind-limb paralysis (5). Moribund mice, 
or those scoring a 5 were euthanized. Vaginal swabs were collected at days 2, 4 and 6 
post-infection using a DMEM soaked urethro-genital calcium alginate swab (Puritan, 
Guilford, ME) and stored in 1mL DMEM at -80°C. Cervicovaginal lavages (CVL) were 
collected from mice by i.vag. instilling ~125 µl sterile PBS and lavaging the vaginal 
cavity using an oral feeding tube (Fisher Scientific, Hampton, NH) as previously 
described (Gardner and Herbst-Kralovetz 2018). The bladder, distal colon, lumbar spinal 
cord, and brainstem were collected from mice during necropsy, weighed, and stored in 
DMEM at -80°C. For titration, tissues were homogenized, and virus titers quantified by 
standard plaque assay. 
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RNA extraction and qPCR analysis 
Mouse vaginal tissue was collected at 24 and 48h post-HSV-2 infection and 
stored in DNA/RNA Shield (Zymo Research, Irvine, CA) prior to RNA extraction using 
the Zymo Quick-RNA plus kit following the manufacturer’s instructions (Zymo 
Research). cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad, Hercules, 
CA) from 1µg RNA and then analyzed by qPCR using iTAQ Universal SYBR Green 
Supermix (Bio-Rad) with an Applied Biosystems QuantStudio6 Flex Real Time PCR 
System (Life Technologies, Grand Island, NY). Gene expression was normalized relative 
to GAPDH, and primer sequences are listed in Table 6. 
 
 
 
Table 6.  
Primers used in qPCR analysis 
Gene Forward (5'-3') Reverse (5'-3') 
Murine Ccl2 GATGATCCCAATGAGTAGGC TCTTGAGCTTGGTGACAAAA 
Murine Ccl20 CGACTGTTGCCTCTCGTACA CACCCAGTTCTGCTTTGGAT 
Murine Ccl7 CCTGGGAAGCTGTTATCTTCAA TGGAGTTGGGGTTTTCATGTC 
Murine Cxcl9 GGAACCCTAGTGATAAGGAATGCA TGAGGTCTTTGAGGGATTTGTAGTG 
Murine Csf2 CCAGCTCTGAATCCAGCTTCTC TCTCTCGTTTGTCTTCCGCTGT 
Murine Csf3 TGGCAGCAGATGGAAAACCTAG AGGTACGAAATGGCCAGGACA 
Murine Cxcl1 CAATGAGCTGCGCTGTCAGTG CTTGGGGACACCTTTTAGCATC 
Murine Cxcl10 CCTGCCCACGTGTTGAGAT TGATGGTCTTAGATTCCGGATTC 
Murine Gapdh AAATTCAACGGCACAGTCAAG TGGTGGTGAAGACACCAGTAG 
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Neutrophil Depletion 
WT C57Bl6/J and IL-36g-/- mice were injected i.p. with InVivoMAb anti-mouse 
Ly6G (a-Ly6G) antibody or InVivoMAb rat IgG2a isotype control (Bio X Cell, West 
Lebanon, NH) to deplete neutrophils using 200 µg of antibody in 200 µl at Day -1 prior 
to infection and then every other day through the duration of the challenge study. CVLs 
were analyzed by flow cytometry to confirm the efficiency of neutrophil depletion. 
 
Flow Cytometry 
All lavages were passed through 40 µm filters (Corning BD Falcon), and cell 
counting and viability were performed by Trypan blue exclusion. Murine vaginal tissue 
was processed into single cell suspensions for flow cytometry analysis using a modified 
protocol as described by Jiang and Kelly (Jiang and Kelly 2012). Briefly, vaginal tissue 
was cut into fine pieces (< 1 mm) with surgical scissors and transferred to a 1.5 ml 
microfuge tube with 1 ml of digestion media: RPMI media (Corning), 10% heat 
inactivate fetal bovine serum (Corning), 1% penicillin/streptomycin (Corning), 10mM 
HEPES (Fisherbrand, Hampton, NH), 0.5 mg/ml Collagenase type VIII (Sigma Aldrich, 
St. Louis, MO). Tissue was incubated at 37°C with shaking for 1h. After 1h, tissue was 
strained through a 40 µm filter (Corning) and washed with fresh RPMI. Remaining tissue 
issue underwent a second incubation with fresh digestion media at 37°C with shaking for 
1h. After second incubation, tissue was lightly dissociated between sterile glass slides and 
filtered through 40 µm filters. Cell counting and viability was then evaluated by Trypan 
blue exclusion. Non-specific binding in samples was blocked by staining with TruStain 
FcX antibody (anti-mouse CD16/32; BioLegend), and cells were then stained with a 
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cocktail of antibodies: CD11b Alexa Fluor 647 (clone M1/70), F4/80 PE (clone BM8), 
Ly6C PerCp (clone HK1.4), Ly6G Alexa Fluor 488 (clone 1A8), and GR-1 FITC (clone 
RB6-8C5; BioLegend). After staining, cells were fixed in 1% paraformaldehyde and data 
was acquired on a BD LSRII flow cytometer (BD Biosciences, San Jose, CA). Unstained, 
single stained, and “Fluorescence minus one” controls were used to determine positive 
and negative staining. Data were analyzed with FlowJo software (Treestar, Ashland, OR). 
Dead cells and debris were excluded by forward and side scatter, and singlet events were 
selected based on forward scatter area, height and width parameters.  
 
Statistics 
Disease severity, scoring, and systemic virus spread were evaluated by Area 
Under Curve (AUC) analysis with an unpaired two-tailed Student t-test with Welch’s 
correction as previously described (Gardner and Herbst-Kralovetz 2018). Disease 
incidence and survival were analyzed by log-rank analysis as previously described 
(Herbst-Kralovetz and Pyles 2006a). Unpaired two-tailed Student t-test with Welch’s 
correction and ordinary one-way and two-way ANOVAs with Bonferroni’s multiple 
comparison test were performed for comparisons as indicated. A p value of < 0.05 was 
considered significant. All statistical analyses were performed using Prism software 
version 8 (GraphPad, San Diego, CA).  
 
 
 
 
  98 
Results 
IL-36g induces transient neutrophil recruitment to the vagina 
We previously demonstrated that i.vag. IL-36g treatment induced the recruitment 
of polymorphonuclear cells to the FRT barrier. Therefore, we sought to further 
understand the role of IL-36g and immune cell recruitment in the vaginal 
microenvironment. CD11b+Ly6G+ neutrophils were the predominant cells in CVLs from 
DMPA-conditioned naïve C57Bl/6 mice, representing approximately 88-94% of all cells 
in lavages (Fig. 13A). This finding is consistent with a recent report from Cora et al. that 
describes neutrophils as the most abundant cells during diestrus in mice (Cora, Kooistra, 
and Travlos 2015). Following treatment with IL-36g, we measured a significant influx of 
neutrophils into the vaginal microenvironment at 4h (4.9-fold, p < 0.0001) and 8h (2.6-
fold, p < 0.001) post-treatment. Neutrophil infiltration was transient, and neutrophil 
counts returned to baseline levels by 12 and 24h post-treatment (Fig. 13C). We identified 
macrophages (CD11b+F4/80+) and monocytes (CD11b+Ly6C+Ly6G-) in CVLs at all time 
points, but these cells were present at low levels and were not significantly altered by IL-
36g treatment at any time point (data not shown). These results further demonstrate that 
IL-36g robustly recruits neutrophils to the vaginal epithelium that can potentially 
contribute to host defense mechanisms. 
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Figure 13. IL-36γ induces transient neutrophil recruitment to the 
vaginal microenvironment in WT mice. Flow cytometry analysis of 
neutrophils in vaginal lavages from IL-36γ treated mice. Female six- to 
eight-week-old C57Bl/6 mice were conditioned with DMPA and i.vag. 
treated with recombinant murine IL-36γ or PBS (n=5 mice/timepoint). 
Representative staining illustrating gating strategy for CVL immune cell 
characterization (A). Red arrow indicates neutrophils (CD11b+Ly6G+). 
Cell counts and positive staining were used to determine total cell (B) and 
CD11b+Ly6G+ neutrophil (C) counts. Data depict mean cell count ± SD 
and are representative of two independent animal studies. Statistical 
significance was determined by two-way ANOVA with Bonferroni’s 
multiple comparison test. ***, p < 0.001; ****, p < 0.0001. 
 
Mature neutrophil recruitment is impaired in IL-36g-/- mice 
We next quantified cellular infiltration in CVLs from IL-36g-/- and wild-type 
(WT) mice before lethal HSV-2 challenge, and then at 24 and 48h post-infection to 
determine if IL-36g is necessary for cell recruitment in response to viral infection. We 
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found that there was no difference in the total number of cells or neutrophils in the 
vaginal microenvironment between naïve IL-36g-/- and WT mice prior to HSV-2 
challenge (Fig. 14). Following HSV-2 challenge in WT mice, the number of neutrophils 
steadily increased in vaginal lavages at 24 (2.4-fold) and 48h (4.8-fold, p < 0.0001) post-
infection (Fig. 14B). In contrast, lavages from IL-36g-/- mice exhibited significantly 
decreased numbers of CD11b+Ly6G+ neutrophils at 24 (-3.4-fold, p < 0.0001) and 48h (-
2.9-fold, p < 0.0001) after HSV-2 challenge. Neutrophil counts in IL-36g-/- mice were 
decreased -11.15-fold (p < 0.05) and -19.15-fold (p < 0.0001) at 24h and 48h post-
infection, respectively, compared to WT mice. Macrophages (CD11b+F4/80+) and 
monocytes (CD11b+Ly6C+Ly6G-) were present at low levels in lavages and were not 
significantly altered in either IL-36g-/- or WT mice at all time points evaluated (Fig. 14C, 
D). Similar to our findings in CVLs, we measured significantly lower neutrophil counts 
in IL-36g-/- mouse vaginal tissue at 24h post-HSV-2 infection compared to WT mice (Fig. 
14E, Appendix C). We additionally detected macrophages and monocytes in vaginal 
tissue, and numbers of these cells were not significantly altered in IL-36g-/- mice relative 
to WT mice (Appendix C). Collectively, these results reveal an impaired recruitment of 
neutrophils to the vaginal microenvironment in IL-36g-/- mice after HSV-2 challenge that 
suggests a crucial function for IL-36g in regulating neutrophil recruitment after viral 
infection.  
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Figure 14. Neutrophil recruitment is significantly reduced in IL-36γ-/- 
mice after genital HSV-2 infection. Flow cytometry analysis of immune 
cells in vaginal lavages. Female six- to eight-week-old DMPA conditioned 
WT and IL-36g-/- mice (n=5 mice/timepoint) were i.vag. challenged with 
103 PFU HSV-2 186. Lavage cell counts and results from flow cytometry 
analysis were used to determine numbers of total cells (A), neutrophils 
(CD11b+Ly6G+) (B), macrophages (CD11b+F4/80+) (C), and monocytes 
(CD11b+Ly6C+Ly6G-) (D) in WT and IL-36γ-/- mice prior to infection, 
and at 24 and 48h post-infection. (E) Comparison of neutrophil counts in 
cervicovaginal lavages (CVL) and vaginal tissue in IL-36g-/- and WT mice 
at 24h post-infection. Data depict mean ± SD and represent results from 
two independent animal studies. Statistical significance was determined by 
two-way ANOVA with Bonferroni’s multiple comparisons test. ***, p < 
0.001; ****, p < 0.0001; ns, not significant. 
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Interestingly, we observed two distinct populations of CD11b+Ly6G+ cells when 
analyzing the neutrophil population in vaginal lavages (Fig. 15A, B). Prior to HSV-2 
challenge, mature (CD11b+Ly6Ghi) neutrophils were the predominant population in 
vaginal lavages from both WT and IL-36g-/- mice, with a small pool of immature 
(CD11b+Ly6Gint) neutrophils present. After virus challenge, wild type mice maintained 
the predominant population of Ly6Ghi stained cells, and a small pool of Ly6Gint cells 
(Fig. 15C). The number of mature neutrophils in WT mice dramatically increased at 24 
and 48h (p < 0.05) post-infection (Fig. 15D), whereas the number of immature 
neutrophils remained relatively constant (Fig. 15E). Unexpectedly, following infection in 
IL-36g-/- mice, we recorded relatively similar proportions of Ly6Gint and Ly6Ghi stained 
cells. The number of mature neutrophils in IL-36g-/- mice significantly (p < 0.0001) 
decreased at 24 and 48h post-infection while counts of immature neutrophils did not 
significantly change, shifting the ratio of mature to immature neutrophils in the vaginal 
microenvironment. This is shown in Fig. 15C, illustrating a shift in the neutrophil 
population in vaginal lavages from IL-36g-/- mice at both 24 and 48h after HSV-2 
infection. Collectively, these results demonstrate an important role for IL-36g in 
mediating mature neutrophil recruitment in response to genital HSV-2 infection. 
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Figure 15. Recruitment of mature neutrophils to the vaginal 
microenvironment is impaired in HSV-2 challenged IL-36γ-/- mice. 
Analysis of neutrophils in vaginal lavages from HSV-2 challenged WT 
and IL-36γ-/- mice. Female six- to eight-week-old WT and IL-36γ-/- DMPA 
conditioned mice were i.vag. challenged with 103 PFU HSV-2 186 (n=5 
mice/timepoint). Representative histograms plot Ly6G staining intensity 
and relative proportions of neutrophils from WT (A) and IL-36g-/- mice at 
24h post-infection (B), and the ratio of mature to immature neutrophils in 
lavages are represented in pie charts (C). Gating on Ly6G staining 
intensity was used to determine counts of CD11b+Ly6Ghi mature 
neutrophils (D), CD11b+Ly6Gint immature neutrophils (E). Data indicate 
mean ± SD and represent results from two independent animal studies. 
Statistical significance was determined by two-way ANOVA with 
Bonferroni’s multiple comparison test. ***, p < 0.001; ****, p < 0.0001. 
 
Reduced Cxcl1/KC expression in IL-36g-/- vaginal tissue 
In an effort to understand mechanisms that may be contributing to IL-36g-
mediated regulation of neutrophil recruitment and the potential impact on other immune 
cells, we evaluated expression of several chemokines in vaginal tissue from IL-36g-/- and 
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WT mice at 24 and 48h post-infection (Fig. 16). These chemokines include those with 
chemotactic activity for macrophages, monocytes, neutrophils, NK cells, and T cells, 
among others. From this panel of chemokines, we found that IL-36g-/- mouse vaginal 
tissue exhibited a significant reduction in Cxcl1 expression relative to WT mice at both 
24 (-6.4-fold, p < 0.05) and 48h (-5.9-fold, p < 0.05) post-infection. We further detected a 
-7.3-fold reduction in Csf3 expression in IL-36g-/- vaginal tissue relative to WT at 24h 
post-infection, although this was not statistically significant. We did not measure any 
significant changes in expression of any of the other chemokine assayed. Together, these 
data suggest that IL-36g may function to regulate neutrophil recruitment in the FRT in-
part through the neutrophil chemoattractant KC. 
  
 
Figure 16. Cxcl1/KC expression is reduced in IL-36g-/- vaginal tissue 
after HSV-2 challenge. qPCR analysis of murine vaginal tissue after 
intravaginal HSV-2 challenge. Female six- to eight-week-old IL-36g-/- and 
WT mice were conditioned with DMPA and i.vag. challenged with 103 
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PFU (LD100) HSV-2 186. Vaginal tissue was collected at 24 and 48h post-
infection (n=5 mice/timepoint), and expression of chemokines assayed by 
qPCR. Gene expression was normalized to GAPDH and depict mean ± 
SD. Data reflect results from two independent animal studies. Statistical 
significance was determined by two-way ANOVA with Bonferroni’s 
multiple comparisons test. *, p < 0.05. 
 
Decreased survival time in IL-36g-/- mice after genital HSV-2 infection 
To assess the requirement for IL-36g in the host response to genital HSV-2 
infection, we evaluated disease progression and survival after lethal i.vag. HSV-2 
challenge in WT and IL-36g-/- mice. We observed that IL-36g-/- mice exhibited more rapid 
disease symptoms (p < 0.0001) compared to WT mice (Fig. 17A). IL-36g-/- mice 
developed hair loss and erythema around the introitus 2.5 days earlier than controls (Fig. 
17B). Corresponding with the more rapid onset of disease symptoms, IL-36g-/- mice 
exhibited significantly (p < 0.0001) reduced survival time, succumbing to disease 2.6 
days sooner than WT mice (Fig. 17C), indicating that IL-36g signaling is involved in the 
host response to genital HSV-2 infection. 
 
We next sought to determine if IL-36g-mediated protection against genital HSV-2 
infection was neutrophil dependent. Using an anti-mouse Ly6G antibody to deplete 
neutrophils in mice, we evaluated disease progression and survival after lethal 
intravaginal challenge. We found that there was no significant difference in disease 
progression, the incidence of hair loss and erythema, or in survival time between WT 
mice and neutrophil depleted WT mice (Fig. 17). Isotype control treated mice exhibited 
similar disease progression and survival as both WT and neutrophil depleted WT mice 
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(Appendix C). These data suggest that although IL-36g regulates neutrophil recruitment 
in response to HSV-2 infection, IL-36g-mediated protection against genital HSV-2 
infection and disease pathogenesis is not neutrophil dependent. 
 
 
Figure 17. IL-36γ protects against genital HSV-2 infection in a 
neutrophil independent manner. Lethal i.vag. HSV-2 challenge in WT 
mice (n=30), neutrophil depleted WT mice (a-Ly6G, n=5), and IL-36γ-/- 
mice (n=27). Female six- to eight-week-old mice were conditioned with 
DMPA and i.vag. challenged with 103 PFU (LD100) HSV-2 186. Disease 
severity (A), incidence (B), and survival (C) were monitored over a 21-
day period. Data are representative of one (Neutrophil depleted WT mice) 
or three independent animal studies (WT and IL-36g-/- mice). Statistical 
significance was determined by AUC analysis with two-tailed Student t-
test with Welch’s correction (A), and log-rank analysis (B, C). ****, p < 
0.0001. 
 
Increased incidence of hind limb paralysis in IL-36g-/- mice 
Surprisingly, while monitoring disease progression and survival after lethal 
challenge, we observed an increased incidence of hind limb paralysis in IL-36g-/- mice, an 
indication of HSV-2 spread to the central nervous system (CNS). We found that 16.67% 
of WT mice developed hind limb paralysis over the course of infection, and that the onset 
of hind limb paralysis was linked to productive HSV-2 infection in the brainstem, as 
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demonstrated by plaque assay (Fig. 18A, B). In contrast, 81.5% of IL-36g-/- mice (p < 
0.0001) developed hind limb paralysis after lethal challenge, and all mice exhibiting hind 
limb paralysis had detectable viral titers in the brainstem. There was no significant 
difference in the viral load in WT and IL-36g-/- mice with productive infections in the 
brainstem (data not shown). The increased spread of HSV-2 to the CNS in IL-36g-/- mice 
indicates a potential neuroprotective function for IL-36g in the antiviral response. 
 
Figure 18. Increased incidence of hind limb paralysis and productive 
infection in the brainstem in IL-36γ-/- mice after genital HSV-2 
infection. Incidence of hind limb paralysis and toxic megacolon in HSV-2 
challenged mice. Female six- to eight-week-old DMPA conditioned mice 
were i.vag. challenged with 103 PFU HSV-2 186 (n=10 mice/strain). 
Animals were monitored daily for disease progression and survival. (A) 
Incidence of hind limb paralysis was recorded, and toxic megacolon was 
assessed upon necropsy. Data represent three independent animal studies 
(B) Productive viral infection in the brainstem was analyzed by standard 
plaque assay. Tissue was collected at time of death. Data represent the 
detection of viral titers in the brainstem of mice with or without hind limb 
paralysis and are representative of two independent animal studies. 
Statistical significance was determined by two-tailed Student t-test with 
Welch’s correction. ****, p < 0.0001. 
 
Delayed clearance of HSV-2 from the vaginal epithelium in IL-36g-/- mice and increased 
systemic spread 
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We then sought to determine the kinetics of the local HSV-2 infection and 
systemic spread in IL-36g-/- mice compared to WT mice to better understand the 
decreased survival time and increased incidence of neurologic disease in IL-36g-/- mice. 
To measure viral titers and clearance of the virus in the vaginal epithelium, vaginal viral 
titers were quantified at 2, 4 and 6 days after lethal HSV-2 challenge (103 PFU; LD100). 
Viral titers in IL-36g-/- mice were comparable to WT at both 2- and 4-days post-infection 
(dPI; Fig. 19A). However, at 6 dPI, IL-36g-/- mice still exhibited detectable titers with 
viral loads comparable to 2 and 4 dPI, whereas WT mice had mostly cleared the virus. 
Vaginal viral titers in neutrophil depleted WT mice were similar to WT and IL-36g-/- 
mice at 2 and 4 dPI and similar to IL-36g-/- mice, exhibited delayed clearance at 6 dPI 
(Appendix C). Trend analyses indicated that IL-36g-/- mice exhibited a significant (p < 
0.05) delay in HSV-2 clearance from the vaginal epithelium relative to WT mice (Fig. 
19E). To evaluate systemic spread of HSV-2 after i.vag. infection, viral titers were 
quantified in the lumbar spinal cord, distal colon, and bladder of IL-36g-/- and WT mice at 
2, 4, and 6 dPI. We detected significantly higher viral titers at 4 and 6 dPI in the spinal 
cord (p < 0.0001, p < 0.01, respectively), distal colon (p < 0.01, p < 0.05, respectively), 
and bladder (p < 0.01, p < 0.05, respectively) in IL-36g-/- mice relative to wild type mice 
(Fig. 19B-D). These differences in titers were most profound at 4 dPI, where there was a 
2.3-log increase in titers in the lumbar spinal cord, a 1-log increase in titers in the distal 
colon, and a 3.3-log increase in HSV-2 titers in the bladder of IL-36g-/- mice relative to 
WT mice. Trend analyses indicated that HSV-2 spread more quickly to the lumbar spinal 
cord (p < 0.05), distal colon (p < 0.05) and bladder (p < 0.01) in IL-36g-/- mice relative to 
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wild type mice (Fig. 19F-H). Altogether, these data suggest that IL-36g may function to 
limit replication and/or systemic spread of HSV-2 through neurons and the nervous 
system to protect against disease pathogenesis. 
 
 
Figure 19. Rapid systemic spread of HSV-2 in IL-36γ-/- mice. Analysis 
of viral titers (A-D) and kinetics of virus spread (E-H) in WT and IL-36g-/- 
mice after lethal HSV-2 challenge. DMPA conditioned WT and IL-36γ-/- 
mice were i.vag. challenged with 103 PFU HSV-2 186 and then sacrificed 
at 2, 4, and 6 days post-infection (n=5-6 mice/timepoint). Viral titers were 
assessed in vaginal swabs (A, E), spinal cord (B, F) distal colon (C, G), 
and bladder (D, H) by standard plaque assay. Dashed line indicates 
minimum detectable level (150 PFU). Data depict mean ± SD and 
represent two (WT mice) or three (IL-36g-/- mice) independent 
experiments. Statistical significance was determined by unpaired two-
tailed Student t-test with Welch’s correction (A-D) and by AUC analysis 
followed by unpaired two-tailed Student t-test with Welch’s correction (E-
H). *, p < 0.05; **, p < 0.01; **** p < 0.0001. 
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Discussion 
Initially, IL-36g was investigated in the context of a chronic inflammatory 
disease, such as psoriasis (Ding et al. 2018). Recently, however, we and others have 
demonstrated that IL-36g plays an important role in host defense mechanisms at mucosal 
sites (Bassoy, Towne, and Gabay 2018, Gabay and Towne 2015, Gardner and Herbst-
Kralovetz 2018, Winkle, Throop, and Herbst-Kralovetz 2016). IL-36g induces the 
production of immune mediators and stimulates immune cell recruitment, suggesting a 
critical role of IL-36g in immune protection (Gardner and Herbst-Kralovetz 2018, 
Kovach et al. 2017, Kovach et al. 2016, Winkle, Throop, and Herbst-Kralovetz 2016). In 
this report, we demonstrate that IL-36g is an essential component of the innate immune 
response to genital HSV-2 infection, influencing both neutrophil recruitment and the 
spread of HSV-2 through the nervous system.  
 
Previously, we showed that IL-36g is expressed by vaginal epithelial cells, and 
that treatment with recombinant IL-36g induced transient polymorphonuclear cell 
recruitment in addition to the production of cytokines and chemokines, including the 
neutrophil chemoattractant KC (Gardner and Herbst-Kralovetz 2018, Winkle, Throop, 
and Herbst-Kralovetz 2016). Using flow cytometry, we performed a time course 
evaluation of IL-36g-mediated neutrophil recruitment in the cervicovaginal compartment. 
Similar to our earlier findings (Gardner and Herbst-Kralovetz 2018), we measured a 
significant increase in levels of CD11b+Ly6G+ neutrophils in vaginal lavages at 4 (p < 
0.0001) and 8h (p < 0.001) post-treatment with recombinant IL-36g (Fig. 2C). Comparing 
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neutrophil infiltration in WT and IL-36g-/- mice, we measured no differences in 
neutrophil counts between the different strains prior to infection, suggesting that the 
normal influx of neutrophils under homeostatic conditions in the FRT is not dependent on 
IL-36g. However, upon exposure to HSV-2 we observed that the number of neutrophils in 
the vaginal microenvironment differed dramatically between WT and IL-36g-/- mice (Fig. 
2). Consistent with a previous report, we measured a sharp increase in neutrophils in WT 
mice following i.vag. HSV-2 challenge (Milligan 1999). Surprisingly, there was a notable 
decrease in neutrophil counts in IL-36g-/- mice after lethal challenge and these neutrophil 
levels remained suppressed through 48h post-infection. This was also reflected in vaginal 
tissue, where we measured a significant decrease in neutrophil counts in IL-36g-/- mice 
relative to WT mice. We did not measure any changes in counts of macrophages or 
monocytes at 24 or 48h post-infection in IL-36g-/- mice relative WT mice, indicating that 
IL-36g signaling may specifically function to regulate neutrophil recruitment in the FRT. 
To determine potential mechanisms of IL-36g-mediated regulation of neutrophil 
recruitment, we evaluated expression of several chemokines in vaginal tissue from IL-
36g-/- and WT mice at 24 and 48h post-infection. Although there was little change in 
expression of several chemokines in vaginal tissue between IL-36g-/- and WT mice, we 
did measure significantly decreased expression of Cxcl1, a robust neutrophil 
chemoattractant, at both 24 and 48h post-infection in IL-36g-/- mice (Fig. 4). Similarly, 
Aoyagi et al. reported decreased KC production coupled with reduced neutrophil 
infiltration to the lungs in IL-36R-/- mice after influenza virus infection (Aoyagi et al. 
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2016), suggesting that in the FRT IL-36 signaling may drive neutrophil recruitment in 
part through KC.  
 
By distinguishing mature and immature neutrophil populations, we unexpectedly 
found that the mature neutrophil population was depleted in the IL-36g-/- mice through 
48h after HSV-2 infection. The drop in mature neutrophil levels created a shift in the 
vaginal epithelium, whereby immature neutrophils became the dominant neutrophil 
population, despite no changes in the overall counts of immature neutrophils. We did 
measure a 7-fold decrease in Csf3, an important factor for neutrophil maturation, in IL-
36g-/- vaginal tissue at 24h post-HSV-2 challenge, although this change was not 
significant. IL-36g signaling may impact neutrophil maturation factors, and future studies 
are needed to better understand the impact of IL-36g on neutrophil mobilization and 
maturation. While specific anti-HSV-2 functions of neutrophils are not well defined, 
neutrophils have been shown to phagocytose virions (Boddingius et al. 1987, Van Strijp 
et al. 1989), secrete inflammatory mediators (Galani and Andreakos 2015, Gonzalez-
Dosal et al. 2011), and play a role in viral clearance (Milligan 1999, Thomas et al. 1997, 
Tumpey et al. 1996). Although immature neutrophils have many of the functions of 
mature neutrophils, immature neutrophils have been reported to exhibit a reduction in 
mobility and trafficking behavior (Deniset et al. 2017, Wright et al. 2017). Additionally, 
immature neutrophils are less efficient in the production of reactive oxygen species 
(ROS) that function as an important component of the host response to infection (Drifte 
et al. 2013). The dramatic drop in counts of mature neutrophils in IL-36g-/- mice did not 
impact viral titers at 2 or 4 dPI, but titers at 6 dPI in the IL-36g-/- mice were similar to 2 
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and 4 dPI, whereas WT mice had almost completely cleared the virus. The decreased 
neutrophil counts and subsequent delayed clearance of the virus in IL-36g-/- mice is 
consistent with our findings using neutrophil depleted mice and from a previous report 
that demonstrated that neutrophil depleted mice exhibit delayed clearance of HSV-2 from 
the vaginal epithelium (Milligan 1999). Milligan et al. further demonstrated that although 
neutrophils function in viral clearance from the vaginal epithelium, they appear to have a 
limited role in preventing virus spread to the dorsal root ganglia after i.vag. inoculation 
(Milligan, Bourne, and Dudley 2001). The specific mechanisms whereby neutrophils 
participate in HSV-2 clearance from the vaginal epithelium remain unclear, and the 
production of ROS (Gonzalez-Dosal et al. 2011), neutrophil extracellular traps  (Agraz-
Cibrian et al. 2017), or phagocytosis (Boddingius et al. 1987, Van Strijp et al. 1989) may 
potentially contribute to viral clearance (Camp and Jonsson 2017, Drescher and Bai 
2013). Although neutrophils function in virus clearance from the vaginal epithelium, we 
found that neutrophils were not essential for protection against genital HSV-2 infection, 
as neutrophil depleted mice exhibited disease progression and an overall survival time 
that was comparable to WT mice. Neutrophils may exhibit a function in protection 
against genital disease pathogenesis, but protection afforded by neutrophils appears to be 
limited. Collectively, our data indicate that IL-36g-mediated neutrophil recruitment plays 
a role in HSV-2 clearance from the vaginal epithelium but is not essential for protection 
against disease pathogenesis or in limiting virus replication during acute infection. 
 
Interestingly, we observed a significant (p < 0.0001) increase in the incidence of 
hind limb paralysis in IL-36g-/- mice after lethal i.vag. challenge compared to WT mice. 
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Approximately 81% of IL-36g-/- mice developed hind limb paralysis and exhibited 
detectable titers in the brainstem, whereas only 16% of WT mice developed hind limb 
paralysis and infection in the brainstem after lethal challenge. Additionally, we measured 
a more rapid spread of HSV-2 to the spinal cord (p < 0.05), and then to peripheral tissues 
including the distal colon (p < 0.05) and bladder (p < 0.01) that corresponded with the 
decreased survival time in IL-36g-/- mice. Further, IL-36g-/- mice exhibited significantly 
elevated HSV-2 titers in the spinal cord, bladder and colon at 4 and 6 dPI. As described 
earlier, there were no significant differences in vaginal titers at 2 or 4 dPI in WT mice, 
neutrophil depleted WT mice, and IL-36g-/- mice, indicating that the increased spread of 
HSV-2 and neuroinvasion may not be due to increased and/or uncontrolled replication of 
the virus in the vaginal epithelium as a result of the decreased neutrophil counts in IL-
36g-/- mice. Rather, these data suggest that IL-36g may function to limit viral infection, 
replication and/or spread in neurons and the nervous system. Related neuroprotective 
functions have also been shown for interferon signaling in neurons that protect against 
HSV replication and pathogenesis (Rosato and Leib 2015, Song et al. 2016). Milora et al. 
suggested that the IL-36 cytokines may have a neurologic role in immune protection 
against HSV-1 in a flank skin model (Milora et al. 2017), and others have shown that IL-
36R is expressed in mixed glial cells (Berglof et al. 2003). A recent report has further 
shown that IL-36g was upregulated in spinal neurons and astrocytes in a chronic 
inflammatory model, indicating an inflammatory function for IL-36g in the central 
nervous system that may function to protect against viral infection and spread (Li et al. 
2018). Together, our findings suggest a dual role for IL-36g in neutrophil recruitment in 
the FRT and in protection against HSV-2 neuroinvasion after lethal genital challenge. 
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In this study, we reveal that IL-36g is a crucial innate immune mediator in the 
FRT that ultimately influences genital HSV-2 disease pathogenesis. Our findings 
demonstrate that IL-36g is essential for recruiting neutrophils to the vaginal 
microenvironment following HSV-2 challenge and may function generally as a regulator 
of neutrophil recruitment in the FRT. Our data additionally indicate that IL-36g-mediated 
protection against genital HSV-2 infection is not neutrophil dependent and suggests that 
IL-36g may function in neurons to protect against HSV-2 neuroinvasion. However, future 
studies are necessary to determine the mechanisms of IL-36g-mediated neuroprotection.  
Ultimately, our findings show that IL-36g is a key component of the antiviral response to 
genital HSV-2 infection and may function broadly in host defense mechanisms in the 
FRT and against other sexually transmitted pathogens. 
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CHAPTER 6: FINAL SUMMARY AND FUTURE DIRECTIONS 
 
An estimated 267 million women worldwide are HSV-2 seropositive, and the 
WHO recently indicated that over one million curable STIs are transmitted on a daily 
basis (Looker et al. 2015b, Rowley et al. 2019). Genital HSV-2 infection results in a 
persistent, life-long infection in individuals that increases risk for additional STI 
acquisition (Freeman et al. 2006, Patel et al. 2012, Wald and Link 2002). While modern 
medicine has greatly improved treatment and prevention in the fight against STIs, 
including genital herpes, there still exists a significant need to understand underlying 
immune mechanisms in the vaginal epithelium that can ultimately impact disease 
pathogenesis. This dissertation details studies investigating the regulation and function of 
the novel pro-inflammatory cytokine IL-36g in host defense against genital HSV-2 
infection in the FRT. These studies addressed the hypothesis that IL-36g functions as a 
key regulator of mucosal inflammation in the FRT and protects against genital HSV-2 
infection. It was demonstrated that the sex hormones estrogen and progesterone function 
in part to regulate expression of IL-36g in the FRT in a mouse model (Chapter 3). 
Exposure to IL-36g prior to infection was shown to protect against genital HSV-2 
infection and disease pathogenesis by promoting transient neutrophil infiltration and 
production of immune mediators (Chapter 4, 5). Additionally, IL-36g was shown to be a 
critical regulator of neutrophil recruitment and potentially exhibit a previously 
uncharacterized function in limiting viral neuroinvasion after intravaginal infection. 
Together, these studies have provided new insights into the mechanisms whereby IL-36g 
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functions in the FRT and has provided new hypotheses that can further define the role of 
IL-36g in host defense against other bacterial and viral pathogens. 
In Chapter 2 of this dissertation, the use of human 3-D epithelial cell culture 
models for virus-host interactions was discussed. These models, including the FRT 
models developed in the Herbst-Kralovetz lab (Vaginal EC, (Hjelm et al. 2010); 
Endocervical EC, (Radtke, Quayle, and Herbst-Kralovetz 2012); and Endometrial EC, 
(Laniewski et al. 2017)) faithfully recapitulate features of host tissue that can be essential 
for virus infection (Gardner and Herbst-Kralovetz 2016, Radtke and Herbst-Kralovetz 
2012). In this dissertation, in vitro data is presented utilizing the human 3-D vaginal EC 
model. These 3-D aggregates robustly produce pro-inflammatory immune mediators in 
response to pathogens, similar to primary human cells (Gardner and Herbst-Kralovetz 
2016, Winkle, Throop, and Herbst-Kralovetz 2016). Altogether, these model systems, 
coupled with animal models, provide a powerful and unique tool to investigate the host 
response to infection in a physiologically relevant manner, and can provide important 
insights into the function of IL-36g in the FRT. 
Because the FRT is regulated by the sex hormones estrogen and progesterone, the 
impact of these hormones on the IL-36 cytokines and host defense in the FRT was 
investigated (Chapter 3). Consistent with a report from Quispe Calla et al., DMPA 
treatment in mice decreased expression of barrier features and pro-inflammatory 
cytokines, including IL-36g and other IL-36 family members, relative to mice that were 
treated with estrogen. Further, it was shown that these immune mediators and barrier 
features were expressed at higher levels in the lower FRT relative to the upper FRT, and 
this may be due to the differences in structure of the epithelium (stratified squamous vs. 
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columnar), and the fact that the lower FRT is exposed to pathogens on a regular basis 
whereas the upper FRT is more protected from potential pathogens. While results from 
animal models, including mice, do not always translate to humans, there is evidence that 
the sex hormones and hormonal contraceptives can impact host immunity in the human 
FRT (Govender et al. 2014, Huijbregts et al. 2013, Huijbregts, Michel, and Hel 2014, 
Ngcapu et al. 2015, Smith-McCune et al. 2017). As a cytokine that is robustly expressed 
in the FRT, the hormonal regulation of IL-36g in the vaginal microenvironment could 
have an important impact on susceptibility to infection and the host response. Several 
clinical studies have investigated the link between DMPA use and levels of pro-
inflammatory cytokines (Govender et al. 2014, Huijbregts, Michel, and Hel 2014, 
Ngcapu et al. 2015, Smith-McCune et al. 2017), but few have measured or reported on 
IL-36g (Birse et al. 2017). Evaluation of IL-36g levels throughout the menstrual cycle and 
in women using hormonal and non-hormonal contraceptives is of great importance in 
understanding the extent to which hormones can regulate IL-36g in the FRT. 
Additionally, investigating the link between the hormonal regulation of IL-36g and 
susceptibility to infection is an important next step, and these studies can be performed in 
the human 3-D vaginal EC model, mouse models, and in clinical studies. Because of the 
widespread use of hormonal contraceptives and recent links to increased STI acquisition 
in high-risk women (Grabowski et al. 2015, Socias et al. 2017), an enhanced 
understanding of hormonal regulation of IL-36g and the immune response will greatly aid 
in the development of safe contraceptives.  
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In Chapter 4, IL-36g treatment was shown to limit HSV-2 replication 3-D human 
vaginal EC, and IL-36g pre-treatment protected mice against a lethal intravaginal HSV-2 
challenge. Interestingly, treatment of 3-D vaginal EC aggregates with IL-36g at either 24 
or 4h prior to infection led to significantly reduced viral titers after 24h. The exact 
mechanism whereby IL-36g treatment limits HSV-2 replication in the human 3-D VEC 
model has not been elucidated, although exposure to IL-36g has been shown to robustly 
induce pro-inflammatory immune mediators (Winkle, Throop, and Herbst-Kralovetz 
2016). IL-36g and IL-36 signaling may limit HSV-2 replication directly or indirectly by 
inhibiting binding of the virus to target cells, suppressing viral mRNA expression, or by 
limiting the release of virus progeny to neighboring cells or the cell culture supernatant. 
Additional studies in human 3-D vaginal EC can elucidate specific mechanisms whereby 
IL-36g treatment limits virus replication in vitro. Viruses have deployed various immune 
evasion strategies over time to promote infection of and replication in target cells, 
including the HSV protein VP22 that is capable of inhibiting IL-1b production and 
secretion (Jensen 2017, Maruzuru et al. 2018), however, at this time there is currently no 
suggestion of or evidence for a similar HSV protein that either inhibits IL-36g production 
or signaling.  
 
Interestingly, in the mouse model for genital HSV-2 infection, treatment with IL-
36g 4h, but not 24h, prior to infection protected mice against lethal challenge and resulted 
in reduced viral titers. The protection that was observed with the 4h pre-treatment 
corresponded with the robust production of immune mediators and the influx of 
  120 
polymorphonuclear cells to the vaginal microenvironment. In contrast to the 3-D in vitro 
model, where EC are the only cell type present, protection against HSV-2 challenge from 
IL-36g treatment in the mouse model appears to be dependent, at least partly, through the 
recruitment PMN corresponding to the time of challenge. Other reports have indicated 
that IL-36g is a crucial factor to promote PMN infiltration at mucosal sites (Aoyagi et al. 
2016, Kovach et al. 2017), and this study demonstrates, for the first time, that IL-36g 
promotes PMN infiltration in the FRT. 
 
Many immune mediators, including other IL-1 family members, can regulate and 
direct the host response to pathogens in the vaginal microenvironment, therefore, the 
requirement for IL-36g in response to genital HSV-2 infection was evaluated in Chapter 
5. In characterizing the IL-36g-mediated immune cell infiltration in CVLs, a robust and 
transient infiltration of CD11b+Ly6G+ neutrophils to the vaginal microenvironment was 
measured after intravaginal IL-36g treatment and IL-36g-/- mice exhibited an impaired 
recruitment of neutrophils to the FRT tissue and CVLs after HSV-2 challenge. Together, 
these data indicate that IL-36g not only promotes neutrophil recruitment but is crucial for 
HSV-2-induced neutrophil recruitment. Neutrophils have been shown to function in viral 
clearance from the vaginal epithelium (Milligan 1999, Milligan, Bourne, and Dudley 
2001), and in vitro studies with primary neutrophils can investigate mechanisms whereby 
neutrophils contribute to clearance of HSV-2 from the vaginal epithelium, as well as, the 
impact of IL-36g exposure on neutrophil maturation and activity.  
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In addition to impaired neutrophil recruitment, IL-36g-/- mice exhibit a more rapid 
systemic spread of the virus to peripheral sites and significantly increased HSV-2 
neuroinvasion that corresponded with decreased overall survival time. Neutrophil 
depletion studies have shown that neutrophils do not participate in controlling virus 
replication during acute infection or limit spread of the virus to the DRG, and these 
reports, coupled with our data, suggest that IL-36g may function in a previously 
uncharacterized manner in the nervous system to protect against viral infection, 
replication, and/or spread in neurons. The mechanisms of IL-36g-mediated 
neuroprotection and sources of neuronal IL-36g that may be critical to protect against 
HSV-2 are currently unknown. IL-36g has recently been shown to be upregulated in a 
model of CNS chronic inflammatory pain (Li et al. 2018) and may potentially drive 
inflammatory signaling in the CNS that could impact the host response to viral infection. 
Primary neurons collected from WT and IL-36g-/- mice cultured in tri-chamber systems 
could provide important insights into the function of IL-36g in virus-neuron interactions 
and indicate the potential requirement for additional cells (e.g. astrocytes) to limit HSV-2 
infection and spread in neurons. TLR3 has been shown to protect against viral 
neuroinvasion by promoting the type I interferon response in astrocytes (Reinert et al. 
2012), and IL-36g may similarly promote an antiviral response in astrocytes to protect 
against HSV-2 neuroinvasion. Performing additional studies to define the function of IL-
36g in the nervous system can further delineate the mechanisms of IL-36g-mediated 
neuroprotection and may be relevant in the context of other neurotropic viruses (e.g. 
Lyssaviruses, Poliovirus, and other Herpesviruses) in addition to inflammatory diseases 
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in the CNS. Research into the function of IL-36g in the context of Zika virus infection 
may be of particular interest to many, as this virus spreads to the brain tissue in 
developing fetuses causing severe birth defects that include microcephaly (Brasil et al. 
2016, Rasmussen et al. 2016). IL-36g may exhibit a crucial function in pregnant women 
to limit virus spread throughout the FRT epithelium, neurons, and ultimately, to the 
developing fetus. In fact, a recent study reported that a Zika DNA vaccine containing an 
IL-36g plasmid adjuvant exhibited enhanced survival and protection against lethal Zika 
virus challenge in a mouse model (Louis et al. 2019), indicating that IL-36g may be a 
critical component of the host response to protect against Zika virus infection. 
 
The studies in this dissertation have highlighted the function of IL-36g in acute 
genital HSV-2 infection but did not investigate the role of IL-36g in HSV-2 latency and 
reactivation. Because genital HSV-2 infection is lethal in mice, the guinea pig model is 
required to evaluate HSV-2 latency and reactivation in vivo (Kollias et al. 2015). HSV-2 
reactivation in guinea pigs mimics virus reactivation and shedding in humans in terms of 
frequency and duration of reactivation episodes (Bernstein et al. 1991). Using the guinea 
pig model, the impact of IL-36g on the establishment of latency in the DRG could be 
investigated. Pre-treatment of mice with IL-36g prior to infection did protect 40% of mice 
against lethal challenge and leads to the hypothesis that intravaginal IL-36g treatment 
could protect against virus spread and the establishment of latency in the DRG. The 
guinea pig model could also be utilized to evaluate the extent to which IL-36g treatment 
could limit the duration of reactivation and shedding episodes. IL-36g-mediated 
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recruitment of neutrophils and production of pro-inflammatory mediators could aid in 
clearing the virus from the vaginal epithelium and decrease the overall time of 
reactivation episodes. Due to the persist latent nature of genital HSV-2 infections, an 
understanding of the function of IL-36g in the establishment of latency and virus 
reactivation is an important next step to further define the function of IL-36g in host-
pathogen interactions. 
 
For several decades researchers have worked towards the development of a 
vaccine to protect against genital herpes. To date, although several candidates have been 
successful in pre-clinical trials, they exhibited limited therapeutic effects and none have 
successfully completed clinical trials and received FDA approval (Whitley and Baines 
2018). Interestingly, as previously mentioned, a recent report by Louis et al. 
demonstrated that an IL-36g encoded plasmid functioned as an effective adjuvant to 
increase the protection afforded by a Zika virus DNA vaccine (Louis et al. 2019). The IL-
36g adjuvant increased the frequency of antigen specific CD4+ and CD8+ T cells to help 
protect against a lethal Zika virus challenge. T cells function in a key manner in the 
cytolytic response to HSV-2 infection, and exhibit critical functions in controlling virus 
shedding (Mueller et al. 2002, Skoberne et al. 2013). The prime-pull strategy for a HSV-2 
vaccine devised by Shin and Iwasaki relies on the initial priming of effector T cells 
followed by their recruitment to the FRT to establish an HSV-2-specific resident memory 
population (Shin and Iwasaki 2012). The use of an IL-36g encoded plasmid adjuvant in 
concert with the prime-pull vaccination may further promote an enhanced T cell response 
that could function as a protective resident population. Ultimately, the utilization of an 
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IL-36g-based adjuvant could be an important and effective strategy in the development of 
a vaccine to protect against genital HSV-2 infection and/or reactivation. 
 
In addition to its function in genital HSV-2 infection and disease pathogenesis, 
IL-36g may exhibit key functions in response to other obstetric and gynecologic diseases. 
Laniewski et al. recently demonstrated that women with newly diagnosed invasive 
cervical carcinoma exhibited elevated levels of IL-36g (Laniewski et al. 2018). IL-36g 
has been shown to also be elevated in colorectal cancer (Weinstein et al. 2019). Two 
recent reports have demonstrated that therapeutic delivery of IL-36g alone, or alongside 
chemotherapeutics, promoted a robust anti-tumor response that decreased the overall 
tumor burden in mice (Chen et al. 2019, Wang et al. 2015). Larger clinical studies can 
investigate the link between IL-36g levels and cervical cancer, and additionally 
investigate potential associations between IL-36g and other gynecologic cancers, 
including ovarian and endometrial cancer.  
 
As mentioned earlier, the WHO recently reported that over one million curable 
STIs are transmitted daily, and IL-36g may contribute to the host response to other 
bacterial and viral STIs. Winkle et al. demonstrated that microbial products induce IL-
36g in human 3-D vaginal EC (Winkle, Throop, and Herbst-Kralovetz 2016), and Patras 
et al. also demonstrated that invasive Group B Streptococcus strains induce IL-36g in 
vitro (Patras et al. 2015, Patras et al. 2013). IL-36g may particularly be relevant in the 
context of STI that are neutrophilic, including gonorrhea. During infection, N. 
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gonorrhoeae causes robust neutrophil infiltration, and the bacteria are resistant to 
neutrophil killing (Johnson and Criss 2011). Extensive neutrophil infiltration can lead to 
damage in the tissue, and IL-36g-mediated neutrophil recruitment may ultimately 
contribute to disease pathogenesis rather than disease resolution (Johnson and Criss 
2011). For example, during influenza virus infection of the lungs, IL-36-mediated 
neutrophil recruitment was shown to exacerbate disease and IL-36R-/- exhibited signs of 
reduced lung damage and increased survival after lethal challenge (Aoyagi et al. 2016). 
Studies investigating the requirement for IL-36g and IL-36g-mediated neutrophil 
recruitment in N. gonorrhoeae infection could provide important insights into the 
mechanisms contributing to disease pathogenesis and the function of IL-36g in a vaginal 
bacterial infection. In addition to gonorrhea, IL-36g may play a role in other STIs, 
including chlamydia, syphilis, human papilloma virus infection, and bacterial vaginosis, 
the most common bacterial infection worldwide (Allsworth and Peipert 2011). 
Investigation into the function of IL-36g in the context of other STIs and gynecologic 
diseases will increase our understanding of mechanisms regulating and contributing to 
the immune response in the FRT and be valuable in the development of novel 
therapeutics to prevent and treat these widely prevalent diseases.  
 
In summary, this dissertation provides the first report on the function of IL-36g in 
the FRT in response to a viral infection. These results provide essential information on 
the regulation of IL-36g and other IL-36 family members in the FRT by the sex hormones 
estrogen and progesterone that can potentially impact susceptibility to infection. The role 
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of IL-36g in protecting against viral infection in the FRT is defined, and these data show 
that IL-36g is a critical regulator of neutrophil recruitment in response to HSV-2 
challenge. Furthermore, these studies provide novel insights into the potential role of IL-
36g in the CNS to protect against viral neuroinvasion and support the further study of IL-
36g signaling and host defense in neurons. Together, these data provide compelling 
evidence that IL-36g is a key mediator of mucosal inflammation in the FRT and may be 
an important factor in the host response to other obstetric and gynecologic sequelae.  
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Figure 20. IL-36g does not limit HSV-2 replication in a dose-
dependent manner and pre-treatment with IL-36Ra does not 
significantly alter HSV-2 replication. HSV-2 replication was measured 
in 3-D VEC treated with recombinant IL-36γ (100 ng/ml or 500 ng/ml), 
Poly(I:C) (100 µg/ml), or left untreated 24h prior or 4h prior to infection 
with HSV-2 186 (MOI 0.1). Aggregates were treated with acyclovir (20 
µg/ml) 2h prior to infection as a positive control. Viral titers were 
measured after 24h as PFU/ml by standard plaque assay. (B) Human 3-D 
VEC were pre-treated with IL-36Ra (100 ng/ml), ACV (20 µg/ml) or PBS 
30 min prior to challenge with HSV-2 186 (MOI 0.1). Aggregates were 
collected after infection for 24h and viral replication was measured as 
PFU/ml by standard plaque assay. Data represent mean ± SD from two 
independent experiments. Statistical significance was determined by one-
way ANOVA with multiple comparisons. ****, P < 0.0001. 
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Figure 21. IL-36g induces expression of cytokines, chemokines and 
immune signaling molecules in murine FRT tissue 4h after treatment. 
Female 6- to 8-week-old C57Bl/6 mice were conditioned with 
medroxyprogesterone as described and then i.vag. treated with 
recombinant murine IL-36g (500 ng) or mock-treated with PBS in 10 µl. 
FRT tissue was collected 4h and 24h after treatment (n = 5 mice/time 
point) for RNA extraction. Gene expression was measured by qRT-PCR 
analysis using Mouse Antiviral response and Mouse Toll-like receptor 
signaling RT2 profiler arrays (Qiagen). Data was normalized to 
endogenous controls and fold change was calculated by delta delta Ct 
analysis. Data is log2 transformed.   
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Table 7. 
 
IL-36g treatment delayed disease onset and increased survival time in a dose- and time-
specific manner when challenged with 35´ LD50 dose of HSV-2 186 
 
Pre-treatment a Time to symptoms b 
(days) 
Survival time c 
(days) 
PBS 5.8 ± 1.1 8.1 ± 0.9 
IL-36g (100 ng) 4h 5.2 ± 0.4 8.4 ± 0.9 
IL-36g (250 ng) 24h 5.5 ± 0.5 8.1 ± 0.9 
IL-36g (250 ng) 4h 7.8 ± 1.7 **** 10.6 ± 1.9 **** 
IL-36g (500 ng) 4h 7.6 ± 0.9 *** 9.1 ± 1.9 
 
    a Intravaginal treatment of IL-36g was delivered 24h or 4h prior to viral challenge with 
1 ´ 104 PFU HSV-2 186 (35´ LD50). 
   b Mean for mice with disease signs (erythema and hair loss). Log rank analysis was 
used to compare the average time to disease in treatment groups and PBS controls. ***, P 
< 0.001; ****, P < 0.0001. 
   c Mean survival time within 15 days. Log rank analysis was used to compare survival 
between the treatment groups and PBS controls. ****, P < 0.0001. 
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Figure 22. Neutrophil recruitment is impaired in vaginal tissue from 
IL-36g-/- mice after genital HSV-2 infection. Flow cytometry analysis of 
immune cells in vaginal tissue after HSV-2 challenge. Female six- to 
eight-week old DMPA conditioned WT (n=7) and IL-36g-/- (n=5) mice 
were i.vag. challenged with 103 PFU HSV-2 186. Vaginal tissue was 
collected 24h post-infection and analyzed by flow cytometry. Total cell 
counts from dissociated tissue and results from flow cytometry analysis 
were used to calculate number of neutrophils (CD11b+Ly6G+) (A), 
macrophages (CD11b+F4/80+) (B), and monocytes (CD11b+Ly6C+Ly6G-) 
(C) in vaginal tissue. Data depict mean ± SD and represent results from 
two independent animal studies. Statistical significance was determined by 
unpaired two-tailed Student t-test with Welch’s correction. *, p < 0.05. 
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Figure 23. Neutrophil depleted mice exhibit disease progression and 
survival similar to WT mice. Female six- to eight-week-old DMPA 
conditioned mice were treated with anti-mouse Ly6G (a-Ly6G, n=5) or 
isotype control (n=5) antibodies one day prior to infection and then every 
other day through the remainder of the study. Mice were challenged with 
103 PFU HSV-2 186. (A) Vaginal swabs were collected at 2, 4, and 6 dPI 
to measure vaginal viral titers. Disease severity (B), incidence (C), and 
survival (D) were monitored over a 21-day period. Data are presented in 
comparison with results from WT (n=30) and IL-36g-/- mice (n=27). Data 
are representative of one (Neutrophil depleted mice and controls) and 
three (WT and IL-36g-/- mice) independent animal experiments. Statistical 
analysis was performed by two-way ANOVA with Bonferroni’s multiple 
comparisons (A), AUC analysis followed by two-tailed Student t-test with 
Welch’s correction (B), and log-rank analysis (C, D).  
 
